

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

Diagnostic Yield of Screening for SARS-CoV-2 among Patients Admitted for Alternate Diagnoses

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-057852
Article Type:	Original research
Date Submitted by the Author:	01-Oct-2021
Complete List of Authors:	Davis, Philip; University of Saskatchewan, Department of Emergency Medicine Rosychuk, Rhonda; University of Alberta, Department of Pediatrics Hau, Jeffrey P; Vancouver Coastal Health Research Institute, Centre for Clinical Epidemiology and Evaluation; University of British Columbia, Department of Emergency Medicine Cheng, Ivy; Sunnybrook Health Sciences Centre, Department of Emergency Medicine; University of Toronto Faculty of Medicine, Department of Emergency Medicine McRae, Andrew; University of Calgary, Department of Emergency Medicine Daoust, Raoul; Université de Montréal, Département Médecine de Famille et Médecine d'Urgence Lang, Eddy; University of Calgary, Department of Emergency Medicine Turner, Joel; McGill University Montreal, Department of Emergency Medicine Khangura, Jaspreet; Northeast Community Health Centre, Department of Emergency Medicine Fok, Patrick T.; Dalhousie University, Department of Emergency Medicine Stachura, Maja; University of British Columbia, Department of Emergency Medicine Brar, Baljeet; University of British Columbia, Department of Emergency Medicine
Keywords:	COVID-19, EPIDEMIOLOGY, Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Diagnostic microbiology < INFECTIOUS DISEASES

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

R. O.

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

BMJ Article Template

Diagnostic Yield of Screening for SARS-CoV-2 among Patients Admitted for Alternate Diagnoses

Phil Davis¹, Rhonda J. Rosychuk², Jeffrey P Hau^{3,14}, Ivy Cheng^{4,5}, Andrew D. McRae⁶, Raoul Daoust⁷,

Eddy Lang⁸, Joel Turner⁹, Jaspreet Khangura¹⁰, Patrick T. Fok¹¹, Maja Stachura¹², Baljeet Brar¹³, and

Corinne Hohl¹⁴ on behalf of the CCEDRRN investigators, and for the Network of Canadian

Emergency Researchers and the Canadian Critical Care Trials Group

Correspondence to: Dr. Philip J.B. Davis; 103 Hospital Drive, Saskatoon, SK, S7N 0W8; Phil.davis@usask.ca

Author affiliations:

¹ Department of Emergency Medicine, University of Saskatchewan, Saskatoon, SK, Canada

² Department of Pediatrics, University of Alberta, Edmonton, AB, Canada

³ Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute, 828 W 10th Ave, Vancouver BC V5Z1M9

⁴ Department of Emergency Medicine, Sunnybrook Health Sciences Center

⁵ Division of Emergency Medicine, Dept of Medicine, University of Toronto

⁶ Department of Emergency Medicine, University of Calgary

⁷ Département Médecine de Famille et Médecine d'Urgence, Faculté de Médecine, Université de Montréal, Department of Emergency Medicine, Research Centre, CIUSSS-Nord-de-l'Île de-Montréal Montréal, Ouébec, Canada

⁸ Department of Emergency Medicine, University of Calgary

⁹ Department of Emergency Medicine, McGill University, Montreal, Qc

¹⁰ Department of Emergency Medicine, University of British Columbia

¹¹ Division of EMS, Department of Emergency Medicine, Dalhousie University

¹² Department of Emergency Medicine, University of British Columbia

¹³ Department of Emergency Medicine, University of British Columbia

¹⁴ Department of Emergency Medicine, Faculty of Medicine, University of British Columbia, 2775 Laurel St., Vancouver BC V5Z 1M9.

Word count (excluding title page, abstract, references, figures, and tables): 2282

Keywords: screening, COVID-19, coronavirus disease, health services utilization, diagnostic testing, pandemic

Abstract:

Objectives: To determine the diagnostic yield of screening patients for SARS-CoV-2 who were admitted with a diagnosis unrelated to COVID-19, and identify risk factors for positive tests.

Design: Cohort from the Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN) registry

Setting: 30 acute care hospitals across Canada

Participants: Patients hospitalized for non-COVID-19 related diagnoses who were tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) between March 1, and December 29, 2020

Main outcome: Positive nucleic acid amplification test (NAAT) for SARS-CoV-2

Outcome measure: Diagnostic yield

Results: We enrolled 15,690 consecutive eligible adults who were admitted to hospital without clinically suspected COVID-19. Among these patients, 122 tested positive for COVID-19, resulting in a diagnostic yield of 0.8% (95% CI 0.64% - 0.92%). Factors associated with a positive test included presence of a fever, being a healthcare worker, having a positive household contact or institutional exposure, and living in an area with higher 7-day average incident COVID-19 cases.

Conclusions: Universal screening of hospitalized patients for COVID-19 across two pandemic waves had a low diagnostic yield and should be informed by individual-level risk assessment in addition to regional COVID-19 prevalence.

Trial registration: NCT04702945

Page 4 of 34

SUMMARY BOXES

Section 1: Universal screening of admitted patients for SARS-CoV-2 was implemented in many hospitals at the beginning of the pandemic. The Infections Diseases Society of America (IDSA) recommended avoiding universal screening of asymptomatic hospitalized patients in areas and times of low-COVID prevalence (defined as <2% prevalence) with very low certainty of evidence, based on studies of COVID-19 prevalence among asymptomatic individuals in the community.

Section 2: This study supports IDSA recommendations to avoid universal screening for COVID-19 in times and areas of low COVID prevalence and identifies patient-level risk factors strongly associated with positive testing that should be considered for screening.

Strengths and Limitations

- Pan-Canadian study including over 40 academic, non-academic, rural, and urban hospitals.
- Inclusion of patient partners, as well as public engagement, who assisted in the development and presentation of this manuscript.
- Inclusion of pertinent clinical variables, as well as relevant demographic and communitylevel variables.
- Exclusion of non-NAAT tests due to their infrequent use in the Canadian context.

BMJ Open

BMJ Article Template

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

INTRODUCTION

Healthcare institutions initiated widespread testing of admitted patients for coronavirus disease 2019 (COVID-19) in the spring of 2020 (1). Patients without any reported symptoms of COVID-19 were routinely tested even in jurisdictions where COVID-19 rates were low in order to identify asymptomatic carriers and prevent hospital outbreaks (2). Some jurisdictions have continued this practice without robust evidence to support this practice. An Alberta study of 3,375 patients admitted to hospital for alternate diagnoses during the first wave of the pandemic when COVID-19 prevalence was very low found that none of the patients tested positive (3). In contrast, other studies from times and regions with higher COVID-19 prevalence reported positive tests in between 2.6 and 15.5% of otherwise asymptomatic patients (4–8).

Universal testing has several potential downsides if diagnostic yield is low. First, it may worsen Emergency Department (ED) crowding, as admitted patients with pending COVID-19 tests are boarded in EDs until their test results are reported. While ED volumes were lower than usual in the early pandemic such that EDs could absorb this delay, high patient volumes have since returned, exacerbating the impact of this practice on hospital crowding (9). This in turn increases patient morbidity and mortality (10). In addition, diagnostic workups and therapeutic interventions may be delayed until COVID-19 test results are back, as it takes longer to move patients on isolation precautions through the system. This can further exacerbate patient outcomes and hospital crowding. Thirdly, diagnostic testing capacity may be limited, potentially delaying processing of tests for symptomatic patients. In addition, the use of Personal Protective Equipment (PPE) may be increased as institutions have placed patients with pending COVID-19 tests under isolation precautions. The use of PPE during resuscitation has been associated with worse patient outcomes (11). Lastly, there is also an opportunity cost for hospitals as money spent on universal testing could be allocated to other areas. These unintended consequences of liberal testing policies need to be weighed carefully against the anticipated diagnostic yield and potential benefits.

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

BMJ Article Template

As for any diagnostic test, rational COVID-19 testing guidelines should be informed by the level of risk of the patient, such that testing is reduced in situations when risk is low, and more widespread when risk is high. Based on expert opinion, the Infectious Diseases Society of America (IDSA) recommended a testing strategy based on the prevalence of the disease in the community (12). They recommended universal testing of asymptomatic hospitalized patients in times and places of high disease prevalence defined as $\geq 10\%$ or $\geq 10,000$ active cases per 100,000 population and did not recommend universal testing in times and places of low prevalence, defined as under 2% prevalence of disease, or less than 2,000 active cases per 100,000. Most jurisdictions never met the proposed screening threshold as public health measures were enacted to reduce disease prevalence to avoid overwhelming hospital capacity. The IDSA was unable to provide further guidance due to lack of available evidence. Our aim was to determine the diagnostic yield of screening patients for SARS-CoV-2 who had been admitted with a diagnosis unrelated to COVID-19 and identify risk factors for positive tests.

METHODS

Study Design and Setting

The Canadian COVID ED Rapid Response Network (CCEDRRN, pronounced 'sedrin') is a pan Canadian population-based registry that has enrolled consecutive eligible patients presenting with suspected or confirmed COVID–19 from EDs across Canada starting on March 1, 2020. The study population, data collection, data quality assurance, management and governance structure are described in the network's methods paper (13). The research ethics boards of all participating institutions approved this study with a waiver of informed consent for data collection and linkage. Thirty CCEDRRN sites in 7 provinces contributed data to this study (Appendix A).

eliez Rz

Patient and Public Involvement

BMJ Open

BMJ Article Template

CCEDRRN has an active patient engagement committee with patient partners who have lived experience with COVID-19 from geographically representative areas of Canada. Patient partners provided input into the development of this research question and study protocol and the final manuscript.

Study Patients

Participating sites needed to demonstrate ≥99% compliance in enrolling consecutive eligible patients for their data to be included in this study. Data from sites and periods that did not meet this quality threshold were excluded. We included consecutive eligible patients who were admitted to hospital and swabbed for SARS-CoV-2 using a nucleic acid amplification test (NAAT) within 24 hours of ED arrival. We enrolled patients between March 1, 2020 and December 29, 2020. To identify a population of admitted patients in whom COVID-19 disease was not suspected, we excluded patients with ED diagnoses that would have been clinically suspicious for COVID-19. These included all patients with ED diagnoses of suspected or confirmed COVID-19, influenza-like-illness (ILI), upper respiratory infections, and pneumonia or viral pneumonia for which testing would have been indicated based on clinical suspicion. We excluded patients who were discharged directly from the ED, diagnosed with COVID-19 before ED arrival (based on a NAAT done in the community), those whose first swab occurred more than 24 hours after their arrival, and repeat admissions. We also excluded patients in whom initial SARS-CoV-2 testing was negative and repeat testing became positive more than 5 days after arrival, as these patients could have contracted nosocomial COVID.

Data Collection

Trained research assistants collected data retrospectively from electronic and/or paper-based medical records into a central, web-based REDCap database (Vanderbilt University; Nashville, TN, USA). Research assistants captured demographics, infection risk, ED vital signs, presenting symptoms, comorbid conditions and the results of COVID-19 tests. The coordinating centre implemented regular data quality checks, including logic checks in REDCap as well as site-level record verifications for nonsensical or outlying values.

BMJ Article Template

In addition to these clinical variables, we calculated the seven-day moving average incident COVID-19 case count for the health region of each participating site using publicly available epidemiological data (14). For each calendar day within each health region represented in the study, we calculated the average daily incident rate of new infections per 100,000 population over the preceding seven days. This sevenday moving average incidence was assigned to each patient based on the date of their index emergency department encounter and the health region of their postal code of residence. We allocated patients with no fixed address to the health region of the hospital in which they were tested. We imputed values for the first five weeks of the pandemic by modeling the reported COVID-19 cases that had accumulated in every health region over time using linear interpolation (0.1% missing), COVID-19 case data were not publicly available for the early pandemic. The seven-day moving average incident COVID-19 case count was categorized as 0 - 1.99 per 100,000 population, 2 - 7.99 per 100,000 population, and ≥ 8 per 100,000 population based on the relationship between incidence and COVID-19 positive results in a previous analysis (15).

Outcome:

The primary outcome was a positive NAAT for SARS-CoV-2 in patients admitted with non-COVIDrelated diagnoses.

Data Analysis:

We divided the cohort into two groups, those without symptoms of COVID-19 and those with symptoms compatible with COVID-19 that were attributed to an alternate diagnosis (i.e., CHF, COPD, Asthma, etc.). We considered cough, dyspnea, fever, general weakness, chest pain, diarrhea, nausea and vomiting, headache, chills, myalgia, sore throat, altered level of consciousness, and dysgeusia/anosmia to be COVID-19-compatible symptoms. We used descriptive statistics to describe the population. We calculated the diagnostic yield by dividing the number of positive NAATs over the total number of NAATs performed. We calculated the exact binomial proportion 95% confidence intervals (95% CI) for

BMJ Open

BMJ Article Template

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

all proportions and used the modified Clopper-Pearson interval for small samples. We completed a planned subgroup analyses for patients presenting with and without COVID compatible symptoms to determine associated factors for a positive test. The initial multivariable logistic regression model to identify factors associated with a positive NAAT considered candidate variables with a p-value cut-off point of 0.20 based on the Wald test from univariable analyses. From the full model, a step-down procedure reduced the model to key predictors based on Akaike's information criterion (AIC) scores (e.g., chose the model with the smallest AIC score). Candidate variables included seven-day moving average incident COVID-19 case count category, patient age, gender, infection risk, and presenting symptoms. We limited the number of predictor variables in the model to one variable for every 10 outcomes in our data to avoid overfitting. Statistical analysis was preformed using Stata (Version 16.1, StataCorp, College Station, Texas).

RESULTS

We identified 19,791 patients admitted to hospital who presented to a participating ED between March 1, 2020, and December 29, 2020 (Figure 1). We excluded 4,101 patients, of which 2,769 had ED diagnoses that were clinically suspicious for COVID-19 and warranted SARS-CoV-2 testing on clinical grounds. The final cohort contained 15,690 patients. During the study period Canada experienced two pandemic waves with the local 7-day average incident case count ranging from between 0 and 42.6 cases per 100,000 population across sites.

We divided the cohort into two groups, those without any COVID-19 compatible symptoms, and those with COVID-19 compatible symptoms that were attributed to an alternate diagnosis in the ED (Table 1). Most patients arrived from home and were full code. The most common comorbidities were hypertension, diabetes and mental health illness. Of 3,113 patients admitted without COVID-19 compatible symptoms, 13 (0.4%, 95% CI 0.19% – 0.64%) tested positive for COVID-19. Of the 12,570 with COVID-19-

BMJ Article Template

compatible symptoms, 109 patients (0.9%, 95% CI 0.70% - 1.03%) tested positive for COVID-19. Among the 122 individuals who tested positive for COVID-19, 33 (27.0%, 95% CI 19.0% - 35.0%) were from a geographic region that had a moving average daily incident rate of ≥ 8 infections per 100,000 population. The diagnostic yield of testing among patients with COVID-19 compatible symptoms admitted for alternative diagnoses did not vary substantially by presenting symptom (Figure 2) or ED diagnosis (Figure 3).

Table 1: Baseline Characteristics of admitted patients without clinical suspicion of COVID-19 (N=15,690)

	Patients without COVID-19 compatible symptoms	Patients with COVID-19 compatible symptoms attributed to an alternate diagnosis
	(N=3,113)	(N=12,570)
Demographics		
Age (mean, SD)	57.6 (22.6)	64.6 (20.4)
Female (%)	1,418 (45.6)	5,924 (47.1)
Arrival From (%)		
Home	2,552 (82.0)	10,943 (87.0)
Long-term care or rehab facility	217 (7.0)	832 (6.6)
Unstable housing*	190 (6.1)	414 (3.3)
Corrections	7 (0.2)	14 (0.1)
Interfacility transfer	121 (3.9)	262 (2.1)
Risk for Infection (%)		
Travel	32 (1.0)	134 (1.1)
Institutional (LTC/prison)	231 (7.4)	721 (5.7)
Household contact	28 (0.9)	144 (1.1)
Occupational	10 (0.3)	38 (0.3)
Unknown	1,502 (48.2)	5,377 (42.8)
Pre-ED Goals of Care (%)		
Full code	2,946 (94.6)	11,259 (89.5)
Intermediate GOC	18 (0.6)	173 (1.4)
Do not resuscitate	149 (4.8)	1,142 (9.1)
Acuity		
Arrival by Ambulance (%)	1,724 (55.4)	7,189 (57.2)
CTAS 1 (Resuscitation)	241 (7.7)	1,053 (8.4)
CTAS 2 (Emergent)	1,000 (32.1)	5,786 (46.0)
CTAS 3 (Urgent)	1,527 (49.1)	5,086 (40.4)
CTAS 4 (Less Urgent)	295 (9.5)	572 (4.6)
CTAS 5 (Non Urgent)	40 (1.3)	59 (0.5)
Arrival Vital Signs, Mean (SD)		
Heart Rate, beats per min Systolic BP, mm Hg	91.2 (21.2) 134.7 (25.1)	95.5 (23.9) 133.6 (27.9)

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

BMJ Article Template

2				
3	Oxygen saturation, (%)	96.6 (3.4)	95.7 (4.1)	
4	Respiratory Rate, beats per min	18.6 (4.4)	21.2 (6.3)	
5	Temperature, degrees Celsius	36.6 (0.6)	36.8 (0.9)	
6	Comorbidities (%)	30.0 (0.0)	30.8 (0.9)	
7	Hypertension	951 (30.6)	5,321 (42.3)	
8		728 (23.4)	2,134 (17.0)	
9 10	Psychiatric Condition			
10 11	Dyslipidemia Diskatas	425 (13.6)	2,434 (19.4)	
12	Diabetes Chronic Neuro Disorder	427 (13.7)	2,577 (20.5)	
13		322 (10.3)	1,406 (11.2)	
14	Coronary Artery Disease	284 (9.1)	1,796 (14.3)	
15	Rheumatologic Disorder	229 (7.4)	1,249 (9.9)	
16	Dementia	199 (6.4)	696 (5.5)	
17	Active Cancer	231 (7.4)	1,647 (12.9)	
18	Chronic Kidney Disease	195 (6.3)	1,319 (10.5)	
19	Chronic Lung Disease (not asthma)	199 (6.4)	1,691 (13.5)	
20 21	Congestive Heart Failure	159 (5.1)	1,392 (11.1)	
21	Asthma	125 (4.0)	712 (5.7)	
22	Obesity	57 (1.8)	344 (2.7)	
24	Symptoms (%)			
25	Cough	V	2,763 (22.0)	
26	Dyspnea	-	4,757 (37.8)	
27	Fever	-	2,531 (20.1)	
28	General Weakness		3,183 (25.3)	
29	Chest Pain	\sim	2,714 (21.6)	
30	Diarrhea	-	1,339 (10.7)	
31 32	Nausea/Vomiting		3,345 (26.6)	
32 33	Headache	- 0	784 (6.2)	
34	Chills	_	957 (7.6)	
35	Myalgia	- 4	466 (3.7)	
36	Sore Throat	_	374 (3.0)	
37	Altered Consciousness	-	2,502 (19.9)	
38	Dysgusea/Anosmia	_	41 (0.3)	
39	Social Factors (%)			
40	Pregnant (%)	18 (0.6)	45 (0.4)	
41 42	Tobacco use (%)	491 (15.8)	1,656 (13.2)	
42 43	Illicit substance use (%)	421 (13.5)	967 (7.7)	
44	ED Diagnosis (%)	, , , , , , , , , , , , , , , , , , ,	· ·	
45	Respiratory Disease, not specified	8 (0.3)	118 (0.9)	
46	COPD Exacerbation	11 (0.4)	648 (5.2)	
47	Asthma Exacerbation	<5	97 (0.8)	
48	Congestive Heart Failure	44 (1.4)	1,003 (8.0)	
49	Shortness of Breath, NYD*	-	466 (3.6)	
50	Cough, NYD*	_	63 (0.5)	
51	Fever, NYD*	_	482 (3.8)	
52	Outcome (%)			
53 54	Positive SARS-CoV-2 NAAT	13 (0.4)	109 (0.9)	
54 55	*NYD denotes "not yet determined"	10(0.7)	103 (0.3)	-
56				

59

BMJ Article Template

When examining the association between patient factors and screening positive self-reported fever, being a healthcare worker, having a positive household contact or institutional exposure, and being from an area where the seven-day moving average incident COVID-19 case count was \geq 8 per 100,000 population were associate with a greater risk of testing positive (Table 2). The most important risk factor was reporting a household contact or being the caregiver of a known COVID-19 case.

Table 2: Multivariable analysis of factors associated with positive SARS-CoV-2 NAATs (N=15,690)

1 2 3

4 5

6 7

8 9

10 11

12 13 14

	Univariate analysis odds ratio (95% CI)	Final model with fully adjusted odds ratio (95% Cl) ¹	P-value
Sex			
Male Female	<i>Reference</i> 0.84 (0.59 – 1.21)	<i>Reference</i> 0.78 (0.54 – 1.12)	0.18
Age			
	1.00 (1.00 – 1.02)	1.00 (0.99 – 1.01)	0.27
7-day average incident COVID-19 cases			
0 – 1.99 daily cases per 100,000 population 2 to 7.99 daily cases per 100,000 population ≥8 daily cases per 100,000 population	<i>Reference</i> 1.42 (0.91 – 2.22) 2.99 (1.95 – 4.59)	<i>Reference</i> 1.47 (0.94 – 2.31) 3.17 (2.05 – 4.89)	< 0.002
COVID-19 compatible symptoms present			
No	Reference	Reference	0.08
Yes	2.08 (1.71 – 3.71)	1.65 (0.90 – 3.00)	
Self-reported fever, or temperature ≥ 37.5 °C			
No	Reference	Reference	< 0.002
Yes	2.72 (1.89 – 3.90)	2.53 (1.74 – 3.67)	
Diarrhea present			
No	Reference	Reference	0.11
Yes	1.74 (1.04 – 2.92)	1.57 (0.93 – 2.67)	
Healthcare worker			
No	Reference	Reference	< 0.002
Yes	5.62 (1.35 – 23.43)	4.67 (1.05 – 20.54)	
Household contact or caregiver			
No	Reference	Reference	< 0.002
Yes	9.48 (5.01 – 17.96)	7.74 (3.98 – 15.04)	
Institutional exposure			
No	Reference	Reference	< 0.002
Yes	3.46 (2.17 – 5.52)	3.39 (2.10 – 5.47)	
Dysgeusia or anosmia present			
For poor rouious only http:/	/bmjopen.bmj.com/site/about	t/quidalinas yhtml	

2			
3	No	Reference	-
4 5	Yes	3.21 (0.43 – 23.52)	-
6	Dyspnea present		
7	No	Reference	-
8 9	Yes	1.16 (0.80 – 1.70)	-
9 10	Nausea or vomiting present		
11	No	Reference	-
12	Yes	0.81 (0.51 – 1.29)	-
13	4		

¹ Final model determined by including variables with a p-value of p<0.20 during the sex and age adjusted analysis and using the Akaike
 Information Criterion (AIC) to determine additional variables to exclude from the final model. Variables adjusted for all other variables
 present in the final model

DISCUSSION

Our aim was to evaluate the diagnostic yield of screening non-COVID-19 admissions for SARS-CoV-2 across Canada in 2020 and identify patient-level risk factors for positive tests. The diagnostic yield of screening patients with non-COVID-19 related ED diagnoses who were admitted to hospital was low overall, and extremely low in patients without COVID compatible symptoms. The most important patient factors associated with a positive test were having a positive household contact, being a healthcare worker, or having had an institutional exposure to COVID-19. Those factors were more important that a high (\geq 8 daily cases per 100,000 population) 7-day moving average incident COVID-19 case count.

Our study has several strengths. We used data from a large pan-Canadian registry that enrolls from large geographically and culturally diverse areas and is one of the largest registries in the world. CCEDRRN's patient enrolment and data verification protocols are rigorous, ensuring consecutive eligible patients and high-quality clinical data (13). We have previously demonstrated the inter-rater reliability for our data collection methods, including for symptoms (13).

Prior studies have examined the diagnostic yield of universal screening in single centers with varied diagnostic yield estimates between 0 and 15.5% (3–8). Many of these were case series with limited methods from the early pandemic. There is one known multi-center study which examines the benefit of universal screening for elective and emergent surgical admissions at 14 centers in the Netherlands (1). Like our study, the authors found that the overall COVID-19 NAAT positivity varied with community

BMJ Article Template

prevalence. Our finding that positive SARS-CoV-2 tests were associated with self-reported or measured fever is in keeping with a prior Cochrane systematic review that noted considerable variability in COVID-19 associated symptoms (17).

Our study is interesting in the context of the IDSA recommendations which were based on expert opinion and of "very low certainty" (12). The IDSA panel recommended avoiding universal screening for COVID-19 in times and areas of low COVID prevalence, defined as a disease prevalence of under 2%, or fewer than 2,000 active cases per 100,000 population, a threshold so high that it was never met at any of our study sites, even though multiple sites were in COVID-19 hotspots in 2020 (12). This threshold would have equated to over 6 million cases of active COVID-19 infection in the United States at any given time, which would have vastly overwhelmed hospital capacity, and thus represents an untenable threshold for hospitals. It is therefore not surprising that the prevalence of COVID-19 during the study period was far below the IDSA recommended threshold for initiating screening. While the number needed to screen to identify one positive case among admitted patients in our study was between 110 and 250 among unvaccinated patients, we propose that the IDSA screening threshold likely needs to be adopted.

A limitation of our study is that we only considered NAATs and did not consider the diagnostic yield of antigen-based COVID-19 tests, as they were not widespread in Canada in 2020 (16). We were unable to examine the sensitivity and specificity of the SARS-CoV-2 NAATs as we were unable to define false positive tests, so it is possible that some of the positive test results we encountered are false positives, leading to an overestimation of diagnostic yield. While our study is based on a Canadian population without international sites, we believe our findings are generalizable given their wide geographic spread, and the cultural and racial diversity of our patient population. Finally, as data becomes available on the fourth wave of the pandemic, a future study should examine the impact of widespread vaccination on the yield of screening. As a larger proportion of the population is protected from severe disease and death through vaccination, decision makers should carefully consider the low diagnostic yield of a universal testing strategy going forward.

BMJ Open

BMJ Article Template

ACKNOWLEDGEMENTS

We gratefully acknowledge the assistance of Mr. Rajan Bola in the preparation of this manuscript. And we thank the UBC clinical coordinating center staff, the UBC legal, ethics, privacy and contract staff and the research staff at each of the participating institutions in the network outlined in the attached Supplement (Supplement Tables 1-4). The network would not exist today without the dedication of these professionals.

Thank you to all of our patient partners who shared their lived experiences and perspectives to ensure that the knowledge we co-create addresses the concerns of patients and the public. Creating the largest network of collaboration across Canadian Emergency Departments would not have been feasible without the tireless efforts of Emergency Department Chiefs, and research coordinators and research assistants at participating sites. Finally, our most humble and sincere gratitude to our colleagues in medicine, nursing, and the allied health professions who have been on the front lines of this pandemic from day one staffing our ambulances, Emergency Departments, hospitals and ICUs bravely facing the risks of COVID-19 to look after our fellow citizens and after one another. We dedicate this network to you.

COMPETING INTERESTS

None identified.

FUNDING

The Canadian Institutes of Health Research (447679), Ontario Ministry of Colleges and Universities (C-655-2129), Saskatchewan Health Research Foundation (5357), Genome BC (COV024) Foundation du CHU de Québec (Octroi No. 4007) and the Public Health Agency of Canada (award no.: N/A) provided peer-reviewed funding. The BC Academic Health Science Network (award no.: N/A) and BioTalent Canada (award no.: N/A) provided non-peer reviewed funding. These organizations are not-for-profit, and had no role in study conduct, analysis, or manuscript preparation.

REFERENCES

- 1. Puylaert CAJ, Scheijmans JCG, Borgstein ABJ, Andeweg CS, Bartels-Rutten A, Beets GL, et al. Yield of Screening for COVID-19 in Asymptomatic Patients Before Elective or Emergency Surgery Using Chest CT and RT-PCR (SCOUT): Multicenter Study. Ann Surg. 2020 Dec;272(6):919–24.
- 2. Sutton D, Fuchs K, D'Alton M, Goffman D. Universal Screening for SARS-CoV-2 in Women Admitted for Delivery. N Engl J Med. 2020 May 28;382(22):2163–4.
- 3. Ravani P, Saxinger L, Chandran U, Fonseca K, Murphy S, Lang E, et al. COVID-19 screening of asymptomatic patients admitted through emergency departments in Alberta: a prospective quality-improvement study. CMAJ Open. 2020 Oct;8(4):E887–94.
- 4. Goldfarb IT, Diouf K, Barth WH, Robinson JN, Katz D, Gregory KE, et al. Universal SARS-CoV-2 testing on admission to the labor and delivery unit: Low prevalence among asymptomatic obstetric patients. Infect Control Hosp Epidemiol. 2020 Sep;41(9):1095–6.
- Ossami Saidy RR, Globke B, Pratschke J, Schoening W, Eurich D. Successful implementation of preventive measures leads to low relevance of SARS-CoV-2 in liver transplant patients: Observations from a German outpatient department. Transpl Infect Dis [Internet]. 2020 Dec [cited 2021 Aug 9];22(6). Available from: https://onlinelibrary.wiley.com/doi/10.1111/tid.13363
- 6. Gruskay JA, Dvorzhinskiy A, Konnaris MA, LeBrun DG, Ghahramani GC, Premkumar A, et al. Universal Testing for COVID-19 in Essential Orthopaedic Surgery Reveals a High Percentage of Asymptomatic Infections. J Bone Jt Surg. 2020 Aug 19;102(16):1379–88.
- London V, McLaren R, Atallah F, Cepeda C, McCalla S, Fisher N, et al. The Relationship between Status at Presentation and Outcomes among Pregnant Women with COVID-19. Am J Perinatol. 2020 Aug;37(10):991–4.
- 8. Bianco A, Buckley AB, Overbey J, Smilen S, Wagner B, Dinglas C, et al. Testing of Patients and Support Persons for Coronavirus Disease 2019 (COVID-19) Infection Before Scheduled Deliveries. Obstet Gynecol. 2020 Aug;136(2):283–7.
- Lee DD, Jung H, Lou W, Rauchwerger D, Chartier L, Masood S, et al. The Impact of COVID-19 on a Large, Canadian Community Emergency Department. West J Emerg Med [Internet]. 2021 Jun 9 [cited 2021 Jul 26];22(3). Available from: https://escholarship.org/uc/item/0xk8j1fj
- Sun BC, Hsia RY, Weiss RE, Zingmond D, Liang L-J, Han W, et al. Effect of Emergency Department Crowding on Outcomes of Admitted Patients. Ann Emerg Med. 2013 Jun;61(6):605-611.e6.
- 11. Shao F, Xu S, Ma X, Xu Z, Lyu J, Ng M, et al. In-hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in Wuhan, China. Resuscitation. 2020 Jun;151:18–23.
- 12. Hanson KE, Caliendo AM, Arias CA, Hayden MK, Englund JA, Lee MJ, et al. The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing. Clin Infect Dis. 2021 Jan 22;ciab048.
- 13. Hohl CM, Rosychuk RJ, McRae AD, Brooks SC, Archambault P, Fok PT, et al. Development of the Canadian COVID-19 Emergency Department Rapid Response Network population-based registry: a methodology study. CMAJ Open. 2021 Jan;9(1):E261–70.

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

- 14. Health Regional Archive (Public View). [Internet]. [cited 2021 Jun 4]. Available from: https://resourcescovid19canada. hub.arcgis.com/datasets/3aa9f7b1428642998fa399c57dad8045/data?layer=1
- 15. McRae AD, Hohl CM, Rosychuk RJ, Vatanpour S, Ghaderi G, Archambault PM, et al. Development and validation of a clinical risk score to predict SARS-CoV-2 infection in emergency department patients: The CCEDRRN COVID-19 Infection Score (CCIS) [Internet]. Emergency Medicine; 2021 Jul [cited 2021 Aug 9]. Available from: http://medrxiv.org/lookup/doi/10.1101/2021.07.15.21260590
- Prince-Guerra JL, Almendares O, Nolen LD, Gunn JKL, Dale AP, Buono SA, et al. Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites — Pima County, Arizona, November 3–17, 2020. 2021;70(3):6.
- 17. Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Infectious Diseases Group, editor. Cochrane Database Syst Rev [Internet]. 2020 Jul 7 [cited 2021 Jul 26]; Available from: https://onlinelibrary.wiley.com/doi/10.1002/14651858.CD013665


For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml


Figure 1. Patient Flow Diagram


Figure 2. Diagnostic Yield by Presenting Symptoms with 95% confidence intervals

Figure 3. Diagnostic Yield by ED Diagnosis with 95% confidence intervals.

 BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright







SUPPLEMENT

Supplement Table 1. Network coordinating center staff at the University of British Columbia

Name	Roles	Contributions
Jeffrey Hau	Data manager	REDCap, data processing and analysis for manuscripts.
Vi Ho	National coordinator	Coordinate with provincial coordinators and training/onboarding of research assistants.
Serena Small	Research coordinator	Ethics & privacy reviews, data management plan, privacy impact assessment, and qualitative analyses
Amber Cragg	Research manager	Data and manuscript management
Wei Zhao	Data analyst	Data processing and analysis for manuscripts.
Vicky Wu	Data analyst	Data processing and analysis for manuscripts.
Elnaz Bodaghkhani	Research associate	Data and manuscript management

Supplement Table 2. Provincial Coordinators

Name	Province	Institutional affiliation	Contributions to CCEDRRN
Corinne DeMone	NS	Dalhousie University, Halifax, Nova Scotia	Research ethics board submission, manages research assistants, data cleaning and quality.
Jacqueline Fraser	NB	Dalhousie University, St. John New Brunswick	Site coordinator as well as research assistant.
Martyne Audet	QC	Centre intégré de santé et de services sociaux de Chaudière- Appalaches (Hôtel- Dieu de Lévis site), Lévis	Provincial research coordinator, translation of research material to French, ethics management.
Connie Taylor	ON	Queen's University, Kingston	Coordination of research assistants in Ontario, maintenance of REB applications for the province
Kate Mackenzie	MB	Health Sciences Centre, Winnipeg	Lead RA for the province

BMJ Article Template

Aimee Goss	SK	University of Saskatchewan, Saskatoon	Screens records in Saskatoon, data/extraction and entry, coordinates research assistants.
Hina Walia	AB	University of Calgary, Calgary	Provincial coordinator lead for Albert oversight of all Alberta sites.
Josie Kanu	BC	University of British Columbia, Vancouver	Provincial coordinator lead for BC, oversight of all BC sites.

For peer review onl	y - http://bmjopen.bmj	.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

2
3 4
5
6
7 8
9 10 11
10
12
13 14
15
16 17
10
19 20
21
22 23
24 25
25 26
27
28 29
30
31 32
33
34 35 36
36
37 38
39
40 41
42
43 44
45
46 47
48
49 50
51
52 53
54
55
56 57
58
59 60

Supplement Table 3	Institutional research assistant (RA) leads
--------------------	---

Name	Province	Institutional affiliation(s)	
Corinne DeMone	NS	Dartmouth General Hospital, Cobequid Community Health Centre Hants Community Hospital	
		Secondary Assessment Centers of the Dartmouth General Hospital and Halifax Infirmary, Halifax	
Jacqueline Fraser	NB	Saint John Regional Hospital, Saint John	
Alexandra Nadeau	QC	CHU de Québec Université Laval, Quebec City	
Audrey Nolet	QC	Centre intégré de santé et de services sociaux de Chaudière- Appalaches (Hôtel-Dieu de Lévis site), Lévis	
Xiaoqing Xue	QC	Jewish General Hospital, Montréal	
David Iannuzzi	QC	McGill University Health Center, Montréal	
Chantal Lanthier	QC	Hôpital du Sacré-Cœur de Montréal, Montréal	
Konika Nirmalanathan	ON	University Health Network, Toronto	
Vlad Latiu	ON	Kingston General Hospital, Hotel Dieu Hospital, Kingston	
Joanna Yeung	ON	Sunnybrook Health Sciences Center, Toronto	
Natasha Clayton	ON	Hamilton General Hospital, Juravinski Hospital, Hamilton	
Tom Chen	ON	London Health Sciences Centre, London	
Jenna Nichols	ON	Health Sciences North, Sudbury	
Kate Mackenzie	MB	Health Sciences Centre, Winnipeg	
Aimee Goss	SK	St. Paul's Hospital, Royal University Hospital, Saskatoon City Hospital, Saskatoon	
Stacy Ruddell	AB	Foothills Medical Centre, Peter Lougheed Centre, Rockyview General Hospital, South Health Campus, Calgary	
Natalie Runham	AB	University of Alberta Hospital, Edmonton	
Karlin Su	AB	Royal Alexandra Hospital/Northeast Community Health Center, Edmonton	
	BC	St. Paul's Hospital, Mount Saint Joseph, Vancouver	
Bernice Huynh	BC	Abbotsford Regional Hospital and Cancer Center, Abbotsford	
Amanda Swirhun	BC	Royal Columbian Hospital, New Westminster	

BMJ Article Template

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

Name	Province	Institutional affiliation(s)
Tracy Taylor	BC	Eagle Ridge Hospital and Health Care Centre, Port Moody
Mai Hayashi	BC	Royal Inland Hospital, Kamloops
Mackenzie Cheyne	BC	Kelowna General Hospital, Kelowna
Sarim Asim	BC	Surrey Memorial Hospital, Surrey
Katherine Lam	BC	Vancouver General Hospital, Vancouver
Kelsey Compagna	BC	Lions Gate Hospital, Vancouver

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

2
5 4
5 6
7
8 9
10 11
12
13 14
15 16
17
18 19
20 21
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
23 24
25 26
20 27
22 23 24 25 26 27 28 29 30
30 21
31 32
33 34
35 36
32 33 34 35 36 37 38
38 39
40 41
42
43 44
45 46
47
48 49
50 51
52
53 54
55 56
57
58 59
60

1

Supplement Table 4. Contributing Study Sites and Investigators

Lead Investigator	Contributing Site / Code	Member Investigators	
Maritime			
Patrick Fok			
Nova Scotia			
Hana Wiemer	Halifax Infirmary/ 902	Patrick Fok	
	Dartmouth General Hospital/903	Hana Wiemer	
	Hants Community Hospital/ 904	Samuel Campbell	
	Cobequid Community Health Centre/ 905	Kory Arsenault	
	Secondary Assessment Centers of Dartmouth	Tara Dahn	
	General and Halifax Infirmary/ 908		
New Brunswick			
Kavish Chandra	Saint John Regional Hospital/ 901	Kavish Chandra	
Quebec			
Patrick Archambault	Hotel-Dieu de Lévis/ 701	Patrick Archambault	
	Jewish General Hospital/ 702	Joel Turner	
	Centre Hospitalier de l'Université Laval (CHU	Éric Mercier	
	de Québec)/ 703		
	L'hôpital Royal Victoria - Royal Victoria	Greg Clark	
	Hospital/ 705		
	Hôpital de l'Enfant-Jésus,CHU de Québec/ 706	Éric Mercier	
	Hôpital du Saint-Sacrement, CHU de Québec/ 707	Éric Mercier	
	Hôpital Saint-François d'Assise, CHU de Québec/ 708	Éric Mercier	
	Hôtel-Dieu de Québec, CHU de Québec/ 709	Éric Mercier	
	IUCPQ: Institut universitaire de cardiologie et de	Sébastien Robert	
	pneumologie de Québec/ 710		
	Hôpital du Sacré-Coeur de Montreal/ 711	Raoul Daoust	
Ontario			
Laurie Morrison &	Sunnybrook/ 401	Ivy Cheng	
Steven Brooks	The Ottawa Hospital - Civic Campus/ 403	Jeffrey Perry	
	The Ottawa Hospital - General Campus/ 404	Jeffrey Perry	
	Kingston/Queens/ 406	Steven Brooks	
	Hamilton General Hospital/ 407	Michelle Welsford	
	Health Science North, Sudbury Ontario/ 408	Rob Ohle	
	University Hospital – LHSC/ 409	Justin Yan	
	North York General Hospital, Toronto/ 410	Rohit Mohindra	
	Victoria Hospital – LHSC/ 412	Justin Yan	
	Toronto Western Hospital/ 414	Megan Landes	
Manitoba		megan Danues	
Tomislav Jelic	Health Sciences Centre/ 307	Tomislav Jelic	
Saskatchewan		I OIIIISIUV JUIU	
Phil Davis	St Paul's Hospital, Saskatoon/ 303	Phil Davis	
	11 I GUL 3 I MAUTUAL DANKAUJUH/ JUJ		

/ 303 Phil Davis / 304 Phil Davis

	Saskatoon City Hospital, Saskatoon/ 305	Phil Davis
Alberta		
Andrew McRae	University of Alberta Hospital, Edmonton/ 201	Brian Rowe
	Foothills, Calgary/ 202	Katie Lin
	Rockyview, Calgary/ 203	Andrew McRae
	Peter Lougheed Centre/ 204	Andrew McRae
	South Campus, Calgary/ 205	Stephanie VandenBerg
	Northeast Community Health Centre, Edmonton/	Jake Hayward, Jaspree
	206	Khangura
	Royal Alexandra Hospital, Edmonton/ 306	Jake Hayward, Jaspree
		Khangura
British Columbia		
Corinne Hohl	Vancouver General Hospital/ 101	Daniel Ting
	Lions Gate Hospital/ 102	Maja Stachura
	Saint Paul's Hospital/ 103	Frank Scheuermeyer
	Mount St Joseph's/ 104	Frank Scheuermeyer
	Surrey Memorial Hospital/ 105	Balijeet Braar
	Royal Columbian Hospital/ 106	John Taylor
	Abbotsford Regional Hospital/ 107	Ian Martin
	Eagle Ridge Hospital/ 108	Sean Wormsbecker
	Royal Inland Hospital/ 112	Ian Martin
	Kelowna General / Hospital/ 115	Lee Graham

Appendix A: List of hospital sites, with an inclusion start and end date for this study.

Site Name	Province	Start Date	End Date
/ancouver General Hospital	British Columbia	1-Mar-2020	31-Aug-2020
ions Gate Hospital	British Columbia	1-Mar-2020	29-Apr-2020
Saint Paul's Hospital	British Columbia	1-Mar-2020	23-May-2020
Mount Saint Joseph Hospital	British Columbia	1-Mar-2020	24-Mar-2020
Surrey Memorial Hospital	British Columbia	19-Mar-2020	30-Apr-2020
Royal Columbian Hospital	British Columbia	1-Mar-2020	31-May-2020
Abbotsford Regional Hospital	British Columbia	20-Apr-2020	15-Jul-2020
Jniversity of Alberta Hospital	Alberta	8-Apr-2020	7-May-2020
Foothills Medical Centre	Alberta	1-Mar-2020	7-Apr-2020
Rockyview General Hospital	Alberta	1-Mar-2020	7-Apr-2020
Peter Lougheed Centre	Alberta	1-Mar-2020	12-Dec-2020
South Health Campus	Alberta	1-Mar-2020	12-Dec-2020
St Paul's Hospital	Saskatchewan	17-Mar-2020	30-Apr-2020
Royal University Hospital	Saskatchewan	17-Mar-2020	31-Oct-2020
askatoon City Hospital	Saskatchewan	17-Mar-2020	30-Apr-2020
Sunnybrook Health Sciences Centre	Ontario	14-May-2020	31-Oct-2020
The Ottawa Hospital - Civic Campus	Ontario	14-May-2020	31-May-2020
Health Science North	Ontario	14-May-2020	29-Dec-2020
Foronto Western Hospital	Ontario	1-Sep-2020	31-Sep-2020
Hotel-Dieu de Lévis	Quebec	4-May-2020	18-May-2020
ewish General Hospital	Quebec	1-Mar-2020	4-Jun-2020
Hôpital de l'Enfant-Jésus,CHU de Québec	Quebec	4-May-2020	23-Jul-2020
UCPQ: Institut universitaire de cardiologie et de pneumologie de Québec	Quebec	4-May-2020	13-May-2020

Hôpital du Sacré-Coeur de		1	
Montreal	Quebec	4-May-2020	18-May-2020
Saint John Regional Hospital	New Brunswick	12-Mar-2020	12-Apr-2020
Halifax Infirmary	Nova Scotia	5-Apr-2020	15-Apr-2020
Dartmouth General Hospital	Nova Scotia	5-Apr-2020	15-Apr-2020
Hants Community Hospital	Nova Scotia	5-Apr-2020	15-Apr-2020
Cobequid Community Health Centre	Nova Scotia	5-Apr-2020	15-Apr-2020
Secondary Assessment Centers of Dartmouth General and Halifax Infirmary	Nova Scotia	26-Mar-2020	15-May-2020

STROBE Statement	—cheo	BMJ Open cklist of items that should be included in reports of observational studies	/bmjopen-2021-05785		Page
	Item No.	Recommendation	7852 on 1	Page	Relevant text from manuscript
Title and abstract	1	(<i>a</i>) Indicate the study's design with a commonly used term in the title or the abstract	2 Angust	bstract)	"Cohort from the CCEDRRN registry"
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2 022.		Included within the results and conclusions of the abstract
Introduction			owr		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Novaded from 4		Relevant scientific literature has been cited and the rationale for the study is outlined.
Objectives	3	State specific objectives, including any prespecified hypotheses	200wihloaded from http://bmjopen.bmj.com/		"Our aim was to determine the diagnostic yield of screening patients admitted to hospital with a diagnosis unrelated to COVID-19 for SARS-CoV-2 in 2020, and identify risk factors for a positive test"
Methods			on A		
Study design	4	Present key elements of study design early in the paper	pril 19		The Study Design and Setting is outlined early in the Methods Section.
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	, 2024 by gu 5		Included in "Study Design and Setting" sub-section.
Participants	6	 (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants 	6		Included in the "Study Patients" sub-section. Eligibility, sources and methods of selection are described.

ge 31 of 34		BMJ Open	/bmjopen-202	
		(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed Case-control study—For matched studies, give matching criteria and the number of controls per case	1-057852	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	0 August 6-	Variables are outlined in the "Data Collection" sub-section.
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	t 2 022. Downloa	Data sources and methods of assessment are outlined in the "Study Design and Setting" and "Data Collection" sub-sections.
Bias	9	Describe any efforts to address potential sources of bias	aded from h	Described within the "Study Patients" and the "Data Collection" sub-sections.
Study size	10	Explain how the study size was arrived at	6 6	Described within the "Study Patients" sub-section.
Continued on next page			024 by guest. Protected by copyright.	
		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xht	ml	

Page 32 of 34

	BMJ Open		bmjopen-202	Pag
Quantitative 11 variables	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-8	<u>.</u>	Included within the "Data Collection" and "Data Analysis" sub-sections.
Statistical 12 methods	(<i>a</i>) Describe all statistical methods, including those used to control for confounding	7-8		Descriptive statistics, sub-group analyses, and regression models were used. Confounding was addressed via multivariable regression.
	(b) Describe any methods used to examine subgroups and interactions	8	Dow	Sub-group analyses were planned for patients presenting with and without COVID compatible symptoms.
	(c) Explain how missing data were addressed	6-7	nloaded from http:	"Participating sites needed to demonstrate \geq 99% compliance in enrolling consecutive eligible patients for their data to be included in this study"
			nloaded from http://bmjopen.bmj.com/ on	"We imputed values for the first five weeks of the pandemic by modeling the reported COVID-19 cases that had accumulated in every health region over time using linear interpolation (0.1% missing)"
	 (d) Cohort study—If applicable, explain how loss to follow-up was addressed Case-control study—If applicable, explain how matching of cases and controls was addressed Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses 	7-8 N/A	April 19, 202	Loss to follow-up was not an issue. Study enrolled consecutive patients who met the inclusion/exclusion criteria and data collected through chart review. Not performed.
Results		11/71	guest.	Not performed.
Participants 13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8	Protectec	"We identified 19,791 patients admitted to hospital who presented to a participating ED between March 1, 2020, and December 29, 2020 (Figure 1). We excluded 4,101 patients, of which 2,769 had ED diagnoses that were clinically

/bmjopen-202 1-057852 suspicious for COVID-19 and warranted SARS-CoV-2 testing on clinical grounds. The final cohort contained 15.690 g patients." 0 (b) Give reasons for non-participation at each stage N/A Study was based on chart review. Figure 19 (c) Consider use of a flow diagram ıst 2022 Descriptive 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information 8-9 Paragraph 2 of the results includes the descriptive summaries. data on exposures and potential confounders 0 (b) Indicate number of participants with missing data for each variable of interest N/A See methods. wnloaded from (c) Cohort study—Summarise follow-up time (eg, average and total amount) "We identified 19,791 patients admitted to 8 hospital who presented to a participating ED between March 1, 2020, and December 29, 2020". http://bmjopen.bmj "During the study period Canada Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time 8 experienced two pandemic waves with the local 7-day average incident case count ranging from between 0 and 42.6 cases per 100,000 population across sites." com/ *Case-control study*—Report numbers in each exposure category, or summary measures of N/A exposure o Cross-sectional study-Report numbers of outcome events or summary measures N/A Ą pril 19, Descriptive results and comparative (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their Main results 16 8-9 findings are described in the latter 2 precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and 2024 paragraphs of the "Results" why they were included Å (b) Report category boundaries when continuous variables were categorized N/A guest (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful N/A time period rotected by copyright Continued on next page

BMJ Open

Page 33 of 34

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22 23

24

25

26 27

28

29

30

31

32

33

34

35

3 4

		BMJ Open	/bmjopen-202	Page 3
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	21- 0 57852 on 10 August 2022. ⊗	Follows the sentence "We divided the cohort into two groups, those without any COVID-19 compatible symptoms, and those with COVID- 19 compatible symptoms that were attributed to an alternate diagnosis in the ED (Table 1)."
Discussion				
Key results	18	Summarise key results with reference to study objectives	9-minioaded	The study objective is recalled and situated within the context of the results.
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	from http://bmjopen.bmj.com/ on April 19, 2024 by g	"A limitation of our study is that we only considered NAATs and did not consider the diagnostic yield of antigen-based COVID-19 tests, as they were not widespread in Canada in 2020 (16). We were unable to examine the sensitivity and specificity of the SARS-CoV-2 NAATs as we were unable to define false positive tests, so it is possible that some of the positive test results we encountered are false positives, leading to an overestimation of diagnostic yield."
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Jules 1 10st. Protec	Key references are recalled, and the study results are situated with these references.
Generalisability	21	Discuss the generalisability (external validity) of the study results	10 ^{dl} by copyright.	"While our study is based on a Canadian population without international sites, we believe our

 /bmjopei

http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

		n-2021-057852	findings are likely generalizable given the wide geographic spread of
Other information	on	on 10	our study sites."
Funding	22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	just	Included under "Funding" Section.
		20	

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohord and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.stro e-statement.org.

BMJ Open

Diagnostic Yield of Screening for SARS-CoV-2 among Patients Admitted to Hospital for Alternate Diagnoses: An Observational Cohort Study

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-057852.R1
Article Type:	Original research
Date Submitted by the Author:	24-Mar-2022
Complete List of Authors:	Davis, Philip; University of Saskatchewan, Emergency Medicine Rosychuk, Rhonda; University of Alberta, Department of Pediatrics Hau, Jeffrey P; Vancouver Coastal Health Research Institute; The University of British Columbia, Department of Emergency Medicine Cheng, Ivy; Sunnybrook Health Sciences Centre, Department of Emergency Medicine; University of Toronto Faculty of Medicine, Department of Emergency Medicine McRae, Andrew; University of Calgary, Department of Emergency Medicine Daoust, Raoul; Université de Montréal, Département Médecine de Famille et Médecine d'Urgence Lang, Eddy; University of Calgary, Department of Emergency Medicine Turner, Joel; McGill University, Department of Emergency Medicine Khangura, Jaspreet; Northeast Community Health Centre, Department of Emergency Medicine Fok, Patrick T.; Dalhousie University, Department of Emergency Medicine Stachura, Maja; The University of British Columbia, Department of Emergency Medicine Brar, Baljeet; The University of British Columbia, Department of Emergency Medicine Hohl, Corinne; The University of British Columbia, Department of Emergency Medicine
Primary Subject Heading :	Emergency medicine
Secondary Subject Heading:	Infectious diseases
Keywords:	COVID-19, EPIDEMIOLOGY, Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Diagnostic microbiology < INFECTIOUS DISEASES

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez on

Diagnostic Yield of Screening for SARS-CoV-2 among Patients Admitted to Hospital for Alternate

Diagnoses: An Observational Cohort Study

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

BMJ Article Template

Phil Davis¹, Rhonda J. Rosychuk², Jeffrey P Hau^{3,14}, Ivy Cheng^{4,5}, Andrew D. McRae⁶, Raoul Daoust⁷,

Eddy Lang⁸, Joel Turner⁹, Jaspreet Khangura¹⁰, Patrick T. Fok¹¹, Maja Stachura¹², Baljeet Brar¹³, and

Corinne Hohl¹⁴ on behalf of the CCEDRRN investigators, and for the Network of Canadian

Emergency Researchers and the Canadian Critical Care Trials Group

Correspondence to: Dr. Philip J.B. Davis; 103 Hospital Drive, Saskatoon, SK, S7N 0W8; Phil.davis@usask.ca

Author affiliations:

¹ Department of Emergency Medicine, University of Saskatchewan, Saskatoon, SK, Canada

² Department of Pediatrics, University of Alberta, Edmonton, AB, Canada

³ Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute, 828 W 10th Ave, Vancouver BC V5Z1M9

⁴ Department of Emergency Medicine, Sunnybrook Health Sciences Center

⁵ Division of Emergency Medicine, Dept of Medicine, University of Toronto

⁶ Department of Emergency Medicine, University of Calgary

⁷ Département Médecine de Famille et Médecine d'Urgence, Faculté de Médecine, Université de Montréal, Department of Emergency Medicine, Research Centre, CIUSSS-Nord-de-l'Île de-Montréal Montréal, Québec, Canada

⁸ Department of Emergency Medicine, University of Calgary

⁹ Department of Emergency Medicine, McGill University, Montreal, Qc

¹⁰ Department of Emergency Medicine, University of British Columbia

¹¹ Division of EMS, Department of Emergency Medicine, Dalhousie University

¹² Department of Emergency Medicine, University of British Columbia

¹³ Department of Emergency Medicine, University of British Columbia

¹⁴ Department of Emergency Medicine, Faculty of Medicine, University of British Columbia, 2775 Laurel St., Vancouver BC V5Z 1M9.

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

Word count (excluding title page, abstract, references, figures, and tables): 2282

Keywords: screening, COVID-19, coronavirus disease, health services utilization, diagnostic testing, pandemic

Abstract:

Objectives: To determine the diagnostic yield of screening patients for SARS-CoV-2 who were admitted with a diagnosis unrelated to COVID-19, and identify risk factors for positive tests.

Design: Cohort from the Canadian COVID-19 Emergency Department Rapid Response Network

(CCEDRRN) registry

Setting: 30 acute care hospitals across Canada

Participants: Patients hospitalized for non-COVID-19 related diagnoses who were tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) between March 1, and December 29, 2020

Main outcome: Positive nucleic acid amplification test (NAAT) for SARS-CoV-2

Outcome measure: Diagnostic yield

Results: We enrolled 15,690 consecutive eligible adults who were admitted to hospital without clinically suspected COVID-19. Among these patients, 122 tested positive for COVID-19, resulting in a diagnostic yield of 0.8% (95% CI 0.64% - 0.92%). Factors associated with a positive test included presence of a fever, being a healthcare worker, having a positive household contact or institutional exposure, and living in an area with higher 7-day average incident COVID-19 cases.

Conclusions: Universal screening of hospitalized patients for COVID-19 across two pandemic waves had a low diagnostic yield and should be informed by individual-level risk assessment in addition to regional COVID-19 prevalence.

Trial registration: NCT04702945

Strengths and Limitations

- Pan-Canadian study including over 40 academic, non-academic, rural, and urban hospitals.
- Inclusion of patient partners, as well as public engagement, who assisted in the development and presentation of this manuscript.
- Inclusion of pertinent clinical variables, as well as relevant demographic and community level variables.

ore review only

• Exclusion of non-NAAT tests due to their infrequent use in the Canadian context.

BMJ Article Template

INTRODUCTION

Healthcare institutions initiated widespread testing of admitted patients for coronavirus disease 2019 (COVID-19) in the spring of 2020 (1). Patients without any reported symptoms of COVID-19 were routinely tested even in jurisdictions where COVID-19 rates were low in order to identify asymptomatic carriers and prevent hospital outbreaks (2). Some jurisdictions have continued this practice without robust evidence to support this practice. An Alberta study of 3,375 patients admitted to hospital for alternate diagnoses during the first wave of the pandemic when COVID-19 prevalence was very low found that none of the patients tested positive (3). In contrast, other studies from times and regions with higher COVID-19 prevalence reported positive tests in between 2.6 and 15.5% of otherwise asymptomatic patients (4–8).

Universal testing has several potential downsides if diagnostic yield is low. First, it may worsen Emergency Department (ED) crowding, as admitted patients with pending COVID-19 tests are boarded in EDs until their test results are reported. While ED volumes were lower than usual in the early pandemic such that EDs could absorb this delay, high patient volumes have since returned, exacerbating the impact of this practice on hospital crowding (9). This in turn increases patient morbidity and mortality (10). In addition, diagnostic workups and therapeutic interventions may be delayed until COVID-19 test results are back, as it takes longer to move patients on isolation precautions through the system. This can further exacerbate patient outcomes and hospital crowding. Thirdly, diagnostic testing capacity may be limited, potentially delaying processing of tests for symptomatic patients. In addition, the use of Personal Protective Equipment (PPE) may be increased as institutions have placed patients with pending COVID-19 tests under isolation precautions. The use of PPE during resuscitation has been associated with worse patient outcomes (11). Lastly, there is also an opportunity cost for hospitals as money spent on universal testing could be allocated to other areas. These unintended consequences of liberal testing policies need to be weighed carefully against the anticipated diagnostic yield and potential benefits.

BMJ Article Template

As for any diagnostic test, rational COVID-19 testing guidelines should be informed by the level of risk of the patient, such that testing is reduced in situations when risk is low, and more widespread when risk is high. Based on expert opinion, the Infectious Diseases Society of America (IDSA) recommended a testing strategy based on the prevalence of the disease in the community (12). They recommended universal testing of asymptomatic hospitalized patients in times and places of high disease prevalence defined as $\geq 10\%$ or $\geq 10,000$ active cases per 100,000 population and did not recommend universal testing in times and places of low prevalence, defined as under 2% prevalence of disease, or less than 2,000 active cases per 100,000. Most jurisdictions never met the proposed screening threshold as public health measures were enacted to reduce disease prevalence to avoid overwhelming hospital capacity. The IDSA was unable to provide further guidance due to lack of available evidence. Our aim was to determine the diagnostic yield of screening patients for SARS-CoV-2 who had been admitted with a diagnosis unrelated to COVID-19 and identify risk factors for positive tests.

METHODS

Study Design and Setting

The Canadian COVID ED Rapid Response Network (CCEDRRN, pronounced 'sedrin') is a pan Canadian population-based registry that has enrolled consecutive eligible patients presenting with suspected or confirmed COVID–19 from EDs across Canada starting on March 1, 2020. The study population, data collection, data quality assurance, management and governance structure are described in the network's methods paper (13). The research ethics boards of all participating institutions approved this study with a waiver of informed consent for data collection and linkage (UBC REB: H20-01015). Thirty CCEDRRN sites in 7 provinces contributed data to this study (Appendix A). Data are available upon reasonable request and can be shared after approval by the Executive Committee through a process outlined on our website (https://www.ccedrrn.com/).

el.ez

BMJ Open

BMJ Article Template

Patient and Public Involvement

CCEDRRN has an active patient engagement committee with patient partners who have lived experience with COVID-19 from geographically representative areas of Canada. Patient partners provided input into the development of this research question and study protocol and the final manuscript.

Study Patients

Participating sites needed to demonstrate ≥99% compliance in enrolling consecutive eligible patients for their data to be included in this study. Data from sites and periods that did not meet this quality threshold were excluded. We included consecutive eligible patients who were admitted to hospital and swabbed for SARS-CoV-2 using a nucleic acid amplification test (NAAT) within 24 hours of ED arrival. We enrolled patients between March 1, 2020 and December 29, 2020. To identify a population of admitted patients in whom COVID-19 disease was not suspected, we excluded patients with ED diagnoses that would have been clinically suspicious for COVID-19. These included all patients with ED diagnoses of suspected or confirmed COVID-19, influenza-like-illness (ILI), upper respiratory infections, and pneumonia or viral pneumonia for which testing would have been indicated based on clinical suspicion. We excluded patients who were discharged directly from the ED, diagnosed with COVID-19 before ED arrival (based on a NAAT done in the community), those whose first swab occurred more than 24 hours after their arrival, and repeat admissions. We also excluded patients in whom initial SARS-CoV-2 testing was negative and repeat testing became positive more than 5 days after arrival, as these patients could have contracted nosocomial COVID.

Data Collection

Trained research assistants collected data retrospectively from electronic and/or paper-based medical records into a central, web-based REDCap database (Vanderbilt University; Nashville, TN, USA). Research assistants captured demographics, infection risk, ED vital signs, presenting symptoms, comorbid conditions and the results of COVID-19 tests. The coordinating centre implemented regular

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

BMJ Article Template

data quality checks, including logic checks in REDCap as well as site-level record verifications for nonsensical or outlying values.

In addition to these clinical variables, we calculated the seven-day moving average incident COVID-19 case count for the health region of each participating site using publicly available epidemiological data (14). For each calendar day within each health region represented in the study, we calculated the average daily incident rate of new infections per 100,000 population over the preceding seven days. This seven-day moving average incidence was assigned to each patient based on the date of their index emergency department encounter and the health region of their postal code of residence. We allocated patients with no fixed address to the health region of the hospital in which they were tested. We imputed values for the first five weeks of the pandemic by modeling the reported COVID-19 cases that had accumulated in every health region over time using linear interpolation (0.1% missing), COVID-19 case data were not publicly available for the early pandemic. The seven-day moving average incident COVID-19 case count was categorized as 0 - 1.99 per 100,000 population, 2 - 7.99 per 100,000 population, and ≥ 8 per 100,000 population based on the relationship between incidence and COVID-19 positive results in a previous analysis (15).

Outcome:

The primary outcome was a positive NAAT for SARS-CoV-2 in patients admitted with non-COVIDrelated diagnoses.

Data Analysis:

We divided the cohort into two groups, those without symptoms of COVID-19 and those with symptoms compatible with COVID-19 that were attributed to an alternate diagnosis (i.e., CHF, COPD, Asthma, etc.). We considered cough, dyspnea, fever, general weakness, chest pain, diarrhea, nausea and vomiting, headache, chills, myalgia, sore throat, altered level of consciousness, and dysgeusia/anosmia to be COVID-19-compatible symptoms. We used descriptive statistics to describe the population. We

BMJ Open

BMJ Article Template

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

calculated the diagnostic yield by dividing the number of positive NAATs over the total number of NAATs performed. We calculated 7-day average of NAAT positivity over the study period by dividing the number of positive NAATs over all tests performed and averaging over a 7-day period. We calculated the exact binomial proportion 95% confidence intervals (95% CI) for all proportions and used the modified Clopper-Pearson interval for small samples. We completed a planned subgroup analyses for patients presenting with and without COVID compatible symptoms to determine associated factors for a positive test. The initial multivariable logistic regression model to identify factors associated with a positive NAAT considered candidate variables with a p-value cut-off point of 0.20 based on the Wald test from univariable analyses. From the full model, a step-down procedure reduced the model to key predictors based on Akaike's information criterion (AIC) scores (e.g., chose the model with the smallest AIC score). Candidate variables included seven-day moving average incident COVID-19 case count category, patient age, gender, infection risk, and presenting symptoms. We limited the number of predictor variables in the model to one variable for every 10 outcomes in our data to avoid overfitting. Statistical analysis was preformed using Stata (Version 16.1, StataCorp, College Station, Texas).

RESULTS

We identified 19,791 patients admitted to hospital who presented to a participating ED between March 1, 2020, and December 29, 2020 (Figure 1). We excluded 4,101 patients, of which 2,769 had ED diagnoses that were clinically suspicious for COVID-19 and warranted SARS-CoV-2 testing on clinical grounds. The final cohort contained 15,690 patients. During the study period Canada experienced two pandemic waves with the local 7-day average incident case count ranging from between 0 and 42.6 cases per 100,000 population across sites. The 7-day average diagnostic test positivity varied between 0 and 2.9% across sites during the study period (Figure 2).

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

BMJ Article Template

We divided the cohort into two groups, those without any COVID-19 compatible symptoms, and those with COVID-19 compatible symptoms that were attributed to an alternate diagnosis in the ED (Table 1). Most patients arrived from home and were full code. The most common comorbidities were hypertension, diabetes and mental health illness.

Of 3,113 patients admitted without COVID-19 compatible symptoms, 13 (0.4%, 95% CI 0.19% – 0.64%) tested positive for COVID-19. Of the 12,570 with COVID-19-compatible symptoms, 109 patients (0.9%, 95% CI 0.70% – 1.03%) tested positive for COVID-19. Among the 122 individuals who tested positive for COVID-19, 33 (27.0%, 95% CI 19.0% - 35.0%) were from a geographic region that had a moving average daily incident rate of \geq 8 infections per 100,000 population. The diagnostic yield of testing among patients with COVID-19 compatible symptoms admitted for alternative diagnoses did not vary substantially by presenting symptom (Figure 3) or ED diagnosis (Figure 4).

When examining the association between patient factors and screening positive self-reported fever, being a healthcare worker, having a positive household contact or institutional exposure, and being from an area where the seven-day moving average incident COVID-19 case count was \geq 8 per 100,000 population were associate with a greater risk of testing positive. The most important risk factor was reporting a household contact or being the caregiver of a known COVID-19 case.

DISCUSSION

Our aim was to evaluate the diagnostic yield of screening non-COVID-19 admissions for SARS-CoV-2 across Canada in 2020 and identify patient-level risk factors for positive tests. The diagnostic yield of screening patients with non-COVID-19 related ED diagnoses who were admitted to hospital was low overall, and extremely low in patients without COVID compatible symptoms. The most important patient factors associated with a positive test were having a positive household contact, being a healthcare worker, or having had an institutional exposure to COVID-19. Those factors were more important than a high (\geq 8 daily cases per 100,000 population) 7-day moving average incident COVID-19 case count.

BMJ Article Template

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

Our study has several strengths. We used data from a large pan-Canadian registry that enrolls from large geographically and culturally diverse areas and is one of the largest registries in the world. CCEDRRN's patient enrolment and data verification protocols are rigorous, ensuring consecutive eligible patients and high-quality clinical data (13). We have previously demonstrated the inter-rater reliability for our data collection methods, including for symptoms (13).

Prior studies have examined the diagnostic yield of universal screening in single centers with varied diagnostic yield estimates between 0 and 15.5% (3–8). Many of these were case series with limited methods from the early pandemic. There is one known multi-center study which examines the benefit of universal screening for elective and emergent surgical admissions at 14 centers in the Netherlands (1). Like our study, the authors found that the overall COVID-19 NAAT positivity varied with community prevalence. Our finding that positive SARS-CoV-2 tests were associated with self-reported or measured fever is in keeping with a prior Cochrane systematic review that noted considerable variability in COVID-19 associated symptoms (16).

Our study is interesting in the context of current IDSA recommendations which were based on expert opinion and of "very low certainty" (12). The IDSA panel recommended avoiding universal screening for COVID-19 in times and areas of low COVID prevalence, defined as a disease prevalence of under 2%, or fewer than 2,000 active cases per 100,000 population, a threshold so high that it was never met at any of our study sites, even though multiple sites were in COVID-19 hotspots in 2020 (12). The IDSA threshold would have equated to over 6 million cases of active COVID-19 infection in the United States at any given time, which would have vastly overwhelmed hospital capacity, and thus represents an untenable threshold for hospitals. It is therefore not surprising that the prevalence of COVID-19 during the study period was far below the IDSA recommended threshold for initiating screening. While the number needed to screen to identify one positive case among admitted patients in our study was between 110 and 250 among unvaccinated patients, we propose that new screening thresholds need to be adopted which would ideally be based on readily available measures of local incident cases or test positivity.

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

BMJ Article Template

A limitation of our study is that we only considered NAATs and did not consider the diagnostic yield of antigen-based COVID-19 tests, as they were not widespread in Canada in 2020 (16). We were unable to examine the sensitivity and specificity of the SARS-CoV-2 NAATs as we were unable to define false positive tests, so it is possible that some of the positive test results we encountered are false positives, leading to an overestimation of diagnostic yield. Additionally, our study was performed before the newer COVID-19 variants, such as Omicron, circulated widely. However, our methods are easily replicated, and we intend to repeat our study in a recent dataset reflective of new COVID-19 variants. While our study is based on a Canadian population without international sites, we believe our findings are generalizable given their wide geographic spread, and the cultural and racial diversity of our patient population. Finally, as data becomes available on the fourth wave of the pandemic, a future study should examine the impact of widespread vaccination on the yield of screening. As a larger proportion of the population is protected from severe disease and death through vaccination, decision makers should carefully consider the low diagnostic yield of a universal testing strategy going forward.

ACKNOWLEDGEMENTS

We gratefully acknowledge the assistance of Mr. Rajan Bola in the preparation of this manuscript. And we thank the UBC clinical coordinating center staff, the UBC legal, ethics, privacy and contract staff and the research staff at each of the participating institutions in the network outlined in the attached Supplement (Supplement Tables 1-4). The network would not exist today without the dedication of these professionals.

Thank you to all of our patient partners who shared their lived experiences and perspectives to ensure that the knowledge we co-create addresses the concerns of patients and the public. Creating the largest network of collaboration across Canadian Emergency Departments would not have been feasible without the tireless efforts of Emergency Department Chiefs, and research coordinators and research assistants at participating sites. Finally, our most humble and sincere gratitude to our colleagues in medicine, nursing,

BMJ Open

BMJ Article Template

and the allied health professions who have been on the front lines of this pandemic from day one staffing our ambulances, Emergency Departments, hospitals and ICUs bravely facing the risks of COVID-19 to look after our fellow citizens and after one another. We dedicate this network to you.

COMPETING INTERESTS

None identified.

FUNDING

The Canadian Institutes of Health Research (447679), Ontario Ministry of Colleges and Universities (C-655-2129), Saskatchewan Health Research Foundation (5357), Genome BC (COV024) Foundation du CHU de Québec (Octroi No. 4007) and the Public Health Agency of Canada provided peer-reviewed funding. The BC Academic Health Science Network and BioTalent Canada provided non-peer reviewed funding. These organizations are not-for-profit, and had no role in study conduct, analysis, or manuscript preparation.

AUTHOR CONTRIBUTION STATEMENT

All authors conceived and planned the study together, and iteratively refined the study objectives and analytic plan. PH, RJR, ADM, EL and CMH obtained funding for the study. PD, IC, ADM, RD, JT, JK, PRF, MS and BB supervised data collection. JPH analyzed the data under the supervision of RJR. All authors interpreted the analysis. PD drafted the manuscript. All authors were actively involved in reporting out work by revising the manuscript for content. All authors take responsibility for the manuscript as a whole.

BMJ Article Template

DATA SHARING

Data are available upon reasonable request. They can be shared after approval by the Executive Committee through a process outlined on our website (<u>https://www.ccedrrn.com/</u>).

to peer terien ont

Demographics Vertical state Age (mean, SD) 57.6 (22.6) 64.6 (20.4) Female (%) 1,418 (45.6) 5,924 (47.1) Pregnant (%) 491 (15.8) 1,656 (13.2) Illicit substance use (%) 491 (15.8) 1,656 (13.2) Arrival by Ambulance (%) 1,724 (55.4) 7,189 (57.2) Arrival by Ambulance (%) 1,724 (55.4) 7,189 (57.2) Arrival From (%) 217 (7.0) 832 (5.6) Long-term care or rehab facility 219 (6.1) 414 (3.3) Corrections 7 (0.2) 14 (0.1) Interfacility transfer 121 (3.9) 262 (2.1) Risk for Infection (%) 231 (7.4) 721 (5.7) Household contact 28 (0.9) 144 (1.1) Occupational 100 (0.3) 38 (0.3) Unknown 1,502 (48.2) 3,77 (42.8) Pre-ED Gols of Care (%) 1 1,259 (89.5) Intermediate GOC 2946 (94.6) 1,259 (89.5) Intermediate GOC 295 (9.5) 5,72 (4.6) Do not resuscitate 1494 (1.8) <		Patients without COVID-19 symptoms (N=3,113)	Patients with COVID-19 compatible symptoms attributed an alternate diagnosi (N=12,570)
Female (%) 1,418 (45.6) 5,924 (47.1) Pregnant (%) 18 (0.6) 45 (0.4) Tobacco use (%) 491 (15.8) 1,656 (13.2) Illicit substance use (%) 421 (13.5) 967 (7.7) Arrival by Ambulance (%) 1,724 (55.4) 7,189 (57.2) Arrival From (%) 1 10.943 (87.0) Long-term care or rehab facility 217 (7.0) 832 (6.6) Unstable housing* 190 (6.1) 414 (3.3) Corrections 7 (0.2) 14 (0.1) Interfacility transfer 121 (3.9) 262 (2.1) Risk for Infection (%) 231 (7.4) 721 (5.7) Travel 32 (1.0) 134 (1.1) Institutional (LTC/prison) 231 (7.4) 721 (5.7) Household contact 28 (0.9) 144 (1.1) Occupational 10 (0.3) 38 (0.3) Unknown 1,502 (48.2) 5,377 (42.8) Pre-ED Goals of Care (%) 17 1,259 (89.5) Intermediate GOC 18 (0.6) 17,35 (8.4) CTAS 1 (Resuscitation) 241 (7.7) <	Demographics		
Pregnant (%) 18 (0.6) 45 (0.4) Tobacco use (%) 491 (15.8) 1,656 (13.2) Illicit substance use (%) 421 (13.5) 967 (7.7) Arrival by Ambulance (%) 1,724 (55.4) 7,189 (57.2) Arrival From (%) 217 (7.0) 832 (6.6) Unstable housing* 190 (6.1) 414 (3.3) Corrections 7 (0.2) 14 (0.1) Interfacility transfer 121 (3.9) 262 (2.1) Risk for Infection (%) T T Travel 32 (1.0) 134 (1.1) Institutional (LTC/prison) 231 (7.4) 721 (5.7) Household contact 28 (0.9) 144 (1.1) Occupational 10 (0.3) 38 (0.3) Unknown 1,502 (48.2) 5,377 (42.8) Pre-ED Goals of Care (%) T T Full code 1,946 (94.6) 11,259 (89.5) Intermediate GOC 18 (0.6) 173 (1.4) Do not resuscitate 149 (4.8) 1,142 (9.1) Acuity 5,086 (40.4) 5,786 (46.0) <td< td=""><td>Age (mean, SD)</td><td>57.6 (22.6)</td><td>64.6 (20.4)</td></td<>	Age (mean, SD)	57.6 (22.6)	64.6 (20.4)
Tobacco use (%) 491 (15.8) 1,656 (13.2) Illicit substance use (%) 421 (13.5) 967 (7.7) Arrival by Ambulance (%) 1,724 (55.4) 7,189 (57.2) Arrival From (%) U U Home 2,552 (82.0) 10,943 (87.0) Long-term care or rehab facility 217 (7.0) 832 (6.6) Unstable housing* 190 (6.1) 414 (3.3) Corrections 7 (0.2) 14 (0.1) Interfacility transfer 121 (3.9) 262 (2.1) Risk for Infection (%) T T Travel 32 (1.0) 134 (1.1) Institutional (LTC/prison) 231 (7.4) 721 (5.7) Household contact 28 (0.9) 144 (1.1) Occupational 10 (0.3) 38 (0.3) Unknown 1,502 (48.2) 5,377 (42.8) Pre-ED Goals of Care (%) T T Fuil code 1,904 (9.4) 1,142 (9.1) Acuty 11,259 (89.5) 572 (42.9) Acuty 1,340 (29.1) 5,786 (46.0) CTAS 1 (Res	Female (%)	1,418 (45.6)	5,924 (47.1)
Illicit substance use (%) 421 (13.5) 967 (7.7) Arrival by Ambulance (%) 1,724 (55.4) 7,189 (57.2) Arrival From (%) Home 2,552 (82.0) 10,943 (87.0) Long-term care or rehab facility 217 (7.0) 832 (6.6) Unstable housing* 190 (6.1) 414 (3.3) Corrections 7 (0.2) 14 (0.1) Interfacility transfer 121 (3.9) 262 (2.1) Risk for Infection (%) Travel 32 (1.0) 134 (1.1) Institutional (LTC/prison) 231 (7.4) 721 (5.7) Household contact 28 (0.9) 144 (1.1) Occupational 10 (0.3) 38 (0.3) Unknown 1,502 (48.2) 5,377 (42.8) Pre-ED Goals of Care (%) 11,259 (89.5) Intermediate GOC 18 (0.6) 173 (1.4) Do not resuscitate 1,949 (48.2) 1,949 (49.1) Actity 1,527 (49.1) 5,086 (40.4) CTAS 1 (Resuscitation) 241 (7.7) 1,053 (8.4)	Pregnant (%)	18 (0.6)	45 (0.4)
Arrival by Ambulance (%) 1,724 (55.4) 7,189 (57.2) Arrival From (%) Home 2,552 (82.0) 10,943 (87.0) Long-term care or rehab facility 217 (7.0) 832 (6.6) Unstable housing* 190 (6.1) 414 (3.3) Corrections 7 (0.2) 14 (0.1) Interfacility transfer 121 (3.9) 262 (2.1) Risk for Infection (%) Travel 32 (1.0) 134 (1.1) Institutional (LTC/prison) 231 (7.4) 721 (5.7) Household contact 28 (0.9) 144 (1.1) Occupational 10 (0.3) 38 (0.3) Unknown 1,502 (48.2) 5,377 (42.8) Pre-ED Goals of Care (%) 11,259 (89.5) Intermediate GOC 18 (0.6) 11,259 (89.5) Intermediate GOC 149 (4.8) 1,142 (9.1) Actity 1,142 (9.1) 5,086 (40.0) CTAS 1 (Resuscitation) 241 (7.7) 1,053 (8.4) CTAS 1 (Resuscitation) 241 (7.7) 5,086 (40.0) CTAS 3 (Urgent) 5,257 (49.1) 5,086 (40.0) CT	Tobacco use (%)	491 (15.8)	1,656 (13.2)
Arrival From (%) Image: Signal S	Illicit substance use (%)	421 (13.5)	967 (7.7)
Home 2,552 (82.0) 10,943 (87.0) Long-term care or rehab facility 217 (7.0) 832 (6.6) Unstable housing* 190 (6.1) 414 (3.3) Corrections 7 (0.2) 14 (0.1) Interfacility transfer 221 (3.9) 262 (2.1) Risk for Infection (%) Travel 32 (1.0) 134 (1.1) Institutional (LTC/prison) 231 (7.4) 721 (5.7) Household contact 28 (0.9) 144 (1.1) Occupational 10 (0.3) 38 (0.3) Unknown 1,502 (48.2) 5,377 (42.8) Pre-ED Goals of Care (%) F F Full code 2,946 (94.6) 11,259 (89.5) Intermediate GOC 18 (0.6) 173 (1.4) Do not resuscitate 149 (4.8) 1,142 (9.1) Acuity 1 1,053 (8.4) CTAS 1 (Resuscitation) 241 (7.7) 1,053 (8.4) CTAS 2 (Emergent) 1,000 (32.1) 5,786 (46.0) CTAS 3 (Urgent) 1,527 (49.1) 5,086 (40.4) CTAS 4 (Less Urgent) 295 (9.5)	Arrival by Ambulance (%)	1,724 (55.4)	7,189 (57.2)
Long-term care or rehab facility 217 (7.0) 832 (6.6) Unstable housing* 190 (6.1) 414 (3.3) Corrections 7 (0.2) 14 (0.1) Interfacility transfer 121 (3.9) 262 (2.1) Risk for Infection (%) 217 (7.4) 721 (5.7) Household contact 28 (0.9) 144 (1.1) Occupational 10 (0.3) 38 (0.3) Unknown 1,502 (48.2) 5,377 (42.8) Pre-ED Goals of Care (%) 11,259 (89.5) Full code 2,946 (94.6) 11,259 (89.5) Intermediate GOC 18 (0.6) 173 (1.4) Do not resuscitate 149 (4.8) 1,142 (9.1) Acuity 1,053 (8.4) 1,142 (9.1) Acuity 1,527 (49.1) 5,086 (40.4) CTAS 1 (Resuscitation) 241 (7.7) 1,053 (8.4) CTAS 4 (Less Urgent) 295 (9.5) 572 (4.6) CTAS 4 (Less Urgent) 295 (9.5) 572 (4.6) CTAS 5 (Non Urgent) 91.2 (21.2) 95.5 (23.9) Systolic BP, mm Hg 134.7 (25.1) 133.6 (27.9)	Arrival From (%)		
Unstable housing* 190 (6.1) 414 (3.3) Corrections 7 (0.2) 14 (0.1) Interfacility transfer 121 (3.9) 262 (2.1) Risk for Infection (%) Travel 32 (1.0) 134 (1.1) Institutional (LTC/prison) 231 (7.4) 721 (5.7) Household contact 28 (0.9) 144 (1.1) Occupational 10 (0.3) 38 (0.3) Unknown 1,502 (48.2) 5,377 (42.8) Pre-ED Goals of Care (%) T T Full code 2,946 (94.6) 11,259 (89.5) Intermediate GOC 18 (0.6) 173 (1.4) Do not resuscitate 149 (4.8) 1,142 (9.1) Acuity 5,786 (46.0) CTAS 1 (Resuscitation) 241 (7.7) 1,053 (8.4) CTAS 2 (Emergent) 1,000 (32.1) 5,786 (46.0) CTAS 3 (Urgent) 295 (9.5) 572 (4.6) CTAS 4 (Less Urgent) 295 (9.5) 572 (4.6) CTAS 5 (Non Urgent) 40 (1.3) 59 (0.5) Arrival Vital Signs, Mean (SD) 54 55	Home	2,552 (82.0)	10,943 (87.0)
Corrections7 (0.2)14 (0.1)Interfacility transfer121 (3.9)262 (2.1)Risk for Infection (%) $121 (3.9)$ 262 (2.1)Travel32 (1.0)134 (1.1)Institutional (LTC/prison)231 (7.4)721 (5.7)Household contact28 (0.9)144 (1.1)Occupational10 (0.3)38 (0.3)Unknown1,502 (48.2)5,377 (42.8)Pre-ED Goals of Care (%) $11,259 (89.5)$ Full code149 (4.8)1,142 (9.1)Acuity $149 (4.8)$ 1,142 (9.1)CTAS 1 (Resuscitation)241 (7.7)1,053 (8.4)CTAS 2 (Emergent)1,000 (32.1)5,786 (46.0)CTAS 3 (Urgent)1,527 (49.1)5,086 (40.4)CTAS 4 (Less Urgent)295 (9.5)572 (4.6)CTAS 5 (Non Urgent)40 (1.3)59 (0.5)Arrival Vital Signs, Mean (SD) $Heart Rate, beats per min91.2 (21.2)Heart Rate, beats per min91.2 (21.2)95.5 (23.9)Systolic BP, mm Hg134.7 (25.1)133.6 (27.9)Oxygen saturation, (%)96.6 (3.4)95.7 (4.1)Respiratory Rate, beats per min18.6 (4.4)21.2 (6.3)Temperature, degrees Celsius36.6 (0.6)36.8 (0.9)Combridities (%)55.1 (42.3)73.2 (42.3)Hypertension951 (30.6)5,321 (42.3)Psychiatric Condition728 (23.4)2,134 (17.0)Dyslipidemia425 (13.6)2,434 (19.4)Diabetes427 (13.7)2,577 (20.5)$	Long-term care or rehab facility	217 (7.0)	832 (6.6)
Interfacility transfer 121 (3.9) 262 (2.1) Risk for Infection (%) Travel 32 (1.0) 134 (1.1) Institutional (LTC/prison) 231 (7.4) 721 (5.7) Household contact 28 (0.9) 144 (1.1) Occupational 10 (0.3) 38 (0.3) Unknown 1,502 (48.2) 5,377 (42.8) Pre-ED Goals of Care (%) T T Full code 2,946 (94.6) 11,259 (89.5) Intermediate GOC 18 (0.6) 173 (1.4) Do not resuscitate 149 (4.8) 1,142 (9.1) Acuity CTAS 1 (Resuscitation) 241 (7.7) 1,053 (8.4) CTAS 2 (Emergent) 1,000 (32.1) 5,786 (46.0) CTAS 3 (Urgent) 1,527 (49.1) 5,086 (40.4) CTAS 4 (Less Urgent) 295 (9.5) 572 (4.6) CTAS 5 (Non Urgent) 40 (1.3) 59 (0.5) Arrival Vital Signs, Mean (SD) Heart Rate, beats per min 91.2 (21.2) 95.5 (23.9) Systolic BP, mm Hg 134.7 (25.1) 133.6 (27.9) 0xygen saturation, (%) 96.6 (3.4) 21.2 (Unstable housing*	190 (6.1)	414 (3.3)
Risk for Infection (%) 32 (1.0) 134 (1.1) Institutional (LTC/prison) 231 (7.4) 721 (5.7) Household contact 28 (0.9) 144 (1.1) Occupational 10 (0.3) 38 (0.3) Unknown 1,502 (48.2) 5,377 (42.8) Pre-ED Goals of Care (%) Full code 2,946 (94.6) 11,259 (89.5) Intermediate GOC 18 (0.6) 173 (1.4) Do not resuscitate 149 (4.8) 1,142 (9.1) Acuity 726 (46.0) CTAS 1 (Resuscitation) 241 (7.7) 1,053 (8.4) CTAS 2 (Emergent) 1,000 (32.1) 5,786 (46.0) CTAS 3 (Urgent) 255 (9.5) 572 (4.6) CTAS 5 (Non Urgent) 295 (9.5) 572 (4.6) CTAS 5 (Non Urgent) 40 (1.3) 59 (0.5) Arrival Vital Signs, Mean (SD) Heart Rate, beats per min 91.2 (21.2) 95.5 (23.9) Systolic BP, mm Hg 134.7 (25.1) 133.6 (27.9) Oxygen saturation, (%) 96.6 (3.4)	Corrections	7 (0.2)	14 (0.1)
Travel 32 (1.0) 134 (1.1) Institutional (LTC/prison) 231 (7.4) 721 (5.7) Household contact 28 (0.9) 144 (1.1) Occupational 10 (0.3) 38 (0.3) Unknown 1,502 (48.2) 5,377 (42.8) Pre-ED Goals of Care (%) 11,259 (89.5) Full code 2,946 (94.6) 11,259 (89.5) Intermediate GOC 18 (0.6) 173 (1.4) Do not resuscitate 149 (4.8) 1,142 (9.1) Acuity 7142.8 1,000 (32.1) 5,786 (46.0) CTAS 1 (Resuscitation) 241 (7.7) 1,053 (8.4) 5,786 (46.0) CTAS 2 (Emergent) 1,000 (32.1) 5,786 (46.0) 5,7286 (46.0) CTAS 3 (Urgent) 295 (9.5) 572 (4.6) 572 (4.6) CTAS 5 (Non Urgent) 40 (1.3) 59 (0.5) 572 (4.6) Arrival Vital Signs, Mean (SD) 133.6 (27.9) 95.5 (23.9) 53.5 (23.9) Systolic BP, mm Hg 134.7 (25.1) 133.6 (27.9) 0xygen saturation, (%) 96.6 (3.4) 95.7 (4.1) Respiratory Rate, beats per min 18.6 (4.4) 21.2 (6.3) 18.6 (4.4) 21.2 (6.3)	Interfacility transfer	121 (3.9)	262 (2.1)
Institutional (LTC/prison) 231 (7.4) 721 (5.7) Household contact 28 (0.9) 144 (1.1) Occupational 10 (0.3) 38 (0.3) Unknown 1,502 (48.2) 5,377 (42.8) Pre-ED Goals of Care (%) Full code 2,946 (94.6) 11,259 (89.5) Intermediate GOC 18 (0.6) 173 (1.4) Do not resuscitate 149 (4.8) 1,142 (9.1) Acuity 5,786 (46.0) CTAS 1 (Resuscitation) 241 (7.7) 1,053 (8.4) CTAS 2 (Emergent) 1,000 (32.1) 5,786 (46.0) CTAS 3 (Urgent) 295 (9.5) 572 (4.6) CTAS 4 (Less Urgent) 295 (9.5) 572 (4.6) CTAS 5 (Non Urgent) 40 (1.3) 59 (0.5) Arrival Vital Sign, Mean (SD) Heart Rate, beats per min 91.2 (21.2) 95.5 (23.9) Systolic BP, mm Hg 134.7 (25.1) 133.6 (27.9) Oxygen saturation, (%) 96.6 (3.4) 95.7 (4.1) Respiratory Rate, beats per min 18.6 (4.4	Risk for Infection (%)		
Household contact 28 (0.9) 144 (1.1) Occupational 10 (0.3) 38 (0.3) Unknown 1,502 (48.2) 5,377 (42.8) Pre-ED Goals of Care (%) Full code 2,946 (94.6) 11,259 (89.5) Intermediate GOC 18 (0.6) 173 (1.4) Do not resuscitate 149 (4.8) 1,142 (9.1) Acuity CTAS 1 (Resuscitation) 241 (7.7) 1,053 (8.4) CTAS 2 (Emergent) 1,000 (32.1) 5,786 (46.0) CTAS 3 (Urgent) 1,527 (49.1) 5,086 (40.4) CTAS 4 (Less Urgent) 295 (9.5) 572 (4.6) CTAS 5 (Non Urgent) 40 (1.3) 59 (0.5) Arrival Vital Signs, Mean (SD) Heart Rate, beats per min 91.2 (21.2) 95.5 (23.9) Systolic BP, mm Hg 134.7 (25.1) 133.6 (27.9) Oxygen saturation, (%) 96.6 (3.4) 95.7 (4.1) Respiratory Rate, beats per min 18.6 (4.4) 21.2 (6.3) Temperature, degrees Celsius 36.6 (0.6) 36.8 (0.9) Comorbidities (%)	Travel	32 (1.0)	134 (1.1)
Occupational 10 (0.3) 38 (0.3) Unknown 1,502 (48.2) 5,377 (42.8) Pre-ED Goals of Care (%)	Institutional (LTC/prison)	231 (7.4)	721 (5.7)
Unknown 1,502 (48.2) 5,377 (42.8) Pre-ED Goals of Care (%) Full code 2,946 (94.6) 11,259 (89.5) Intermediate GOC 18 (0.6) 173 (1.4) Do not resuscitate 149 (4.8) 1,142 (9.1) Acuity CTAS 1 (Resuscitation) 241 (7.7) 1,053 (8.4) CTAS 2 (Emergent) 1,000 (32.1) 5,786 (46.0) CTAS 3 (Urgent) 1,527 (49.1) 5,086 (40.4) CTAS 4 (Less Urgent) 295 (9.5) 572 (4.6) CTAS 5 (Non Urgent) 295 (9.5) 572 (4.6) CTAS 5 (Non Urgent) 40 (1.3) 59 (0.5) Arrival Vital Signs, Mean (SD) Heart Rate, beats per min 91.2 (21.2) 95.5 (23.9) Systolic BP, mm Hg 134.7 (25.1) 133.6 (27.9) 0xygen saturation, (%) 96.6 (3.4) 95.7 (4.1) Respiratory Rate, beats per min 18.6 (4.4) 11.2 (6.3) 12.8 (6.3) Temperature, degrees Celsius 36.6 (0.6) 36.8 (0.9) 0xygen saturation, (%) 951 (30.6) 5,321 (42.3) Psychiatric Condition 728 (23.4) 2,134 (17.0) 2,434 (19.4)	Household contact	28 (0.9)	144 (1.1)
Pre-ED Goals of Care (%) Intermediate GOC 11,259 (89.5) Intermediate GOC 18 (0.6) 173 (1.4) Do not resuscitate 149 (4.8) 1,142 (9.1) Acuity Intermediate GOC 1,000 (32.1) 5,786 (46.0) CTAS 1 (Resuscitation) 241 (7.7) 1,053 (8.4) 5,786 (46.0) CTAS 2 (Emergent) 1,000 (32.1) 5,786 (46.0) 5,786 (40.4) CTAS 3 (Urgent) 295 (9.5) 572 (4.6) 572 (4.6) CTAS 5 (Non Urgent) 40 (1.3) 59 (0.5) 572 (4.6) Arrival Vital Signs, Mean (SD) Part Rate, beats per min 91.2 (21.2) 95.5 (23.9) Systolic BP, mm Hg 134.7 (25.1) 133.6 (27.9) 0xygen saturation, (%) 96.6 (3.4) 95.7 (4.1) Respiratory Rate, beats per min 18.6 (4.4) 21.2 (6.3) 12.2 (6.3) 12.2 (6.3) Temperature, degrees Celsius 36.6 (0.6) 36.8 (0.9) 0 0 Comorbidities (%) Pupertension 951 (30.6) 5,321 (42.3) 9 Psychiatric Condition 728 (23.4) 2,134 (17.0) 2,937 (20.5	Occupational	10 (0.3)	38 (0.3)
Full code 2,946 (94.6) 11,259 (89.5) Intermediate GOC 18 (0.6) 173 (1.4) Do not resuscitate 149 (4.8) 1,142 (9.1) Acuity 1,000 (32.1) 5,786 (46.0) CTAS 1 (Resuscitation) 241 (7.7) 1,053 (8.4) CTAS 2 (Emergent) 1,000 (32.1) 5,786 (46.0) CTAS 3 (Urgent) 1,527 (49.1) 5,086 (40.4) CTAS 4 (Less Urgent) 295 (9.5) 572 (4.6) CTAS 5 (Non Urgent) 40 (1.3) 59 (0.5) Arrival Vital Signs, Mean (SD) Heart Rate, beats per min 91.2 (21.2) 95.5 (23.9) Systolic BP, mm Hg 134.7 (25.1) 133.6 (27.9) Oxygen saturation, (%) 96.6 (3.4) 95.7 (4.1) Respiratory Rate, beats per min 18.6 (4.4) 21.2 (6.3) Temperature, degrees Celsius 36.6 (0.6) 36.8 (0.9) Comorbidities (%) Hypertension 951 (30.6) 5,321 (42.3) Psychiatric Condition 728 (23.4) 2,134 (17.0) Dyslipidemia 425 (13.6) 2,434 (19.4)	Unknown	1,502 (48.2)	5,377 (42.8)
Intermediate GOC 18 (0.6) 173 (1.4) Do not resuscitate 149 (4.8) 1,142 (9.1) Acuity	Pre-ED Goals of Care (%)		
Do not resuscitate149 (4.8)1,142 (9.1)Acuity	Full code	2,946 (94.6)	11,259 (89.5)
Acuity 1,053 (8.4) CTAS 1 (Resuscitation) 241 (7.7) 1,053 (8.4) CTAS 2 (Emergent) 1,000 (32.1) 5,786 (46.0) CTAS 3 (Urgent) 1,527 (49.1) 5,086 (40.4) CTAS 4 (Less Urgent) 295 (9.5) 572 (4.6) CTAS 5 (Non Urgent) 40 (1.3) 59 (0.5) Arrival Vital Signs, Mean (SD) 744.1 Heart Rate, beats per min 91.2 (21.2) 95.5 (23.9) Systolic BP, mm Hg 134.7 (25.1) 133.6 (27.9) Oxygen saturation, (%) 96.6 (3.4) 95.7 (4.1) Respiratory Rate, beats per min 18.6 (4.4) 21.2 (6.3) Temperature, degrees Celsius 36.6 (0.6) 36.8 (0.9) Comorbidities (%) 951 (30.6) 5,321 (42.3) Psychiatric Condition 728 (23.4) 2,134 (17.0) Dyslipidemia 425 (13.6) 2,434 (19.4) Diabetes 427 (13.7) 2,577 (20.5)	Intermediate GOC	18 (0.6)	173 (1.4)
CTAS 1 (Resuscitation)241 (7.7)1,053 (8.4)CTAS 2 (Emergent)1,000 (32.1)5,786 (46.0)CTAS 3 (Urgent)1,527 (49.1)5,086 (40.4)CTAS 4 (Less Urgent)295 (9.5)572 (4.6)CTAS 5 (Non Urgent)40 (1.3)59 (0.5)Arrival Vital Signs, Mean (SD)Heart Rate, beats per min91.2 (21.2)95.5 (23.9)Systolic BP, mm Hg134.7 (25.1)133.6 (27.9)Oxygen saturation, (%)96.6 (3.4)95.7 (4.1)Respiratory Rate, beats per min18.6 (4.4)21.2 (6.3)Temperature, degrees Celsius36.6 (0.6)36.8 (0.9)Comorbidities (%)Hypertension951 (30.6)5,321 (42.3)Psychiatric Condition728 (23.4)2,134 (17.0)Dyslipidemia425 (13.6)2,434 (19.4)Diabetes427 (13.7)2,577 (20.5)	Do not resuscitate	149 (4.8)	1,142 (9.1)
CTAS 2 (Emergent)1,000 (32.1)5,786 (46.0)CTAS 3 (Urgent)1,527 (49.1)5,086 (40.4)CTAS 4 (Less Urgent)295 (9.5)572 (4.6)CTAS 5 (Non Urgent)40 (1.3)59 (0.5)Arrival Vital Signs, Mean (SD)Heart Rate, beats per min91.2 (21.2)95.5 (23.9)Systolic BP, mm Hg134.7 (25.1)133.6 (27.9)Oxygen saturation, (%)96.6 (3.4)95.7 (4.1)Respiratory Rate, beats per min18.6 (4.4)21.2 (6.3)Temperature, degrees Celsius36.6 (0.6)36.8 (0.9)Comorbidities (%)Hypertension951 (30.6)5,321 (42.3)Psychiatric Condition728 (23.4)2,134 (17.0)Dyslipidemia425 (13.6)2,434 (19.4)Diabetes427 (13.7)2,577 (20.5)	Acuity		
CTAS 3 (Urgent)1,527 (49.1)5,086 (40.4)CTAS 4 (Less Urgent)295 (9.5)572 (4.6)CTAS 5 (Non Urgent)40 (1.3)59 (0.5)Arrival Vital Signs, Mean (SD)Heart Rate, beats per min91.2 (21.2)95.5 (23.9)Systolic BP, mm Hg134.7 (25.1)133.6 (27.9)Oxygen saturation, (%)96.6 (3.4)95.7 (4.1)Respiratory Rate, beats per min18.6 (4.4)21.2 (6.3)Temperature, degrees Celsius36.6 (0.6)36.8 (0.9)Comorbidities (%)Hypertension951 (30.6)5,321 (42.3)Psychiatric Condition728 (23.4)2,134 (17.0)Dyslipidemia425 (13.6)2,434 (19.4)Diabetes427 (13.7)2,577 (20.5)	CTAS 1 (Resuscitation)	241 (7.7)	1,053 (8.4)
CTAS 4 (Less Urgent)295 (9.5)572 (4.6)CTAS 5 (Non Urgent)40 (1.3)59 (0.5)Arrival Vital Signs, Mean (SD)Heart Rate, beats per min91.2 (21.2)95.5 (23.9)Systolic BP, mm Hg134.7 (25.1)133.6 (27.9)Oxygen saturation, (%)96.6 (3.4)95.7 (4.1)Respiratory Rate, beats per min18.6 (4.4)21.2 (6.3)Temperature, degrees Celsius36.6 (0.6)36.8 (0.9)Comorbidities (%)Hypertension951 (30.6)5,321 (42.3)Psychiatric Condition728 (23.4)2,134 (17.0)Dyslipidemia425 (13.6)2,434 (19.4)Diabetes427 (13.7)2,577 (20.5)	CTAS 2 (Emergent)	1,000 (32.1)	· · · · ·
CTAS 5 (Non Urgent)40 (1.3)59 (0.5)Arrival Vital Signs, Mean (SD)Heart Rate, beats per min91.2 (21.2)95.5 (23.9)Systolic BP, mm Hg134.7 (25.1)133.6 (27.9)Oxygen saturation, (%)96.6 (3.4)95.7 (4.1)Respiratory Rate, beats per min18.6 (4.4)21.2 (6.3)Temperature, degrees Celsius36.6 (0.6)36.8 (0.9)Comorbidities (%)Hypertension951 (30.6)5,321 (42.3)Psychiatric Condition728 (23.4)2,134 (17.0)Dyslipidemia425 (13.6)2,434 (19.4)Diabetes427 (13.7)2,577 (20.5)			
Arrival Vital Signs, Mean (SD) Heart Rate, beats per min 91.2 (21.2) 95.5 (23.9) Systolic BP, mm Hg 134.7 (25.1) 133.6 (27.9) Oxygen saturation, (%) 96.6 (3.4) 95.7 (4.1) Respiratory Rate, beats per min 18.6 (4.4) 21.2 (6.3) Temperature, degrees Celsius 36.6 (0.6) 36.8 (0.9) Comorbidities (%) Hypertension 951 (30.6) 5,321 (42.3) Psychiatric Condition 728 (23.4) 2,134 (17.0) Dyslipidemia 425 (13.6) 2,434 (19.4) Diabetes 427 (13.7) 2,577 (20.5)			
Heart Rate, beats per min91.2 (21.2)95.5 (23.9)Systolic BP, mm Hg134.7 (25.1)133.6 (27.9)Oxygen saturation, (%)96.6 (3.4)95.7 (4.1)Respiratory Rate, beats per min18.6 (4.4)21.2 (6.3)Temperature, degrees Celsius36.6 (0.6)36.8 (0.9)Comorbidities (%)Hypertension951 (30.6)5,321 (42.3)Psychiatric Condition728 (23.4)2,134 (17.0)Dyslipidemia425 (13.6)2,434 (19.4)Diabetes427 (13.7)2,577 (20.5)		40 (1.3)	59 (0.5)
Systolic BP, mm Hg 134.7 (25.1) 133.6 (27.9) Oxygen saturation, (%) 96.6 (3.4) 95.7 (4.1) Respiratory Rate, beats per min 18.6 (4.4) 21.2 (6.3) Temperature, degrees Celsius 36.6 (0.6) 36.8 (0.9) Comorbidities (%) Hypertension 951 (30.6) 5,321 (42.3) Psychiatric Condition 728 (23.4) 2,134 (17.0) Dyslipidemia 425 (13.6) 2,434 (19.4) Diabetes 427 (13.7) 2,577 (20.5)			
Oxygen saturation, (%)96.6 (3.4)95.7 (4.1)Respiratory Rate, beats per min18.6 (4.4)21.2 (6.3)Temperature, degrees Celsius36.6 (0.6)36.8 (0.9)Comorbidities (%)Hypertension951 (30.6)5,321 (42.3)Psychiatric Condition728 (23.4)2,134 (17.0)Dyslipidemia425 (13.6)2,434 (19.4)Diabetes427 (13.7)2,577 (20.5)	•		
Respiratory Rate, beats per min18.6 (4.4)21.2 (6.3)Temperature, degrees Celsius36.6 (0.6)36.8 (0.9)Comorbidities (%)951 (30.6)5,321 (42.3)Hypertension951 (23.4)2,134 (17.0)Psychiatric Condition728 (23.4)2,134 (17.0)Dyslipidemia425 (13.6)2,434 (19.4)Diabetes427 (13.7)2,577 (20.5)	Systolic BP, mm Hg		
Temperature, degrees Celsius36.6 (0.6)36.8 (0.9)Comorbidities (%)951 (30.6)5,321 (42.3)Hypertension951 (30.6)5,321 (42.3)Psychiatric Condition728 (23.4)2,134 (17.0)Dyslipidemia425 (13.6)2,434 (19.4)Diabetes427 (13.7)2,577 (20.5)			. ,
Comorbidities (%)951 (30.6)5,321 (42.3)Hypertension951 (30.6)5,321 (42.3)Psychiatric Condition728 (23.4)2,134 (17.0)Dyslipidemia425 (13.6)2,434 (19.4)Diabetes427 (13.7)2,577 (20.5)			
Hypertension951 (30.6)5,321 (42.3)Psychiatric Condition728 (23.4)2,134 (17.0)Dyslipidemia425 (13.6)2,434 (19.4)Diabetes427 (13.7)2,577 (20.5)	• • -	36.6 (0.6)	36.8 (0.9)
Psychiatric Condition728 (23.4)2,134 (17.0)Dyslipidemia425 (13.6)2,434 (19.4)Diabetes427 (13.7)2,577 (20.5)			
Dyslipidemia425 (13.6)2,434 (19.4)Diabetes427 (13.7)2,577 (20.5)			
Diabetes 427 (13.7) 2,577 (20.5)	•		
Chronic Neuro Disorder 322 (10.3) 1,406 (11.2)			

Coronary Artery Disease	284 (9.1)	1,796 (14.3)
Rheumatologic Disorder	229 (7.4)	1,249 (9.9)
Dementia	199 (6.4)	696 (5.5)
Active Cancer	231 (7.4)	1,647 (12.9)
Chronic Kidney Disease	195 (6.3)	1,319 (10.5)
Chronic Lung Disease (not asthma)	199 (6.4)	1,691 (13.5)
Congestive Heart Failure	159 (5.1)	1,392 (11.1)
Asthma	125 (4.0)	712 (5.7)
Obesity	57 (1.8)	344 (2.7)
Symptoms (%)		
Cough	-	2,763 (22.0)
Dyspnea	-	4,757 (37.8)
Fever	-	2,531 (20.1)
General Weakness	-	3,183 (25.3)
Chest Pain	-	2,714 (21.6)
Diarrhea	-	1,339 (10.7)
Nausea/Vomiting	-	3,345 (26.6)
Headache	-	784 (6.2)
Chills	-	957 (7.6)
Myalgia	V -	466 (3.7)
Sore Throat	-	374 (3.0)
Altered Consciousness	-	2,502 (19.9)
Dysgusea/Anosmia		41 (0.3)
ED Diagnosis (%)		
Respiratory Disease, not specified	8 (0.3)	118 (0.9)
COPD Exacerbation	11 (0.4)	648 (5.2)
Asthma Exacerbation	<5	97 (0.8)
Congestive Heart Failure	44 (1.4)	1,003 (8.0)
Shortness of Breath, NYD*	- 7	466 (3.6)
Cough, NYD*	_	63 (0.5)
Fever, NYD*	-	482 (3.8)
Outcome (%)		
Positive SARS-CoV-2 NAAT	13 (0.4)	109 (0.9)

	Univariate analysis odds ratio (95% CI)	Final model with fully adjusted odds ratio (95% Cl) ¹	P-value
Sex			
Male	Reference	Reference	0.18
Female	0.84 (0.59 – 1.21)	0.78 (0.54 – 1.12)	
Age			
	1.00 (1.00 – 1.02)	1.00 (0.99 – 1.01)	0.27
7-day average incident COVID-19 cases			
0 – 1.99 daily cases per 100,000 population	Reference	Reference	< 0.001
2 to 7.99 daily cases per 100,000 population	1.42 (0.91 – 2.22)	1.47 (0.94 – 2.31)	
≥8 daily cases per 100,000 population	2.99 (1.95 – 4.59)	3.17 (2.05 – 4.89)	
COVID-19 compatible symptoms present			
No	Reference	Reference	0.08
Yes	2.08 (1.71 – 3.71)	1.65 (0.90 – 3.00)	
Self-reported fever, or temperature ≥ 37.5 °C			
No	Reference	Reference	< 0.001
Yes	2.72 (1.89 – 3.90)	2.53 (1.74 – 3.67)	
Diarrhea present			
No	Reference	Reference	0.11
Yes	1.74 (1.04 – 2.92)	1.57 (0.93 – 2.67)	
Healthcare worker			
No	Reference	Reference	0.06
Yes	5.62 (1.35 – 23.43)	4.67 (1.05 – 20.54)	
Household contact or caregiver		D (
No	Reference	Reference	< 0.001
Yes	9.48 (5.01 – 17.96)	7.74 (3.98 – 15.04)	
Institutional exposure	Defenses	Deference	10.001
No	Reference	Reference	< 0.001
Yes	3.46 (2.17 – 5.52)	3.39 (2.10 – 5.47)	
Dysgeusia or anosmia present	Reference		
No Yes	3.21 (0.43 – 23.52)	-	
Dyspnea present	5.21 (0.45 - 23.52)	-	
No	Reference		
Yes	1.16 (0.80 – 1.70)	_	
Nausea or vomiting present	1.10 (0.80 - 1.70)	-	
No	Reference	_	
Yes	0.81 (0.51 – 1.29)	-	
	0.01 (0.31 - 1.23)		

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

BMJ Article Template

¹ Final model determined by including variables with a p-value of p<0.20 during the sex and age adjusted analysis, and using the Akaike Information Criterion (AIC) to determine additional variables to exclude from the final model. Variables adjusted for all other variables present in the final model

<text>

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

Figure 1: Patient Flow Diagram

Figure 2: 7-day working average of COVID-19 NAAT positivity over the study period across sites.

Figure 3: Diagnostic Yield by Presenting Symptoms

Figure 4: Diagnostic Yield by ED Diagnosis

ETHICAL APPROVAL STATEMENT

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

BMJ Article Template

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml


The research ethics boards of all participating institutions approved this study with a waiver of informed consent for data collection and linkage (UBC REB: H20-01015). to peer terien only

REFERENCES


- 1. Puylaert CAJ, Scheijmans JCG, Borgstein ABJ, Andeweg CS, Bartels-Rutten A, Beets GL, et al. Yield of Screening for COVID-19 in Asymptomatic Patients Before Elective or Emergency Surgery Using Chest CT and RT-PCR (SCOUT): Multicenter Study. Ann Surg. 2020 Dec;272(6):919–24.
- 2. Sutton D, Fuchs K, D'Alton M, Goffman D. Universal Screening for SARS-CoV-2 in Women Admitted for Delivery. N Engl J Med. 2020 May 28;382(22):2163–4.
- 3. Ravani P, Saxinger L, Chandran U, Fonseca K, Murphy S, Lang E, et al. COVID-19 screening of asymptomatic patients admitted through emergency departments in Alberta: a prospective quality-improvement study. CMAJ Open. 2020 Oct;8(4):E887–94.
- 4. Goldfarb IT, Diouf K, Barth WH, Robinson JN, Katz D, Gregory KE, et al. Universal SARS-CoV-2 testing on admission to the labor and delivery unit: Low prevalence among asymptomatic obstetric patients. Infect Control Hosp Epidemiol. 2020 Sep;41(9):1095–6.
- Ossami Saidy RR, Globke B, Pratschke J, Schoening W, Eurich D. Successful implementation of preventive measures leads to low relevance of SARS-CoV-2 in liver transplant patients: Observations from a German outpatient department. Transpl Infect Dis [Internet]. 2020 Dec [cited 2021 Aug 9];22(6). Available from: https://onlinelibrary.wiley.com/doi/10.1111/tid.13363
- 6. Gruskay JA, Dvorzhinskiy A, Konnaris MA, LeBrun DG, Ghahramani GC, Premkumar A, et al. Universal Testing for COVID-19 in Essential Orthopaedic Surgery Reveals a High Percentage of Asymptomatic Infections. J Bone Jt Surg. 2020 Aug 19;102(16):1379–88.
- London V, McLaren R, Atallah F, Cepeda C, McCalla S, Fisher N, et al. The Relationship between Status at Presentation and Outcomes among Pregnant Women with COVID-19. Am J Perinatol. 2020 Aug;37(10):991–4.
- 8. Bianco A, Buckley AB, Overbey J, Smilen S, Wagner B, Dinglas C, et al. Testing of Patients and Support Persons for Coronavirus Disease 2019 (COVID-19) Infection Before Scheduled Deliveries. Obstet Gynecol. 2020 Aug;136(2):283–7.
- Lee DD, Jung H, Lou W, Rauchwerger D, Chartier L, Masood S, et al. The Impact of COVID-19 on a Large, Canadian Community Emergency Department. West J Emerg Med [Internet]. 2021 Jun 9 [cited 2021 Jul 26];22(3). Available from: https://escholarship.org/uc/item/0xk8j1fj
- Sun BC, Hsia RY, Weiss RE, Zingmond D, Liang L-J, Han W, et al. Effect of Emergency Department Crowding on Outcomes of Admitted Patients. Ann Emerg Med. 2013 Jun;61(6):605-611.e6.
- 11. Shao F, Xu S, Ma X, Xu Z, Lyu J, Ng M, et al. In-hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in Wuhan, China. Resuscitation. 2020 Jun;151:18–23.
- 12. Hanson KE, Caliendo AM, Arias CA, Hayden MK, Englund JA, Lee MJ, et al. The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing. Clin Infect Dis. 2021 Jan 22;ciab048.
- 13. Hohl CM, Rosychuk RJ, McRae AD, Brooks SC, Archambault P, Fok PT, et al. Development of the Canadian COVID-19 Emergency Department Rapid Response Network population-based registry: a methodology study. CMAJ Open. 2021 Jan;9(1):E261–70.

- 14. Health Regional Archive (Public View). [Internet]. [cited 2021 Jun 4]. Available from: https://resourcescovid19canada. hub.arcgis.com/datasets/3aa9f7b1428642998fa399c57dad8045/data?layer=1
- 15. McRae AD, Hohl CM, Rosychuk RJ, Vatanpour S, Ghaderi G, Archambault PM, et al. Development and validation of a clinical risk score to predict SARS-CoV-2 infection in emergency department patients: The CCEDRRN COVID-19 Infection Score (CCIS) [Internet]. Emergency Medicine; 2021 Jul [cited 2021 Aug 9]. Available from: http://medrxiv.org/lookup/doi/10.1101/2021.07.15.21260590
- 16. Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Infectious Diseases Group, editor. Cochrane Database Syst Rev [Internet]. 2020 Jul 7 [cited 2021 Jul 26]; Available from: https://coline.line.com/doi/10.1002/14/51059.CD0126/5


https://onlinelibrary.wiley.com/doi/10.1002/14651858.CD013665








For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml





APPENDIX & SUPPLEMENT

Appendix A: List of hospital sites, with an inclusion start and end date for this study.

	Site Name	Province	Start Date	End Date
	Vancouver General Hospital	British Columbia	1-Mar-2020	31-Aug-2020
	Lions Gate Hospital	British Columbia	1-Mar-2020	29-Apr-2020
0	Saint Paul's Hospital	British Columbia	1-Mar-2020	23-May-2020
1 2	Mount Saint Joseph Hospital	British Columbia	1-Mar-2020	24-Mar-2020
3	Surrey Memorial Hospital	British Columbia	19-Mar-2020	30-Apr-2020
4	Royal Columbian Hospital	British Columbia	1-Mar-2020	31-May-2020
5	Abbotsford Regional Hospital	British Columbia	20-Apr-2020	15-Jul-2020
5	University of Alberta Hospital	Alberta	8-Apr-2020	7-May-2020
7	Foothills Medical Centre	Alberta	1-Mar-2020	7-Apr-2020
3 Ə	Rockyview General Hospital	Alberta	1-Mar-2020	7-Apr-2020
5	Peter Lougheed Centre	Alberta	1-Mar-2020	12-Dec-2020
	South Health Campus	Alberta	1-Mar-2020	12-Dec-2020
2	St Paul's Hospital	Saskatchewan	17-Mar-2020	30-Apr-2020
	Royal University Hospital	Saskatchewan	17-Mar-2020	31-Oct-2020
ŀ	Saskatoon City Hospital	Saskatchewan	17-Mar-2020	30-Apr-2020
	Sunnybrook Health Sciences Centre	Ontario	14-May-2020	31-Oct-2020
	The Ottawa Hospital - Civic Campus	Ontario	14-May-2020	31-May-2020
)	Health Science North	Ontario	14-May-2020	29-Dec-2020
	Toronto Western Hospital	Ontario	1-Sep-2020	31-Sep-2020
2	Hotel-Dieu de Lévis	Quebec	4-May-2020	18-May-2020
ļ	Jewish General Hospital	Quebec	1-Mar-2020	4-Jun-2020
5	Hôpital de l'Enfant-Jésus,CHU de Québec	Quebec	4-May-2020	23-Jul-2020
7 8 9 0	IUCPQ: Institut universitaire de cardiologie et de pneumologie de Québec	Quebec	4-May-2020	13-May-2020
	Hôpital du Sacré-Coeur de Montreal	Quebec	4-May-2020	18-May-2020
3	Saint John Regional Hospital	New Brunswick	12-Mar-2020	12-Apr-2020
4	Halifax Infirmary	Nova Scotia	5-Apr-2020	15-Apr-2020
5	Dartmouth General Hospital	Nova Scotia	5-Apr-2020	15-Apr-2020
5	Hants Community Hospital	Nova Scotia	5-Apr-2020	15-Apr-2020
7 3 9	Cobequid Community Health Centre	Nova Scotia	5-Apr-2020	15-Apr-2020
2 1 2 3	Secondary Assessment Centers of Dartmouth General and Halifax Infirmary	Nova Scotia	26-Mar-2020	15-May-2020

BMJ Article Template

torpeer eview only

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Name	Roles	Contributions
Jeffrey Hau	Data manager	REDCap, data processing and analysis for manuscripts.
Vi Ho	National coordinator	Coordinate with provincial coordinators and
		training/onboarding of research assistants.
Serena Small	Research	Ethics & privacy reviews, data management plan, privacy
	coordinator	impact assessment, and qualitative analyses
Amber Cragg	Research manager	Data and manuscript management
Wei Zhao	Data analyst	Data processing and analysis for manuscripts.
Vicky Wu	Data analyst	Data processing and analysis for manuscripts.
Elnaz Bodaghkhani	Research associate	Data and manuscript management

Supplement Table 1. Network coordinating center staff at the University of British Columbia

Supplement Table 2. Provincial Coordinators

Name	Province	Institutional affiliation	Contributions to CCEDRRN
Corinne DeMone	NS	Dalhousie University, Halifax, Nova Scotia	Research ethics board submission, manages research assistants, data cleaning and quality.
Jacqueline Fraser	NB	Dalhousie University, St. John New Brunswick	Site coordinator as well as research assistant.
Martyne Audet	QC	Centre intégré de santé et de services sociaux de Chaudière- Appalaches (Hôtel- Dieu de Lévis site), Lévis	Provincial research coordinator, translation of research material to French, ethics management.
Connie Taylor	ON	Queen's University, // Kingston	Coordination of research assistants in Ontario, maintenance of REB applications for the province
Kate Mackenzie	MB	Health Sciences Centre, Winnipeg	Lead RA for the province
Aimee Goss	SK	University of Saskatchewan, Saskatoon	Screens records in Saskatoon, data/extraction and entry, coordinates research assistants.
Hina Walia	AB	University of Calgary, Calgary	Provincial coordinator lead for Alberta, oversight of all Alberta sites.
Josie Kanu	BC	University of British Columbia, Vancouver	Provincial coordinator lead for BC, oversight of all BC sites.

1	
2 3	
4 5	
6 7 8	
9	
10 11	
12	
13 14	
15	
16 17	
18	
19 20	
21	
22 23	
24	
25 26	
27	
28 29	
30	
31 32	
33	
34 35	
35 36 37	
37 38	
39	
40 41	
42	
43 44	
45	
46 47	
48	
49 50	
51	
52 53	
54	
55 56	
57	
58 59	
60	

Supplement Table 3. Institutional research assistant (RA) leads

Name	Province	Institutional affiliation(s)
Corinne DeMone	NS	Dartmouth General Hospital, Cobequid Community Health Centre, Hants Community Hospital
		Secondary Assessment Centers of the Dartmouth General Hospital, and Halifax Infirmary, Halifax
Jacqueline Fraser	NB	Saint John Regional Hospital, Saint John
Alexandra Nadeau	QC	CHU de Québec Université Laval, Quebec City
Audrey Nolet	QC	Centre intégré de santé et de services sociaux de Chaudière- Appalaches (Hôtel-Dieu de Lévis site), Lévis
Xiaoqing Xue	QC	Jewish General Hospital, Montréal
David Iannuzzi	QC	McGill University Health Center, Montréal
Chantal Lanthier	QC	Hôpital du Sacré-Cœur de Montréal, Montréal
Konika Nirmalanathan	ON	University Health Network, Toronto
Vlad Latiu	ON	Kingston General Hospital, Hotel Dieu Hospital, Kingston
Joanna Yeung	ON	Sunnybrook Health Sciences Center, Toronto
Natasha Clayton	ON	Hamilton General Hospital, Juravinski Hospital, Hamilton
Tom Chen	ON	London Health Sciences Centre, London
Jenna Nichols	ON	Health Sciences North, Sudbury
Kate Mackenzie	MB	Health Sciences Centre, Winnipeg
Aimee Goss	SK	St. Paul's Hospital, Royal University Hospital, Saskatoon City Hospital, Saskatoon
Stacy Ruddell	AB	Foothills Medical Centre, Peter Lougheed Centre, Rockyview General Hospital, South Health Campus, Calgary
Natalie Runham	AB	University of Alberta Hospital, Edmonton
Karlin Su	AB	Royal Alexandra Hospital/Northeast Community Health Center, Edmonton
	BC	St. Paul's Hospital, Mount Saint Joseph, Vancouver
Bernice Huynh	BC	Abbotsford Regional Hospital and Cancer Center, Abbotsford
Amanda Swirhun	BC	Royal Columbian Hospital, New Westminster
Tracy Taylor	BC	Eagle Ridge Hospital and Health Care Centre, Port Moody
Mai Hayashi	BC	Royal Inland Hospital, Kamloops
Mackenzie Cheyne	BC	Kelowna General Hospital, Kelowna
Sarim Asim	BC	Surrey Memorial Hospital, Surrey
Katherine Lam	BC	Vancouver General Hospital, Vancouver
Kelsey Compagna	BC	Lions Gate Hospital, Vancouver

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

Lead Investigator	Contributing Site / Code	Member Investigators
Maritime		0
Patrick Fok		
Nova Scotia		
Hana Wiemer	Halifax Infirmary/ 902	Patrick Fok
	Dartmouth General Hospital/903	Hana Wiemer
	Hants Community Hospital/ 904	Samuel Campbell
	Cobequid Community Health Centre/ 905	Kory Arsenault
	Secondary Assessment Centers of Dartmouth	Tara Dahn
	General and Halifax Infirmary/ 908	
New Brunswick		
Kavish Chandra	Saint John Regional Hospital/ 901	Kavish Chandra
Quebec		
Patrick Archambault	Hotel-Dieu de Lévis/ 701	Patrick Archambault
	Jewish General Hospital/ 702	Joel Turner
	Centre Hospitalier de l'Université Laval (CHU	Éric Mercier
	de Québec)/ 703	
	L'hôpital Royal Victoria - Royal Victoria	Greg Clark
	Hospital/ 705	
	Hôpital de l'Enfant-Jésus,CHU de Québec/ 706	Éric Mercier
	Hôpital du Saint-Sacrement, CHU de Québec/	Éric Mercier
	707	
	Hôpital Saint-François d'Assise, CHU de	Éric Mercier
	Québec/ 708	,
	Hôtel-Dieu de Québec, CHU de Québec/709	Éric Mercier
	IUCPQ: Institut universitaire de cardiologie et de	Sébastien Robert
	pneumologie de Québec/ 710	
	Hôpital du Sacré-Coeur de Montreal/711	Raoul Daoust
Ontario		
Laurie Morrison &	Sunnybrook/ 401	Ivy Cheng
Steven Brooks	The Ottawa Hospital - Civic Campus/ 403	Jeffrey Perry
	The Ottawa Hospital - General Campus/ 404	Jeffrey Perry
	Kingston/Queens/ 406	Steven Brooks
	Hamilton General Hospital/ 407	Michelle Welsford
	Health Science North, Sudbury Ontario/ 408	Rob Ohle
	University Hospital – LHSC/ 409	Justin Yan
	North York General Hospital, Toronto/ 410	Rohit Mohindra
	Victoria Hospital – LHSC/ 412	Justin Yan
	Toronto Western Hospital/ 414	Megan Landes
Manitoba		
Tomislav Jelic	Health Sciences Centre/ 307	Tomislav Jelic
Saskatchewan		
Phil Davis	St Paul's Hospital, Saskatoon/ 303 Royal University, Saskatoon/ 304	Phil Davis

	Saskatoon City Hospital, Saskatoon/ 305	Phil Davis
Alberta		
Andrew McRae	University of Alberta Hospital, Edmonton/ 201	Brian Rowe
	Foothills, Calgary/ 202	Katie Lin
	Rockyview, Calgary/ 203	Andrew McRae
	Peter Lougheed Centre/ 204	Andrew McRae
	South Campus, Calgary/ 205	Stephanie VandenBerg
	Northeast Community Health Centre, Edmonton/	Jake Hayward, Jaspreet
	206	Khangura
	Royal Alexandra Hospital, Edmonton/ 306	Jake Hayward, Jaspreet
		Khangura
British Columbia		
Corinne Hohl	Vancouver General Hospital/ 101	Daniel Ting
	Lions Gate Hospital/ 102	Maja Stachura
	Saint Paul's Hospital/ 103	Frank Scheuermeyer
	Mount St Joseph's/ 104	Frank Scheuermeyer
	Surrey Memorial Hospital/ 105	Balijeet Braar
	Royal Columbian Hospital/ 106	John Taylor
	Abbotsford Regional Hospital/ 107	Ian Martin
	Eagle Ridge Hospital/ 108	Sean Wormsbecker
	Royal Inland Hospital/ 112	Ian Martin
	Kelowna General / Hospital/ 115	Lee Graham
	i z.	



Page 33 of 37

33 34

44 45

STROBE Statement	-cheo	cklist of items that should be included in reports of observational studies	/bmjopen-2021-057852		
	Item No.	Recommendation	2 on 10	Page	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2 (agus	ostract)	"Cohort from the CCEDRRN registry"
		(<i>b</i>) Provide in the abstract an informative and balanced summary of what was done and what was found	2 022. I		Included within the results and conclusions of the abstract
Introduction			Dow		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	hloaded fror		Relevant scientific literature h been cited and the rationale fo the study is outlined.
Objectives	3	State specific objectives, including any prespecified hypotheses	Downloaded from http://bmjopen.bmj.com/o		"Our aim was to determine the diagnostic yield of screening patients admitted to hospital with a diagnosis unrelated to COVID-19 for SARS-CoV-2 2020, and identify risk factors for a positive test"
Methods			on A		
Study design	4	Present key elements of study design early in the paper	pril 19, 202 5		The Study Design and Setting outlined early in the Methods Section.
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	2024 by gu		Included in "Study Design and Setting" sub-section.
Participants	6	 (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants 	est. Protected by copyright.		Included in the "Study Patient sub-section. Eligibility, source and methods of selection are described.

	BMJ Open	/bmjopen-202	Pag
	(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed Case-control study—For matched studies, give matching criteria and the number of controls p case	1-057852	
Variables 7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers Give diagnostic criteria, if applicable		Variables are outlined in the "Data Collection" sub-section.
Data sources/ 8* measurement	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-62	Data sources and methods of assessment are outlined in the "Study Design and Setting" and "Data Collection" sub-sections.
Bias 9	Describe any efforts to address potential sources of bias	from h	Described within the "Study Patients" and the "Data Collection" sub-sections.
Study size 10	Explain how the study size was arrived at	6 to	Described within the "Study Patients" sub-section.
	eview on	open.bmj.com/ on April 19, 2024 by guest. Protected by copyright.	
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xl		

37	BMJ Open		/bmjopen-202	
Quantitative 11 variables	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-8	1-057852 on	Included within the "Data Collection" and "Data Analysis" sub-sections.
Statistical 12 methods	(<i>a</i>) Describe all statistical methods, including those used to control for confounding	7-8	2 on 10 August 2022.	Descriptive statistics, sub-group analyses, and regression models were used. Confounding was addressed via multivariable regression.
	(<i>b</i>) Describe any methods used to examine subgroups and interactions	8		Sub-group analyses were planned for patients presenting with and without COVID compatible symptoms.
	(c) Explain how missing data were addressed	6-7	nloaded from http:	"Participating sites needed to demonstrate \geq 99% compliance in enrollin consecutive eligible patients for their data to be included in this study"
			Downloaded from http://bmjopen.bmj.com/ on	"We imputed values for the first five weeks of the pandemic by modeling the reported COVID-19 cases that had accumulated in every health region over time using linear interpolation (0.1% missing)"
	(d) Cohort study—If applicable, explain how loss to follow-up was addressed Case-control study—If applicable, explain how matching of cases and controls was addressed Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy	7-8	April 19, 2024 by g	Loss to follow-up was not an issue. Study enrolled consecutive patients who met the inclusion/exclusion criteria and data collected through chart review.
Descrite	(<i>e</i>) Describe any sensitivity analyses	N/A	/ guest.	Not performed.
Results Participants 13	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8	st Protected by copyright.	"We identified 19,791 patients admitted t hospital who presented to a participating ED between March 1, 2020, and December 29, 2020 (Figure 1). We excluded 4,101 patients, of which 2,769 had ED diagnoses that were clinically

		BMJ Open		bmjopen-202	Pag
				1-057852 on 1	suspicious for COVID-19 and warranted SARS-CoV-2 testing on clinical grounds. The final cohort contained 15,690 patients."
		(b) Give reasons for non-participation at each stage	N/A	0 A	Study was based on chart review.
		(c) Consider use of a flow diagram	Figure	l ngr	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8-9	st 2022.	Paragraph 2 of the results includes the descriptive summaries.
		(b) Indicate number of participants with missing data for each variable of interest	N/A	Do	See methods.
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	8	wnloaded from	"We identified 19,791 patients admitted the hospital who presented to a participating ED between March 1, 2020, and December 29, 2020".
Outcome data	15*	Cohort study—Report numbers of outcome events or summary measures over time	8	http://bmjopen.bmj	"During the study period Canada experienced two pandemic waves with th local 7-day average incident case count ranging from between 0 and 42.6 cases per 100,000 population across sites."
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	N/A	.com/ on	
		Cross-sectional study—Report numbers of outcome events or summary measures	N/A	Apr	
Main results	16	(<i>a</i>) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	8-9	ril 19, 2024	Descriptive results and comparative findings are described in the latter 2 paragraphs of the "Results"
		(b) Report category boundaries when continuous variables were categorized	N/A	by	
		(<i>c</i>) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A	guest. F	
Continued on next page		^ 		rotected by copyright.	
		For peer review only - http://bmjopen.bmj.com/site/about/guidelines	.xhtml	ht.	

	BMJ Open	/bmjopen-202	
17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	<u> </u>	Follows the sentence "We divided the cohort into two groups, those without any COVID-19 compatible symptoms, and those with COVID- 19 compatible symptoms that were attributed to an alternate diagnosis in the ED (Table 1)."
18	Summarise key results with reference to study objectives	9- 9-	The study objective is recalled and situated within the context of the results.
19	both direction and magnitude of any potential bias	f@m http://bmjopen.bmj.com/ on April 19, 2024 by g	"A limitation of our study is that we only considered NAATs and did not consider the diagnostic yield of antigen-based COVID-19 tests, as they were not widespread in Canada in 2020 (16). We were unable to examine the sensitivity and specificity of the SARS-CoV-2 NAATs as we were unable to define false positive tests, so it is possible that some of the positive test results we encountered are false positives, leading to an overestimation of diagnostic yield."
20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of	10 8 1	Key references are recalled, and the
	analyses, results from similar studies, and other relevant evidence	Protec	study results are situated with these references.
21	Discuss the generalisability (external validity) of the study results	1 10 by copyright.	"While our study is based on a Canadian population without international sites, we believe our
	18 19 20	 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of 	17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses 8 18 Summarise key results with reference to study objectives 9-90 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss 109 19 Discuss limitations of the study, taking into account sources of potential bias 109 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence 109 21 Discuss the generalisability (external validity) of the study results 109

/bmjoper

http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

			רו-202`	
			1-057852	findings are likely generalizable given the wide geographic spread of
			2 on 1	our study sites."
Other inform	nation		0	
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the		Included under "Funding" Section.
		original study on which the present article is based	Jst	
			202	

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

 Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.stro e-statement.org.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

Diagnostic Yield of Screening for SARS-CoV-2 among Patients Admitted to Hospital for Alternate Diagnoses: An Observational Cohort Study

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-057852.R2
Article Type:	Original research
Date Submitted by the Author:	25-Jun-2022
Complete List of Authors:	Davis, Philip; University of Saskatchewan, Emergency Medicine Rosychuk, Rhonda; University of Alberta, Department of Pediatrics Hau, Jeffrey P; Vancouver Coastal Health Research Institute; The University of British Columbia, Department of Emergency Medicine Cheng, Ivy; Sunnybrook Health Sciences Centre, Department of Emergency Medicine; University of Toronto Faculty of Medicine, Department of Emergency Medicine McRae, Andrew; University of Calgary, Department of Emergency Medicine Daoust, Raoul; Université de Montréal, Département Médecine de Famille et Médecine d'Urgence Lang, Eddy; University of Calgary, Department of Emergency Medicine Turner, Joel; McGill University, Department of Emergency Medicine Khangura, Jaspreet; Northeast Community Health Centre, Department of Emergency Medicine Fok, Patrick T.; Dalhousie University, Department of Emergency Medicine Stachura, Maja; The University of British Columbia, Department of Emergency Medicine Brar, Baljeet; The University of British Columbia, Department of Emergency Medicine Hohl, Corinne; The University of British Columbia, Department of Emergency Medicine
Primary Subject Heading :	Emergency medicine
Secondary Subject Heading:	Infectious diseases
Keywords:	COVID-19, EPIDEMIOLOGY, Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Diagnostic microbiology < INFECTIOUS DISEASES
	·

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

relievont

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

BMJ Article Template

Diagnostic Yield of Screening for SARS-CoV-2 among Patients Admitted to Hospital for Alternate Diagnoses: An Observational Cohort Study

Phil Davis¹, Rhonda J. Rosychuk², Jeffrey P Hau^{3,14}, Ivy Cheng^{4,5}, Andrew D. McRae⁶, Raoul Daoust⁷,

Eddy Lang⁸, Joel Turner⁹, Jaspreet Khangura¹⁰, Patrick T. Fok¹¹, Maja Stachura¹², Baljeet Brar¹³, and

Corinne Hohl¹⁴ on behalf of the CCEDRRN investigators, and for the Network of Canadian

Emergency Researchers and the Canadian Critical Care Trials Group

Correspondence to: Dr. Philip J.B. Davis; 103 Hospital Drive, Saskatoon, SK, S7N 0W8; Phil.davis@usask.ca

Author affiliations:

¹ Department of Emergency Medicine, University of Saskatchewan, Saskatoon, SK, Canada

² Department of Pediatrics, University of Alberta, Edmonton, AB, Canada

³ Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute, 828 W 10th Ave, Vancouver BC V5Z1M9

⁴ Department of Emergency Medicine, Sunnybrook Health Sciences Center

⁵ Division of Emergency Medicine, Dept of Medicine, University of Toronto

⁶ Department of Emergency Medicine, University of Calgary

⁷ Département Médecine de Famille et Médecine d'Urgence, Faculté de Médecine, Université de Montréal, Department of Emergency Medicine, Research Centre, CIUSSS-Nord-de-l'Île de-Montréal Montréal, Québec, Canada

⁸ Department of Emergency Medicine, University of Calgary

⁹ Department of Emergency Medicine, McGill University, Montreal, Qc

¹⁰ Department of Emergency Medicine, University of British Columbia

¹¹ Division of EMS, Department of Emergency Medicine, Dalhousie University

¹² Department of Emergency Medicine, University of British Columbia

¹³ Department of Emergency Medicine, University of British Columbia

¹⁴ Department of Emergency Medicine, Faculty of Medicine, University of British Columbia, 2775 Laurel St., Vancouver BC V5Z 1M9.

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

Word count (excluding title page, abstract, references, figures, and tables): 2282

Keywords: screening, COVID-19, coronavirus disease, health services utilization, diagnostic testing, pandemic

Abstract:

Objectives: To determine the diagnostic yield of screening patients for SARS-CoV-2 who were admitted with a diagnosis unrelated to COVID-19, and identify risk factors for positive tests.

Design: Cohort from the Canadian COVID-19 Emergency Department Rapid Response Network

(CCEDRRN) registry

Setting: 30 acute care hospitals across Canada

Participants: Patients hospitalized for non-COVID-19 related diagnoses who were tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) between March 1, and December 29, 2020

Main outcome: Positive nucleic acid amplification test (NAAT) for SARS-CoV-2

Outcome measure: Diagnostic yield

Results: We enrolled 15,690 consecutive eligible adults who were admitted to hospital without clinically suspected COVID-19. Among these patients, 122 tested positive for COVID-19, resulting in a diagnostic yield of 0.8% (95% CI 0.64% – 0.92%). Factors associated with a positive test included presence of a fever, being a healthcare worker, having a positive household contact or institutional exposure, and living in an area with higher 7-day average incident COVID-19 cases.

Conclusions: Universal screening of hospitalized patients for COVID-19 across two pandemic waves had a low diagnostic yield and should be informed by individual-level risk assessment in addition to regional COVID-19 prevalence.

Trial registration: NCT04702945

Strengths and Limitations

- Pan-Canadian study including over 40 academic, non-academic, rural, and urban hospitals.
- Inclusion of patient partners, as well as public engagement, who assisted in the development and presentation of this manuscript.
- Inclusion of pertinent clinical variables, as well as relevant demographic and community level variables.

• Exclusion of non-NAAT tests due to their infrequent use in the Canadian context.

BMJ Open

BMJ Article Template

INTRODUCTION

Healthcare institutions initiated widespread testing of admitted patients for coronavirus disease 2019 (COVID-19) in the spring of 2020 (1). Patients without any reported symptoms of COVID-19 were routinely tested even in jurisdictions where COVID-19 rates were low in order to identify asymptomatic carriers and prevent hospital outbreaks (2). Some jurisdictions have continued this practice without robust evidence to support this practice. An Alberta study of 3,375 patients admitted to hospital for alternate diagnoses during the first wave of the pandemic when COVID-19 prevalence was very low found that none of the patients tested positive (3). In contrast, other studies from times and regions with higher COVID-19 prevalence reported positive tests in between 2.6 and 15.5% of otherwise asymptomatic patients (4–8).

Universal testing has several potential downsides if diagnostic yield is low. First, it may worsen Emergency Department (ED) crowding, as admitted patients with pending COVID-19 tests are boarded in EDs until their test results are reported. While ED volumes were lower than usual in the early pandemic such that EDs could absorb this delay, high patient volumes have since returned, exacerbating the impact of this practice on hospital crowding (9). This in turn increases patient morbidity and mortality (10). In addition, diagnostic workups and therapeutic interventions may be delayed until COVID-19 test results are back, as it takes longer to move patients on isolation precautions through the system. This can further exacerbate patient outcomes and hospital crowding. Thirdly, diagnostic testing capacity may be limited, potentially delaying processing of tests for symptomatic patients. In addition, the use of Personal Protective Equipment (PPE) may be increased as institutions have placed patients with pending COVID-19 tests under isolation precautions. The use of PPE during resuscitation has been associated with worse patient outcomes (11). Lastly, there is also an opportunity cost for hospitals as money spent on universal testing could be allocated to other areas. These unintended consequences of liberal testing policies need to be weighed carefully against the anticipated diagnostic yield and potential benefits.

BMJ Article Template

As for any diagnostic test, rational COVID-19 testing guidelines should be informed by the level of risk of the patient, such that testing is reduced in situations when risk is low, and more widespread when risk is high. Based on expert opinion, the Infectious Diseases Society of America (IDSA) recommended a testing strategy based on the prevalence of the disease in the community (12). They recommended universal testing of asymptomatic hospitalized patients in times and places of high disease prevalence defined as $\geq 10\%$ or $\geq 10,000$ active cases per 100,000 population and did not recommend universal testing in times and places of low prevalence, defined as under 2% prevalence of disease, or less than 2,000 active cases per 100,000. Most jurisdictions never met the proposed screening threshold as public health measures were enacted to reduce disease prevalence to avoid overwhelming hospital capacity. The IDSA was unable to provide further guidance due to lack of available evidence. Our aim was to determine the diagnostic yield of screening patients for SARS-CoV-2 who had been admitted with a diagnosis unrelated to COVID-19 and identify risk factors for positive tests.

METHODS

Study Design and Setting

The Canadian COVID ED Rapid Response Network (CCEDRRN, pronounced 'sedrin') is a pan Canadian population-based registry that has enrolled consecutive eligible patients presenting with suspected or confirmed COVID–19 from EDs across Canada starting on March 1, 2020. The study population, data collection, data quality assurance, management and governance structure are described in the network's methods paper (13). The research ethics boards of all participating institutions approved this study with a waiver of informed consent for data collection and linkage (UBC REB: H20-01015). Thirty CCEDRRN sites in 7 provinces contributed data to this study (Appendix A). Data are available upon reasonable request and can be shared after approval by the Executive Committee through a process outlined on our website (https://www.ccedrrn.com/).

el.ez

BMJ Open

BMJ Article Template

Patient and Public Involvement

CCEDRRN has an active patient engagement committee with patient partners who have lived experience with COVID-19 from geographically representative areas of Canada. Patient partners provided input into the development of this research question and study protocol and the final manuscript.

Study Patients

Participating sites needed to demonstrate ≥99% compliance in enrolling consecutive eligible patients for their data to be included in this study. Data from sites and periods that did not meet this quality threshold were excluded. We included consecutive eligible patients who were admitted to hospital and swabbed for SARS-CoV-2 using a nucleic acid amplification test (NAAT) within 24 hours of ED arrival. We enrolled patients between March 1, 2020 and December 29, 2020. To identify a population of admitted patients in whom COVID-19 disease was not suspected, we excluded patients with ED diagnoses that would have been clinically suspicious for COVID-19. These included all patients with ED diagnoses of suspected or confirmed COVID-19, influenza-like-illness (ILI), upper respiratory infections, and pneumonia or viral pneumonia for which testing would have been indicated based on clinical suspicion. We excluded patients who were discharged directly from the ED, diagnosed with COVID-19 before ED arrival (based on a NAAT done in the community), those whose first swab occurred more than 24 hours after their arrival, and repeat admissions. We also excluded patients in whom initial SARS-CoV-2 testing was negative and repeat testing became positive more than 5 days after arrival, as these patients could have contracted nosocomial COVID.

Data Collection

Trained research assistants collected data retrospectively from electronic and/or paper-based medical records into a central, web-based REDCap database (Vanderbilt University; Nashville, TN, USA). Research assistants captured demographics, infection risk, ED vital signs, presenting symptoms, comorbid conditions and the results of COVID-19 tests. The coordinating centre implemented regular

BMJ Article Template

data quality checks, including logic checks in REDCap as well as site-level record verifications for nonsensical or outlying values.

In addition to these clinical variables, we calculated the seven-day moving average incident COVID-19 case count for the health region of each participating site using publicly available epidemiological data (14). For each calendar day within each health region represented in the study, we calculated the average daily incident rate of new infections per 100,000 population over the preceding seven days. This seven-day moving average incidence was assigned to each patient based on the date of their index emergency department encounter and the health region of their postal code of residence. We allocated patients with no fixed address to the health region of the hospital in which they were tested. We imputed values for the first five weeks of the pandemic by modeling the reported COVID-19 cases that had accumulated in every health region over time using linear interpolation (0.1% missing), COVID-19 case data were not publicly available for the early pandemic. The seven-day moving average incident COVID-19 case count was categorized as 0 - 1.99 per 100,000 population, 2 - 7.99 per 100,000 population, and ≥ 8 per 100,000 population based on the relationship between incidence and COVID-19 positive results in a previous analysis (15).

Outcome:

The primary outcome was a positive NAAT for SARS-CoV-2 in patients admitted with non-COVIDrelated diagnoses.

Data Analysis:

We divided the cohort into two groups, those without symptoms of COVID-19 and those with symptoms compatible with COVID-19 that were attributed to an alternate diagnosis (i.e., CHF, COPD, Asthma, etc.). We considered cough, dyspnea, fever, general weakness, chest pain, diarrhea, nausea and vomiting, headache, chills, myalgia, sore throat, altered level of consciousness, and dysgeusia/anosmia to be COVID-19-compatible symptoms. We used descriptive statistics to describe the population. We

BMJ Open

BMJ Article Template

calculated the diagnostic yield by dividing the number of positive NAATs over the total number of NAATs performed. We calculated 7-day average of NAAT positivity over the study period by dividing the number of positive NAATs over all tests performed and averaging over a 7-day period. We calculated the exact binomial proportion 95% confidence intervals (95% CI) for all proportions and used the modified Clopper-Pearson interval for small samples. We completed a planned subgroup analyses for patients presenting with and without COVID compatible symptoms to determine associated factors for a positive test. The initial multivariable logistic regression model to identify factors associated with a positive NAAT considered candidate variables with a p-value cut-off point of 0.20 based on the Wald test from univariable analyses. From the full model, a step-down procedure reduced the model to key predictors based on Akaike's information criterion (AIC) scores (e.g., chose the model with the smallest AIC score). Candidate variables included seven-day moving average incident COVID-19 case count category, patient age, gender, infection risk, and presenting symptoms. We limited the number of predictor variables in the model to one variable for every 10 outcomes in our data to avoid overfitting. Statistical analysis was preformed using Stata (Version 16.1, StataCorp, College Station, Texas).

RESULTS

We identified 19,791 patients admitted to hospital who presented to a participating ED between March 1, 2020, and December 29, 2020 (Figure 1). We excluded 4,101 patients, of which 2,769 had ED diagnoses that were clinically suspicious for COVID-19 and warranted SARS-CoV-2 testing on clinical grounds. The final cohort contained 15,690 patients. During the study period Canada experienced two pandemic waves with the local 7-day average incident case count ranging from between 0 and 42.6 cases per 100,000 population across sites. The 7-day average diagnostic test positivity varied between 0 and 2.9% across sites during the study period (Figure 2).

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

BMJ Article Template

We divided the cohort into two groups, those without any COVID-19 compatible symptoms, and those with COVID-19 compatible symptoms that were attributed to an alternate diagnosis in the ED (Table 1). Most patients arrived from home and were full code. The most common comorbidities were hypertension, diabetes and mental health illness.

Of 3,113 patients admitted without COVID-19 compatible symptoms, 13 (0.4%, 95% CI 0.19% – 0.64%) tested positive for COVID-19. Of the 12,570 with COVID-19-compatible symptoms, 109 patients (0.9%, 95% CI 0.70% – 1.03%) tested positive for COVID-19. Among the 122 individuals who tested positive for COVID-19, 33 (27.0%, 95% CI 19.0% - 35.0%) were from a geographic region that had a moving average daily incident rate of \geq 8 infections per 100,000 population. The diagnostic yield of testing among patients with COVID-19 compatible symptoms admitted for alternative diagnoses did not vary substantially by presenting symptom (Figure 3) or ED diagnosis (Figure 4).

When examining the association between patient factors and screening positive self-reported fever, being a healthcare worker, having a positive household contact or institutional exposure, and being from an area where the seven-day moving average incident COVID-19 case count was \geq 8 per 100,000 population were associate with a greater risk of testing positive (Table 2). The most important risk factor was reporting a household contact or being the caregiver of a known COVID-19 case.

DISCUSSION

Our aim was to evaluate the diagnostic yield of screening non-COVID-19 admissions for SARS-CoV-2 across Canada in 2020 and identify patient-level risk factors for positive tests. The diagnostic yield of screening patients with non-COVID-19 related ED diagnoses who were admitted to hospital was low overall, and extremely low in patients without COVID compatible symptoms. The most important patient factors associated with a positive test were having a positive household contact, being a healthcare worker, or having had an institutional exposure to COVID-19. Those factors were more important than a high (\geq 8 daily cases per 100,000 population) 7-day moving average incident COVID-19 case count.

BMJ Article Template

Our study has several strengths. We used data from a large pan-Canadian registry that enrolls from large geographically and culturally diverse areas and is one of the largest registries in the world. CCEDRRN's patient enrolment and data verification protocols are rigorous, ensuring consecutive eligible patients and high-quality clinical data (13). We have previously demonstrated the inter-rater reliability for our data collection methods, including for symptoms (13).

Prior studies have examined the diagnostic yield of universal screening in single centers with varied diagnostic yield estimates between 0 and 15.5% (3–8). Many of these were case series with limited methods from the early pandemic. There is one known multi-center study which examines the benefit of universal screening for elective and emergent surgical admissions at 14 centers in the Netherlands (1). Like our study, the authors found that the overall COVID-19 NAAT positivity varied with community prevalence. Our finding that positive SARS-CoV-2 tests were associated with self-reported or measured fever is in keeping with a prior Cochrane systematic review that noted considerable variability in COVID-19 associated symptoms (16).

Our study is interesting in the context of current IDSA recommendations which were based on expert opinion and of "very low certainty" (12). The IDSA panel recommended avoiding universal screening for COVID-19 in times and areas of low COVID prevalence, defined as a disease prevalence of under 2%, or fewer than 2,000 active cases per 100,000 population, a threshold so high that it was never met at any of our study sites, even though multiple sites were in COVID-19 hotspots in 2020 (12). The IDSA threshold would have equated to over 6 million cases of active COVID-19 infection in the United States at any given time, which would have vastly overwhelmed hospital capacity, and thus represents an untenable threshold for hospitals. It is therefore not surprising that the prevalence of COVID-19 during the study period was far below the IDSA recommended threshold for initiating screening. While the number needed to screen to identify one positive case among admitted patients in our study was between 110 and 250 among unvaccinated patients, we propose that new screening thresholds need to be adopted which would ideally be based on readily available measures of local incident cases or test positivity.

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

BMJ Article Template

A limitation of our study is that we only considered NAATs and did not consider the diagnostic yield of antigen-based COVID-19 tests, as they were not widespread in Canada in 2020 (16). We were unable to examine the sensitivity and specificity of the SARS-CoV-2 NAATs as we were unable to define false positive tests, so it is possible that some of the positive test results we encountered are false positives, leading to an overestimation of diagnostic yield. Additionally, our study was performed before the newer COVID-19 variants, such as Omicron, circulated widely. However, our methods are easily replicated, and we intend to repeat our study in a recent dataset reflective of new COVID-19 variants. While our study is based on a Canadian population without international sites, we believe our findings are generalizable given their wide geographic spread, and the cultural and racial diversity of our patient population. Finally, as data becomes available on the fourth wave of the pandemic, a future study should examine the impact of widespread vaccination on the yield of screening. As a larger proportion of the population is protected from severe disease and death through vaccination, decision makers should carefully consider the low diagnostic yield of a universal testing strategy going forward.

ACKNOWLEDGEMENTS

We gratefully acknowledge the assistance of Mr. Rajan Bola in the preparation of this manuscript. And we thank the UBC clinical coordinating center staff, the UBC legal, ethics, privacy and contract staff and the research staff at each of the participating institutions in the network outlined in the attached Supplement (Supplement Tables 1-4). The network would not exist today without the dedication of these professionals.

Thank you to all of our patient partners who shared their lived experiences and perspectives to ensure that the knowledge we co-create addresses the concerns of patients and the public. Creating the largest network of collaboration across Canadian Emergency Departments would not have been feasible without the tireless efforts of Emergency Department Chiefs, and research coordinators and research assistants at participating sites. Finally, our most humble and sincere gratitude to our colleagues in medicine, nursing,

BMJ Open

BMJ Article Template

and the allied health professions who have been on the front lines of this pandemic from day one staffing our ambulances, Emergency Departments, hospitals and ICUs bravely facing the risks of COVID-19 to look after our fellow citizens and after one another. We dedicate this network to you.

COMPETING INTERESTS

None identified.

FUNDING

The Canadian Institutes of Health Research (447679), Ontario Ministry of Colleges and Universities (C-655-2129), Saskatchewan Health Research Foundation (5357), Genome BC (COV024) Foundation du CHU de Québec (Octroi No. 4007) and the Public Health Agency of Canada provided peer-reviewed funding. The BC Academic Health Science Network and BioTalent Canada provided non-peer reviewed funding. These organizations are not-for-profit, and had no role in study conduct, analysis, or manuscript preparation.

AUTHOR CONTRIBUTION STATEMENT

All authors conceived and planned the study together, and iteratively refined the study objectives and analytic plan. PH, RJR, ADM, EL and CMH obtained funding for the study. PD, IC, ADM, RD, JT, JK, PRF, MS and BB supervised data collection. JPH analyzed the data under the supervision of RJR. All authors interpreted the analysis. PD drafted the manuscript. All authors were actively involved in reporting out work by revising the manuscript for content. All authors take responsibility for the manuscript as a whole.

BMJ Article Template

DATA SHARING

Data are available upon reasonable request. They can be shared after approval by the Executive Committee through a process outlined on our website (<u>https://www.ccedrm.com/</u>).

to peet eview only

	Patients without COVID-19 symptoms (N=3,113)	Patients with COVID-19 compatible symptoms attributed an alternate diagnos (N=12,570)
Demographics		
Age (mean, SD)	57.6 (22.6)	64.6 (20.4)
Female (%)	1,418 (45.6)	5,924 (47.1)
Pregnant (%)	18 (0.6)	45 (0.4)
Tobacco use (%)	491 (15.8)	1,656 (13.2)
Illicit substance use (%)	421 (13.5)	967 (7.7)
Arrival by Ambulance (%)	1,724 (55.4)	7,189 (57.2)
Arrival From (%)		
Home	2,552 (82.0)	10,943 (87.0)
Long-term care or rehab facility	217 (7.0)	832 (6.6)
Unstable housing*	190 (6.1)	414 (3.3)
Corrections	7 (0.2)	14 (0.1)
Interfacility transfer	121 (3.9)	262 (2.1)
Risk for Infection (%)		
Travel	32 (1.0)	134 (1.1)
Institutional (LTC/prison)	231 (7.4)	721 (5.7)
Household contact	28 (0.9)	144 (1.1)
Occupational	10 (0.3)	38 (0.3)
Unknown	1,502 (48.2)	5,377 (42.8)
Pre-ED Goals of Care (%)		
Full code	2,946 (94.6)	11,259 (89.5)
Intermediate GOC	18 (0.6)	173 (1.4)
Do not resuscitate	149 (4.8)	1,142 (9.1)
Acuity		
CTAS 1 (Resuscitation)	241 (7.7)	1,053 (8.4)
CTAS 2 (Emergent)	1,000 (32.1)	5,786 (46.0)
CTAS 3 (Urgent)	1,527 (49.1)	5,086 (40.4)
CTAS 4 (Less Urgent)	295 (9.5)	572 (4.6)
CTAS 5 (Non Urgent)	40 (1.3)	59 (0.5)
Arrival Vital Signs, Mean (SD)		
Heart Rate, beats per min	91.2 (21.2)	95.5 (23.9)
Systolic BP, mm Hg	134.7 (25.1)	133.6 (27.9)
Oxygen saturation, (%)	96.6 (3.4)	95.7 (4.1)
Respiratory Rate, beats per min	18.6 (4.4)	21.2 (6.3)
Temperature, degrees Celsius	36.6 (0.6)	36.8 (0.9)
Comorbidities (%)		
Hypertension	951 (30.6)	5,321 (42.3)
Psychiatric Condition	728 (23.4)	2,134 (17.0)
Dyslipidemia	425 (13.6)	2,434 (19.4)
Diabetes	427 (13.7)	2,577 (20.5)
Chronic Neuro Disorder	322 (10.3)	1,406 (11.2)

2 3		284 (0.1)	1 705 (14 2)
4	Coronary Artery Disease	284 (9.1)	1,796 (14.3)
5	Rheumatologic Disorder Dementia	229 (7.4)	1,249 (9.9)
6	Active Cancer	199 (6.4)	696 (5.5) 1 647 (12 0)
7		231 (7.4)	1,647 (12.9)
8	Chronic Kidney Disease	195 (6.3)	1,319 (10.5)
9	Chronic Lung Disease (not asthma)	199 (6.4)	1,691 (13.5)
10 11	Congestive Heart Failure	159 (5.1)	1,392 (11.1)
11	Asthma	125 (4.0)	712 (5.7)
13	Obesity	57 (1.8)	344 (2.7)
14	Symptoms (%)		
15	Cough	-	2,763 (22.0)
16	Dyspnea	-	4,757 (37.8)
17	Fever	-	2,531 (20.1)
18	General Weakness	-	3,183 (25.3)
19 20	Chest Pain	-	2,714 (21.6)
20 21	Diarrhea	-	1,339 (10.7)
21	Nausea/Vomiting	-	3,345 (26.6)
23	Headache	-	784 (6.2)
24	Chills	-	957 (7.6)
25	Myalgia	N	466 (3.7)
26	Sore Throat	-	374 (3.0)
27	Altered Consciousness	-	2,502 (19.9)
28	Dysgusea/Anosmia	_	41 (0.3)
29	ED Diagnosis (%)		
30 31	Respiratory Disease, not specified	8 (0.3)	118 (0.9)
32	COPD Exacerbation	11 (0.4)	648 (5.2)
33	Asthma Exacerbation	<5	97 (0.8)
34	Congestive Heart Failure	44 (1.4)	1,003 (8.0)
35	Shortness of Breath, NYD*	- 7	466 (3.6)
36	Cough, NYD*	_	63 (0.5)
37	Fever, NYD*	-	482 (3.8)
38	Outcome (%)		
39	Positive SARS-CoV-2 NAAT	13 (0.4)	109 (0.9)
40 41	*NYD denotes "not yet determined"		
41			

	Univariate analysis odds ratio (95% CI)	Final model with fully adjusted odds ratio (95% Cl) ¹	P-value
Sex			
Male	Reference	Reference	0.18
Female	0.84 (0.59 – 1.21)	0.78 (0.54 – 1.12)	
Age			
	1.00 (1.00 – 1.02)	1.00 (0.99 – 1.01)	0.27
7-day average incident COVID-19 cases			
0 – 1.99 daily cases per 100,000 population	Reference	Reference	< 0.002
2 to 7.99 daily cases per 100,000 population	1.42 (0.91 – 2.22)	1.47 (0.94 – 2.31)	
≥8 daily cases per 100,000 population	2.99 (1.95 – 4.59)	3.17 (2.05 – 4.89)	
COVID-19 compatible symptoms present	- (- <i>(</i>	
No	Reference	Reference	0.08
Yes	2.08 (1.71 – 3.71)	1.65 (0.90 – 3.00)	
Self-reported fever, or temperature ≥ 37.5 °C		D (
No	Reference	Reference	< 0.002
Yes	2.72 (1.89 – 3.90)	2.53 (1.74 – 3.67)	
Diarrhea present		D (0.44
No	Reference	Reference	0.11
Yes	1.74 (1.04 – 2.92)	1.57 (0.93 – 2.67)	
lealthcare worker	Defense	Deferrere	0.00
No	Reference	Reference	0.06
Yes	5.62 (1.35 – 23.43)	4.67 (1.05 – 20.54)	
Household contact or caregiver	Deference	Deference	< 0.002
No Yes	Reference 9.48 (5.01 – 17.96)	<i>Reference</i> 7.74 (3.98 – 15.04)	< 0.00.
nstitutional exposure	9.48 (3.01 - 17.90)	7.74 (3.98 - 13.04)	
No	Reference	Reference	< 0.002
Yes	3.46 (2.17 – 5.52)	3.39 (2.10 – 5.47)	< 0.00.
Dysgeusia or anosmia present	5.40(2.17 - 5.52)	5.55 (2.10 - 5.47)	
No	Reference	-	
Yes	3.21 (0.43 – 23.52)	_	
Dyspnea present	5.22 (0.15 25.52)		
No	Reference	-	
Yes	1.16 (0.80 – 1.70)	-	
Nausea or vomiting present	1.10 (0.00 1.70)		
No	Reference	-	
Yes	0.81 (0.51 – 1.29)	-	
	0.01 (0.01 1.12)		

BMJ Article Template

¹ Final model determined by including variables with a p-value of p<0.20 during the sex and age adjusted analysis, and using the Akaike Information Criterion (AIC) to determine additional variables to exclude from the final model. Variables adjusted for all other variables present in the final model

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

Figure 1: Patient Flow Diagram

Figure 2: 7-day working average of COVID-19 NAAT positivity over the study period across sites.

Figure 3: Diagnostic Yield by Presenting Symptoms

Figure 4: Diagnostic Yield by ED Diagnosis

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Article Template

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

ETHICAL APPROVAL STATEMENT

The research ethics boards of all participating institutions approved this study with a waiver of informed

tor beer terien only

consent for data collection and linkage (UBC REB: H20-01015).

REFERENCES


- 1. Puylaert CAJ, Scheijmans JCG, Borgstein ABJ, Andeweg CS, Bartels-Rutten A, Beets GL, et al. Yield of Screening for COVID-19 in Asymptomatic Patients Before Elective or Emergency Surgery Using Chest CT and RT-PCR (SCOUT): Multicenter Study. Ann Surg. 2020 Dec;272(6):919–24.
- 2. Sutton D, Fuchs K, D'Alton M, Goffman D. Universal Screening for SARS-CoV-2 in Women Admitted for Delivery. N Engl J Med. 2020 May 28;382(22):2163–4.
- 3. Ravani P, Saxinger L, Chandran U, Fonseca K, Murphy S, Lang E, et al. COVID-19 screening of asymptomatic patients admitted through emergency departments in Alberta: a prospective quality-improvement study. CMAJ Open. 2020 Oct;8(4):E887–94.
- 4. Goldfarb IT, Diouf K, Barth WH, Robinson JN, Katz D, Gregory KE, et al. Universal SARS-CoV-2 testing on admission to the labor and delivery unit: Low prevalence among asymptomatic obstetric patients. Infect Control Hosp Epidemiol. 2020 Sep;41(9):1095–6.
- Ossami Saidy RR, Globke B, Pratschke J, Schoening W, Eurich D. Successful implementation of preventive measures leads to low relevance of SARS-CoV-2 in liver transplant patients: Observations from a German outpatient department. Transpl Infect Dis [Internet]. 2020 Dec [cited 2021 Aug 9];22(6). Available from: https://onlinelibrary.wiley.com/doi/10.1111/tid.13363
- 6. Gruskay JA, Dvorzhinskiy A, Konnaris MA, LeBrun DG, Ghahramani GC, Premkumar A, et al. Universal Testing for COVID-19 in Essential Orthopaedic Surgery Reveals a High Percentage of Asymptomatic Infections. J Bone Jt Surg. 2020 Aug 19;102(16):1379–88.
- London V, McLaren R, Atallah F, Cepeda C, McCalla S, Fisher N, et al. The Relationship between Status at Presentation and Outcomes among Pregnant Women with COVID-19. Am J Perinatol. 2020 Aug;37(10):991–4.
- Bianco A, Buckley AB, Overbey J, Smilen S, Wagner B, Dinglas C, et al. Testing of Patients and Support Persons for Coronavirus Disease 2019 (COVID-19) Infection Before Scheduled Deliveries. Obstet Gynecol. 2020 Aug;136(2):283–7.
- Lee DD, Jung H, Lou W, Rauchwerger D, Chartier L, Masood S, et al. The Impact of COVID-19 on a Large, Canadian Community Emergency Department. West J Emerg Med [Internet]. 2021 Jun 9 [cited 2021 Jul 26];22(3). Available from: https://escholarship.org/uc/item/0xk8j1fj
- Sun BC, Hsia RY, Weiss RE, Zingmond D, Liang L-J, Han W, et al. Effect of Emergency Department Crowding on Outcomes of Admitted Patients. Ann Emerg Med. 2013 Jun;61(6):605-611.e6.
- 11. Shao F, Xu S, Ma X, Xu Z, Lyu J, Ng M, et al. In-hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in Wuhan, China. Resuscitation. 2020 Jun;151:18–23.
- 12. Hanson KE, Caliendo AM, Arias CA, Hayden MK, Englund JA, Lee MJ, et al. The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing. Clin Infect Dis. 2021 Jan 22;ciab048.
- 13. Hohl CM, Rosychuk RJ, McRae AD, Brooks SC, Archambault P, Fok PT, et al. Development of the Canadian COVID-19 Emergency Department Rapid Response Network population-based registry: a methodology study. CMAJ Open. 2021 Jan;9(1):E261–70.

- 14. Health Regional Archive (Public View). [Internet]. [cited 2021 Jun 4]. Available from: https://resourcescovid19canada. hub.arcgis.com/datasets/3aa9f7b1428642998fa399c57dad8045/data?layer=1
- 15. McRae AD, Hohl CM, Rosychuk RJ, Vatanpour S, Ghaderi G, Archambault PM, et al. Development and validation of a clinical risk score to predict SARS-CoV-2 infection in emergency department patients: The CCEDRRN COVID-19 Infection Score (CCIS) [Internet]. Emergency Medicine; 2021 Jul [cited 2021 Aug 9]. Available from: http://medrxiv.org/lookup/doi/10.1101/2021.07.15.21260590
- 16. Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Infectious Diseases Group, editor. Cochrane Database Syst Rev [Internet]. 2020 Jul 7 [cited 2021 Jul 26]; Available from: https://uplineliburg.com/doi/10.1002/14/51059.CD0126/5


https://onlinelibrary.wiley.com/doi/10.1002/14651858.CD013665


		 Exclude: 1. 95 Patients diagnosed with COVID before the index admission or had history of Covid-19 2. 925 Patients not swabbed within 24 hours of ED arrival 3. 291 Patients swabbed prior to ED arrival 4. 21 Patients diagnosed with COVID-19 > 5 days after ED arrival 5. 2,769 Patients with ED diagnosis of (1-6): a. 288 Suspect COVID-19 b. 297 Confirmed COVID-19 b. 297 Confirmed COVID-19 c. 299 Influenza like illness d. 111 Upper Respiratory Infection e. 1,667 Pneumonia f. 107 Viral Pneumonia
15.690	Cohort	
	15,690	15,690 Cohort

Figure 2: The 7-day working average of COVID-19 NAAT positivity among all eligible study patients over the study period across study sites.



1 2 3 4 5 6 7 8 9 10	
3	
5	
6 7	
8 9	
11 12	
13 14	
15 16	
17	
18 19	
20 21	
22 23	
24	
25 26	
27 28	
29 30	
31	
32 33	
34 35	
36 37	
38	
39 40	
41 42	
43 44	
45	
46 47	
48 49	
50 51	
52	
53 54	
55 56	
57	
58 59	For peer review only - http://bmjopen.bmj.com/site/about/quidelines.xhtml
60	For peer review only - http://pmiopen.bmi.com/site/about/guidelines.xhtml





BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

APPENDIX & SUPPLEMENT

Appendix A: List of hospital sites, with an inclusion start and end date for this study.

Site Name	Province	Start Date	End Date
Vancouver General Hospital	British Columbia	1-Mar-2020	31-Aug-2020
Lions Gate Hospital	British Columbia	1-Mar-2020	29-Apr-2020
Saint Paul's Hospital	British Columbia	1-Mar-2020	23-May-2020
Mount Saint Joseph Hospital	British Columbia	1-Mar-2020	24-Mar-2020
Surrey Memorial Hospital	British Columbia	19-Mar-2020	30-Apr-2020
Royal Columbian Hospital	British Columbia	1-Mar-2020	31-May-2020
Abbotsford Regional Hospital	British Columbia	20-Apr-2020	15-Jul-2020
University of Alberta Hospital	Alberta	8-Apr-2020	7-May-2020
Foothills Medical Centre	Alberta	1-Mar-2020	7-Apr-2020
Rockyview General Hospital	Alberta	1-Mar-2020	7-Apr-2020
Peter Lougheed Centre	Alberta	1-Mar-2020	12-Dec-2020
South Health Campus	Alberta	1-Mar-2020	12-Dec-2020
St Paul's Hospital	Saskatchewan	17-Mar-2020	30-Apr-2020
Royal University Hospital	Saskatchewan	17-Mar-2020	31-Oct-2020
Saskatoon City Hospital	Saskatchewan	17-Mar-2020	30-Apr-2020
Sunnybrook Health Sciences Centre	Ontario	14-May-2020	31-Oct-2020
The Ottawa Hospital - Civic Campus	Ontario	14-May-2020	31-May-2020
Health Science North	Ontario	14-May-2020	29-Dec-2020
Toronto Western Hospital	Ontario	1-Sep-2020	31-Sep-2020
Hotel-Dieu de Lévis	Quebec	4-May-2020	18-May-2020
Jewish General Hospital	Quebec	1-Mar-2020	4-Jun-2020
Hôpital de l'Enfant-Jésus,CHU de Québec	Quebec	4-May-2020	23-Jul-2020
IUCPQ: Institut universitaire de cardiologie et de pneumologie de Québec	Quebec	4-May-2020	13-May-2020
Hôpital du Sacré-Coeur de Montreal	Quebec	4-May-2020	18-May-2020
Saint John Regional Hospital	New Brunswick	12-Mar-2020	12-Apr-2020
Halifax Infirmary	Nova Scotia	5-Apr-2020	15-Apr-2020
Dartmouth General Hospital	Nova Scotia	5-Apr-2020	15-Apr-2020
Hants Community Hospital	Nova Scotia	5-Apr-2020	15-Apr-2020
Cobequid Community Health Centre	Nova Scotia	5-Apr-2020	15-Apr-2020
Secondary Assessment Centers of Dartmouth General and Halifax Infirmary	Nova Scotia	26-Mar-2020	15-May-2020

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Name	Roles	Contributions	
Jeffrey Hau	Data manager	REDCap, data processing and analysis for manuscripts.	
Vi Ho	National coordinator	Coordinate with provincial coordinators and	
		training/onboarding of research assistants.	
Serena Small	Research	Ethics & privacy reviews, data management plan, privacy	
	coordinator	impact assessment, and qualitative analyses	
Amber Cragg	Research manager	Data and manuscript management	
Wei Zhao	Data analyst	Data processing and analysis for manuscripts.	
Vicky Wu	Data analyst	Data processing and analysis for manuscripts.	
Elnaz Bodaghkhani	Research associate	Data and manuscript management	

Supplement Table 1. Network coordinating center staff at the University of British Columbia

Supplement Table 2. Provincial Coordinators

Name	Province	Institutional affiliation	Contributions to CCEDRRN
Corinne DeMone	NS	Dalhousie University, Halifax, Nova Scotia	Research ethics board submission, manages research assistants, data cleaning and quality.
Jacqueline Fraser	NB	Dalhousie University, St. John New Brunswick	Site coordinator as well as research assistant.
Martyne Audet	QC	Centre intégré de santé et de services sociaux de Chaudière- Appalaches (Hôtel- Dieu de Lévis site), Lévis	Provincial research coordinator, translation of research material to French, ethics management.
Connie Taylor	ON	Queen's University, // Kingston	Coordination of research assistants in Ontario, maintenance of REB applications for the province
Kate Mackenzie	MB	Health Sciences Centre, Winnipeg	Lead RA for the province
Aimee Goss	SK	University of Saskatchewan, Saskatoon	Screens records in Saskatoon, data/extraction and entry, coordinates research assistants.
Hina Walia	AB	University of Calgary, Calgary	Provincial coordinator lead for Alberta, oversight of all Alberta sites.
Josie Kanu	BC	University of British Columbia, Vancouver	Provincial coordinator lead for BC, oversight of all BC sites.

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

Name	Province	Institutional affiliation(s)	
Corinne DeMone	NS	Dartmouth General Hospital, Cobequid Community Health Centre	
		Hants Community Hospital	
		Secondary Assessment Centers of the Dartmouth General Hospital	
		and Halifax Infirmary, Halifax	
Jacqueline Fraser	NB	Saint John Regional Hospital, Saint John	
Alexandra Nadeau	QC	CHU de Québec Université Laval, Quebec City	
Audrey Nolet	QC	Centre intégré de santé et de services sociaux de Chaudière-	
		Appalaches (Hôtel-Dieu de Lévis site), Lévis	
Xiaoqing Xue	QC	Jewish General Hospital, Montréal	
David Iannuzzi	QC	McGill University Health Center, Montréal	
Chantal Lanthier	QC	Hôpital du Sacré-Cœur de Montréal, Montréal	
Konika Nirmalanathan	ON	University Health Network, Toronto	
Vlad Latiu	ON	Kingston General Hospital, Hotel Dieu Hospital, Kingston	
Joanna Yeung	ON	Sunnybrook Health Sciences Center, Toronto	
Natasha Clayton	ON	Hamilton General Hospital, Juravinski Hospital, Hamilton	
Tom Chen	ON	London Health Sciences Centre, London	
Jenna Nichols	ON	Health Sciences North, Sudbury	
Kate Mackenzie	MB	Health Sciences Centre, Winnipeg	
Aimee Goss	SK	St. Paul's Hospital, Royal University Hospital, Saskatoon City	
		Hospital, Saskatoon	
Stacy Ruddell	AB	Foothills Medical Centre, Peter Lougheed Centre, Rockyview	
		General Hospital, South Health Campus, Calgary	
Natalie Runham	AB	University of Alberta Hospital, Edmonton	
Karlin Su	AB	Royal Alexandra Hospital/Northeast Community Health Center,	
		Edmonton	
	BC	St. Paul's Hospital, Mount Saint Joseph, Vancouver	
Bernice Huynh	BC	Abbotsford Regional Hospital and Cancer Center, Abbotsford	
Amanda Swirhun	BC	Royal Columbian Hospital, New Westminster	
Tracy Taylor	BC	Eagle Ridge Hospital and Health Care Centre, Port Moody	
Mai Hayashi	BC	Royal Inland Hospital, Kamloops	
Mackenzie Cheyne	BC	Kelowna General Hospital, Kelowna	
Sarim Asim	BC	Surrey Memorial Hospital, Surrey	
Katherine Lam	BC	Vancouver General Hospital, Vancouver	
Kelsey Compagna	BC	Lions Gate Hospital, Vancouver	

Supplement Table 3. Institutional research assistant (RA) leads

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	
24 25 26 27 28	
29 30 31 32 33	
34 35 36 37	
38 39 40 41	
42 43 44 45 46	
47 48 49 50 51	
51 52 53 54 55	
56 57 58 59 60	
00	

Supplement Table 4. Contributing Study Sites and Investigators

Lead Investigator	Contributing Site / Code	Member Investigators
Maritime		
Patrick Fok		
Nova Scotia		
Hana Wiemer	Halifax Infirmary/ 902	Patrick Fok
	Dartmouth General Hospital/ 903	Hana Wiemer
	Hants Community Hospital/ 904	Samuel Campbell
	Cobequid Community Health Centre/ 905	Kory Arsenault
	Secondary Assessment Centers of Dartmouth	Tara Dahn
	General and Halifax Infirmary/ 908	
New Brunswick		
Kavish Chandra	Saint John Regional Hospital/ 901	Kavish Chandra
Quebec		
Patrick Archambault	Hotel-Dieu de Lévis/ 701	Patrick Archambault
	Jewish General Hospital/ 702	Joel Turner
	Centre Hospitalier de l'Université Laval (CHU	Éric Mercier
	de Québec)/ 703	
	L'hôpital Royal Victoria - Royal Victoria	Greg Clark
	Hospital/ 705	
	Hôpital de l'Enfant-Jésus,CHU de Québec/ 706	Éric Mercier
	Hôpital du Saint-Sacrement, CHU de Québec/	Éric Mercier
	707	
	Hôpital Saint-François d'Assise, CHU de	Éric Mercier
	Québec/708	
	Hôtel-Dieu de Québec, CHU de Québec/ 709	Éric Mercier
	IUCPQ: Institut universitaire de cardiologie et de	Sébastien Robert
	pneumologie de Québec/ 710	
	Hôpital du Sacré-Coeur de Montreal/711	Raoul Daoust
Ontario		
Laurie Morrison &	Sunnybrook/ 401	Ivy Cheng
Steven Brooks	The Ottawa Hospital - Civic Campus/ 403	Jeffrey Perry
	The Ottawa Hospital - General Campus/ 404	Jeffrey Perry
	Kingston/Queens/ 406	Steven Brooks
	Hamilton General Hospital/ 407	Michelle Welsford
	Health Science North, Sudbury Ontario/ 408	Rob Ohle
	University Hospital – LHSC/ 409	Justin Yan
	North York General Hospital, Toronto/ 410	Rohit Mohindra
	Victoria Hospital – LHSC/ 412	Justin Yan
	Toronto Western Hospital/ 414	Megan Landes
Manitoba		
Tomislav Jelic	Health Sciences Centre/ 307	Tomislav Jelic
Saskatchewan	Treata Serences Conder 567	
Phil Davis	St Paul's Hospital, Saskatoon/ 303	Phil Davis
	Royal University, Saskatoon/ 304	Phil Davis

BMJ Open

	Saskatoon City Hospital, Saskatoon/ 305	Phil Davis
Alberta		
Andrew McRae	University of Alberta Hospital, Edmonton/ 201	Brian Rowe
	Foothills, Calgary/ 202	Katie Lin
	Rockyview, Calgary/ 203	Andrew McRae
	Peter Lougheed Centre/ 204	Andrew McRae
	South Campus, Calgary/ 205	Stephanie VandenBerg
	Northeast Community Health Centre, Edmonton/	Jake Hayward, Jaspree
	206	Khangura
	Royal Alexandra Hospital, Edmonton/ 306	Jake Hayward, Jaspree
		Khangura
British Columbia		
Corinne Hohl	Vancouver General Hospital/ 101	Daniel Ting
	Lions Gate Hospital/ 102	Maja Stachura
	Saint Paul's Hospital/ 103	Frank Scheuermeyer
	Mount St Joseph's/ 104	Frank Scheuermeyer
	Surrey Memorial Hospital/ 105	Balijeet Braar
	Royal Columbian Hospital/ 106	John Taylor
	Abbotsford Regional Hospital/ 107	Ian Martin
	Eagle Ridge Hospital/ 108	Sean Wormsbecker
	Royal Inland Hospital/ 112	Ian Martin
	Kelowna General / Hospital/ 115	Lee Graham
	Kelowna General / Hospital/ 115	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

STROBE Statement	-chec	cklist of items that should be included in reports of observational studies	omjupen-zuzi-uoraa		
	Item No.	Recommendation			Relevant text from manuscript
Title and abstract	1	(<i>a</i>) Indicate the study's design with a commonly used term in the title or the abstract	2 guys	ibstract)	"Cohort from the CCEDRRN registry"
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2 022.	_	Included within the results and conclusions of the abstract
Introduction			DOWIN		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-aded Iron		Relevant scientific literature has been cited and the rationale for the study is outlined.
Objectives	3	State specific objectives, including any prespecified hypotheses	4-4-5		"Our aim was to determine the diagnostic yield of screening patients admitted to hospital with a diagnosis unrelated to COVID-19 for SARS-CoV-2 in 2020, and identify risk factors for a positive test"
Methods			יי חט	>	
Study design	4	Present key elements of study design early in the paper	5 5 5 202		The Study Design and Setting is outlined early in the Methods Section.
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	2024 by gu		Included in "Study Design and Setting" sub-section.
Participants	6	 (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants 	6		Included in the "Study Patients' sub-section. Eligibility, sources and methods of selection are described.

Page 3	5 of 3	8
--------	--------	---

ge 35 of 38		BMJ Open	/bmjopen-202	
		(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed Case-control study—For matched studies, give matching criteria and the number of controls per case	1-057852	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	0 August 6-	Variables are outlined in the "Data Collection" sub-section.
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	t 2022. Downloa	Data sources and methods of assessment are outlined in the "Study Design and Setting" and "Data Collection" sub-sections.
Bias	9	Describe any efforts to address potential sources of bias	6- 6-	Described within the "Study Patients" and the "Data Collection" sub-sections.
Study size	10	Explain how the study size was arrived at	ttp://bm	Described within the "Study Patients" sub-section.
Continued on next page		i feview on	024 by guest. Protected by copyright.	
		For peer review only - http://bmjope 2 .bmj.com/site/about/guidelines.xht	tml	

Page 36 of 38

/bmjopen-20

				02	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-8	1-057852	Included within the "Data Collection" and "Data Analysis" sub-sections.
Statistical methods	12	(<i>a</i>) Describe all statistical methods, including those used to control for confounding	7-8	on 10 August	Descriptive statistics, sub-group analyses, and regression models were used. Confounding was addressed via multivariable regression.
		(b) Describe any methods used to examine subgroups and interactions	8	2022. Dow	Sub-group analyses were planned for patients presenting with and without COVID compatible symptoms.
		(c) Explain how missing data were addressed	6-7	nloaded from http:	"Participating sites needed to demonstrate \geq 99% compliance in enrolling consecutive eligible patients for their data to be included in this study"
				nloaded from http://bmjopen.bmj.com/ on	"We imputed values for the first five weeks of the pandemic by modeling the reported COVID-19 cases that had accumulated in every health region over time using linear interpolation (0.1% missing)"
		(<i>d</i>) Cohort study—If applicable, explain how loss to follow-up was addressed Case-control study—If applicable, explain how matching of cases and controls was addressed Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy	7-8	April 19, 2024 t	Loss to follow-up was not an issue. Study enrolled consecutive patients who met the inclusion/exclusion criteria and data collected through chart review.
		(<u>e</u>) Describe any sensitivity analyses	N/A	by guest.	Not performed.
Results Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8	st. Protected by copyright.	"We identified 19,791 patients admitted to hospital who presented to a participating ED between March 1, 2020, and December 29, 2020 (Figure 1). We excluded 4,101 patients, of which 2,769 had ED diagnoses that were clinically

/bmjopen-202 1-057852 suspicious for COVID-19 and warranted SARS-CoV-2 testing on clinical grounds. The final cohort contained 15.690 g patients." 0 (b) Give reasons for non-participation at each stage N/A Study was based on chart review. Figure 19 (c) Consider use of a flow diagram ıst 2022 Descriptive 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information 8-9 Paragraph 2 of the results includes the descriptive summaries. data on exposures and potential confounders 0 (b) Indicate number of participants with missing data for each variable of interest N/A See methods. wnloaded from (c) Cohort study—Summarise follow-up time (eg, average and total amount) "We identified 19,791 patients admitted to 8 hospital who presented to a participating ED between March 1, 2020, and December 29, 2020". http://bmjopen.bmj "During the study period Canada Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time 8 experienced two pandemic waves with the local 7-day average incident case count ranging from between 0 and 42.6 cases per 100,000 population across sites." com/ *Case-control study*—Report numbers in each exposure category, or summary measures of N/A exposure o Cross-sectional study-Report numbers of outcome events or summary measures N/A Ą pril 19, Descriptive results and comparative (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their Main results 16 8-9 findings are described in the latter 2 precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and 2024 paragraphs of the "Results" why they were included Å (b) Report category boundaries when continuous variables were categorized N/A guest (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful N/A time period rotected by copyright Continued on next page

BMJ Open

Page 37 of 38

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22 23

24

25

26 27

28

29

30

31

32

33

34

35

		BMJ Open	/bmjopen-202	Page 3
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	1- 0 57852 on 10 August 2022	Follows the sentence "We divided the cohort into two groups, those without any COVID-19 compatible symptoms, and those with COVID- 19 compatible symptoms that were attributed to an alternate diagnosis in the ED (Table 1)."
Discussion				
Key results	18	Summarise key results with reference to study objectives	9-miloaded	The study objective is recalled and situated within the context of the results.
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	figm http://bmjopen.bmj.com/ on April 19, 2024 by g	"A limitation of our study is that we only considered NAATs and did not consider the diagnostic yield of antigen-based COVID-19 tests, as they were not widespread in Canada in 2020 (16). We were unable to examine the sensitivity and specificity of the SARS-CoV-2 NAATs as we were unable to define false positive tests, so it is possible that some of the positive test results we encountered are false positives, leading to an overestimation of diagnostic yield."
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	u%11 10號1. Protectt웹1	Key references are recalled, and the study results are situated with these references.
Generalisability	21	Discuss the generalisability (external validity) of the study results	t똆 by copyright.	"While our study is based on a Canadian population without international sites, we believe our

 /bmjopei

http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

	n-2021	
	I-057852 or	findings are likely generalizable given the wide geographic spread of our study sites."
nation	n 10	
22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	August 2	Included under "Funding" Section.
	22 Give the source of funding and the role of the funders for the present study and, if applicable, for the	Station Station 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the 112

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohord and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.stro e-statement.org.

BMJ Open

Diagnostic Yield of Screening for SARS-CoV-2 among Patients Admitted to Hospital for Alternate Diagnoses: An Observational Cohort Study

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-057852.R3
Article Type:	Original research
Date Submitted by the Author:	05-Jul-2022
Complete List of Authors:	Davis, Philip; University of Saskatchewan, Emergency Medicine Rosychuk, Rhonda; University of Alberta, Department of Pediatrics Hau, Jeffrey P; Vancouver Coastal Health Research Institute; The University of British Columbia, Department of Emergency Medicine Cheng, Ivy; Sunnybrook Health Sciences Centre, Department of Emergency Medicine; University of Toronto Faculty of Medicine, Department of Emergency Medicine McRae, Andrew; University of Calgary, Department of Emergency Medicine Daoust, Raoul; Université de Montréal, Département Médecine de Famille et Médecine d'Urgence Lang, Eddy; University of Calgary, Department of Emergency Medicine Turner, Joel; McGill University, Department of Emergency Medicine Khangura, Jaspreet; Northeast Community Health Centre, Department of Emergency Medicine Fok, Patrick T.; Dalhousie University, Department of Emergency Medicine Stachura, Maja; The University of British Columbia, Department of Emergency Medicine Brar, Baljeet; The University of British Columbia, Department of Emergency Medicine Hohl, Corinne; The University of British Columbia, Department of Emergency Medicine
Primary Subject Heading :	Emergency medicine
Secondary Subject Heading:	Infectious diseases
Keywords:	COVID-19, EPIDEMIOLOGY, Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Diagnostic microbiology < INFECTIOUS DISEASES

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

relievont

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

BMJ Article Template

Diagnostic Yield of Screening for SARS-CoV-2 among Patients Admitted to Hospital for Alternate Diagnoses: An Observational Cohort Study

Phil Davis¹, Rhonda J. Rosychuk², Jeffrey P Hau^{3,14}, Ivy Cheng^{4,5}, Andrew D. McRae⁶, Raoul Daoust⁷,

Eddy Lang⁸, Joel Turner⁹, Jaspreet Khangura¹⁰, Patrick T. Fok¹¹, Maja Stachura¹², Baljeet Brar¹³, and

Corinne Hohl¹⁴ on behalf of the CCEDRRN investigators, and for the Network of Canadian

Emergency Researchers and the Canadian Critical Care Trials Group

Correspondence to: Dr. Philip J.B. Davis; 103 Hospital Drive, Saskatoon, SK, S7N 0W8; Phil.davis@usask.ca

Author affiliations:

¹ Department of Emergency Medicine, University of Saskatchewan, Saskatoon, SK, Canada

² Department of Pediatrics, University of Alberta, Edmonton, AB, Canada

³ Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute, 828 W 10th Ave, Vancouver BC V5Z1M9

⁴ Department of Emergency Medicine, Sunnybrook Health Sciences Center

⁵ Division of Emergency Medicine, Dept of Medicine, University of Toronto

⁶ Department of Emergency Medicine, University of Calgary

⁷ Département Médecine de Famille et Médecine d'Urgence, Faculté de Médecine, Université de Montréal, Department of Emergency Medicine, Research Centre, CIUSSS-Nord-de-l'Île de-Montréal Montréal, Québec, Canada

⁸ Department of Emergency Medicine, University of Calgary

⁹ Department of Emergency Medicine, McGill University, Montreal, Qc

¹⁰ Department of Emergency Medicine, University of British Columbia

¹¹ Division of EMS, Department of Emergency Medicine, Dalhousie University

¹² Department of Emergency Medicine, University of British Columbia

¹³ Department of Emergency Medicine, University of British Columbia

¹⁴ Department of Emergency Medicine, Faculty of Medicine, University of British Columbia, 2775 Laurel St., Vancouver BC V5Z 1M9.

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

Word count (excluding title page, abstract, references, figures, and tables): 2282

Keywords: screening, COVID-19, coronavirus disease, health services utilization, diagnostic testing, pandemic

Abstract:

Objectives: To determine the diagnostic yield of screening patients for SARS-CoV-2 who were admitted with a diagnosis unrelated to COVID-19, and identify risk factors for positive tests.

Design: Cohort from the Canadian COVID-19 Emergency Department Rapid Response Network

(CCEDRRN) registry

Setting: 30 acute care hospitals across Canada

Participants: Patients hospitalized for non-COVID-19 related diagnoses who were tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) between March 1, and December 29, 2020

Main outcome: Positive nucleic acid amplification test (NAAT) for SARS-CoV-2

Outcome measure: Diagnostic yield

Results: We enrolled 15,690 consecutive eligible adults who were admitted to hospital without clinically suspected COVID-19. Among these patients, 122 tested positive for COVID-19, resulting in a diagnostic yield of 0.8% (95% CI 0.64% – 0.92%). Factors associated with a positive test included presence of a fever, being a healthcare worker, having a positive household contact or institutional exposure, and living in an area with higher 7-day average incident COVID-19 cases.

Conclusions: Universal screening of hospitalized patients for COVID-19 across two pandemic waves had a low diagnostic yield and should be informed by individual-level risk assessment in addition to regional COVID-19 prevalence.

Trial registration: NCT04702945

Strengths and Limitations

- Pan-Canadian study including over 40 academic, non-academic, rural, and urban hospitals.
- Inclusion of patient partners, as well as public engagement, who assisted in the development and presentation of this manuscript.
- Inclusion of pertinent clinical variables, as well as relevant demographic and community level variables.

• Exclusion of non-NAAT tests due to their infrequent use in the Canadian context.

BMJ Open

BMJ Article Template

INTRODUCTION

Healthcare institutions initiated widespread testing of admitted patients for coronavirus disease 2019 (COVID-19) in the spring of 2020 (1). Patients without any reported symptoms of COVID-19 were routinely tested even in jurisdictions where COVID-19 rates were low in order to identify asymptomatic carriers and prevent hospital outbreaks (2). Some jurisdictions have continued this practice without robust evidence to support this practice. An Alberta study of 3,375 patients admitted to hospital for alternate diagnoses during the first wave of the pandemic when COVID-19 prevalence was very low found that none of the patients tested positive (3). In contrast, other studies from times and regions with higher COVID-19 prevalence reported positive tests in between 2.6 and 15.5% of otherwise asymptomatic patients (4–8).

Universal testing has several potential downsides if diagnostic yield is low. First, it may worsen Emergency Department (ED) crowding, as admitted patients with pending COVID-19 tests are boarded in EDs until their test results are reported. While ED volumes were lower than usual in the early pandemic such that EDs could absorb this delay, high patient volumes have since returned, exacerbating the impact of this practice on hospital crowding (9). This in turn increases patient morbidity and mortality (10). In addition, diagnostic workups and therapeutic interventions may be delayed until COVID-19 test results are back, as it takes longer to move patients on isolation precautions through the system. This can further exacerbate patient outcomes and hospital crowding. Thirdly, diagnostic testing capacity may be limited, potentially delaying processing of tests for symptomatic patients. In addition, the use of Personal Protective Equipment (PPE) may be increased as institutions have placed patients with pending COVID-19 tests under isolation precautions. The use of PPE during resuscitation has been associated with worse patient outcomes (11). Lastly, there is also an opportunity cost for hospitals as money spent on universal testing could be allocated to other areas. These unintended consequences of liberal testing policies need to be weighed carefully against the anticipated diagnostic yield and potential benefits.

BMJ Article Template

As for any diagnostic test, rational COVID-19 testing guidelines should be informed by the level of risk of the patient, such that testing is reduced in situations when risk is low, and more widespread when risk is high. Based on expert opinion, the Infectious Diseases Society of America (IDSA) recommended a testing strategy based on the prevalence of the disease in the community (12). They recommended universal testing of asymptomatic hospitalized patients in times and places of high disease prevalence defined as $\geq 10\%$ or $\geq 10,000$ active cases per 100,000 population and did not recommend universal testing in times and places of low prevalence, defined as under 2% prevalence of disease, or less than 2,000 active cases per 100,000. Most jurisdictions never met the proposed screening threshold as public health measures were enacted to reduce disease prevalence to avoid overwhelming hospital capacity. The IDSA was unable to provide further guidance due to lack of available evidence. Our aim was to determine the diagnostic yield of screening patients for SARS-CoV-2 who had been admitted with a diagnosis unrelated to COVID-19 and identify risk factors for positive tests.

METHODS

Study Design and Setting

The Canadian COVID ED Rapid Response Network (CCEDRRN, pronounced 'sedrin') is a pan Canadian population-based registry that has enrolled consecutive eligible patients presenting with suspected or confirmed COVID–19 from EDs across Canada starting on March 1, 2020. The study population, data collection, data quality assurance, management and governance structure are described in the network's methods paper (13). The research ethics boards of all participating institutions approved this study with a waiver of informed consent for data collection and linkage (UBC REB: H20-01015). Thirty CCEDRRN sites in 7 provinces contributed data to this study (Appendix A). Data are available upon reasonable request and can be shared after approval by the Executive Committee through a process outlined on our website (https://www.ccedrrn.com/).

el.ez

BMJ Open

BMJ Article Template

Patient and Public Involvement

CCEDRRN has an active patient engagement committee with patient partners who have lived experience with COVID-19 from geographically representative areas of Canada. Patient partners provided input into the development of this research question and study protocol and the final manuscript.

Study Patients

Participating sites needed to demonstrate ≥99% compliance in enrolling consecutive eligible patients for their data to be included in this study. Data from sites and periods that did not meet this quality threshold were excluded. We included consecutive eligible patients who were admitted to hospital and swabbed for SARS-CoV-2 using a nucleic acid amplification test (NAAT) within 24 hours of ED arrival. We enrolled patients between March 1, 2020 and December 29, 2020. To identify a population of admitted patients in whom COVID-19 disease was not suspected, we excluded patients with ED diagnoses that would have been clinically suspicious for COVID-19. These included all patients with ED diagnoses of suspected or confirmed COVID-19, influenza-like-illness (ILI), upper respiratory infections, and pneumonia or viral pneumonia for which testing would have been indicated based on clinical suspicion. We excluded patients who were discharged directly from the ED, diagnosed with COVID-19 before ED arrival (based on a NAAT done in the community), those whose first swab occurred more than 24 hours after their arrival, and repeat admissions. We also excluded patients in whom initial SARS-CoV-2 testing was negative and repeat testing became positive more than 5 days after arrival, as these patients could have contracted nosocomial COVID.

Data Collection

Trained research assistants collected data retrospectively from electronic and/or paper-based medical records into a central, web-based REDCap database (Vanderbilt University; Nashville, TN, USA). Research assistants captured demographics, infection risk, ED vital signs, presenting symptoms, comorbid conditions and the results of COVID-19 tests. The coordinating centre implemented regular

BMJ Article Template

data quality checks, including logic checks in REDCap as well as site-level record verifications for nonsensical or outlying values.

In addition to these clinical variables, we calculated the seven-day moving average incident COVID-19 case count for the health region of each participating site using publicly available epidemiological data (14). For each calendar day within each health region represented in the study, we calculated the average daily incident rate of new infections per 100,000 population over the preceding seven days. This seven-day moving average incidence was assigned to each patient based on the date of their index emergency department encounter and the health region of their postal code of residence. We allocated patients with no fixed address to the health region of the hospital in which they were tested. We imputed values for the first five weeks of the pandemic by modeling the reported COVID-19 cases that had accumulated in every health region over time using linear interpolation (0.1% missing), COVID-19 case data were not publicly available for the early pandemic. The seven-day moving average incident COVID-19 case count was categorized as 0 - 1.99 per 100,000 population, 2 - 7.99 per 100,000 population, and ≥ 8 per 100,000 population based on the relationship between incidence and COVID-19 positive results in a previous analysis (15).

Outcome:

The primary outcome was a positive NAAT for SARS-CoV-2 in patients admitted with non-COVIDrelated diagnoses.

Data Analysis:

We divided the cohort into two groups, those without symptoms of COVID-19 and those with symptoms compatible with COVID-19 that were attributed to an alternate diagnosis (i.e., CHF, COPD, Asthma, etc.). We considered cough, dyspnea, fever, general weakness, chest pain, diarrhea, nausea and vomiting, headache, chills, myalgia, sore throat, altered level of consciousness, and dysgeusia/anosmia to be COVID-19-compatible symptoms. We used descriptive statistics to describe the population. We

BMJ Open

BMJ Article Template

calculated the diagnostic yield by dividing the number of positive NAATs over the total number of NAATs performed. We calculated 7-day average of NAAT positivity over the study period by dividing the number of positive NAATs over all tests performed and averaging over a 7-day period. We calculated the exact binomial proportion 95% confidence intervals (95% CI) for all proportions and used the modified Clopper-Pearson interval for small samples. We completed a planned subgroup analyses for patients presenting with and without COVID compatible symptoms to determine associated factors for a positive test. The initial multivariable logistic regression model to identify factors associated with a positive NAAT considered candidate variables with a p-value cut-off point of 0.20 based on the Wald test from univariable analyses. From the full model, a step-down procedure reduced the model to key predictors based on Akaike's information criterion (AIC) scores (e.g., chose the model with the smallest AIC score). Candidate variables included seven-day moving average incident COVID-19 case count category, patient age, gender, infection risk, and presenting symptoms. We limited the number of predictor variables in the model to one variable for every 10 outcomes in our data to avoid overfitting. Statistical analysis was preformed using Stata (Version 16.1, StataCorp, College Station, Texas).

RESULTS

We identified 19,791 patients admitted to hospital who presented to a participating ED between March 1, 2020, and December 29, 2020 (Figure 1). We excluded 4,101 patients, of which 2,769 had ED diagnoses that were clinically suspicious for COVID-19 and warranted SARS-CoV-2 testing on clinical grounds. The final cohort contained 15,690 patients. During the study period Canada experienced two pandemic waves with the local 7-day average incident case count ranging from between 0 and 42.6 cases per 100,000 population across sites. The 7-day average diagnostic test positivity varied between 0 and 2.9% across sites during the study period (Figure 2).

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

BMJ Article Template

We divided the cohort into two groups, those without any COVID-19 compatible symptoms, and those with COVID-19 compatible symptoms that were attributed to an alternate diagnosis in the ED (Table 1). Most patients arrived from home and were full code. The most common comorbidities were hypertension, diabetes and mental health illness.

Of 3,113 patients admitted without COVID-19 compatible symptoms, 13 (0.4%, 95% CI 0.19% – 0.64%) tested positive for COVID-19. Of the 12,570 with COVID-19-compatible symptoms, 109 patients (0.9%, 95% CI 0.70% – 1.03%) tested positive for COVID-19. Among the 122 individuals who tested positive for COVID-19, 33 (27.0%, 95% CI 19.0% - 35.0%) were from a geographic region that had a moving average daily incident rate of \geq 8 infections per 100,000 population. The diagnostic yield of testing among patients with COVID-19 compatible symptoms admitted for alternative diagnoses did not vary substantially by presenting symptom (Figure 3) or ED diagnosis (Figure 4).

When examining the association between patient factors and screening positive self-reported fever, being a healthcare worker, having a positive household contact or institutional exposure, and being from an area where the seven-day moving average incident COVID-19 case count was \geq 8 per 100,000 population were associate with a greater risk of testing positive (Table 2). The most important risk factor was reporting a household contact or being the caregiver of a known COVID-19 case.

DISCUSSION

Our aim was to evaluate the diagnostic yield of screening non-COVID-19 admissions for SARS-CoV-2 across Canada in 2020 and identify patient-level risk factors for positive tests. The diagnostic yield of screening patients with non-COVID-19 related ED diagnoses who were admitted to hospital was low overall, and extremely low in patients without COVID compatible symptoms. The most important patient factors associated with a positive test were having a positive household contact, being a healthcare worker, or having had an institutional exposure to COVID-19. Those factors were more important than a high (\geq 8 daily cases per 100,000 population) 7-day moving average incident COVID-19 case count.

BMJ Article Template

Our study has several strengths. We used data from a large pan-Canadian registry that enrolls from large geographically and culturally diverse areas and is one of the largest registries in the world. CCEDRRN's patient enrolment and data verification protocols are rigorous, ensuring consecutive eligible patients and high-quality clinical data (13). We have previously demonstrated the inter-rater reliability for our data collection methods, including for symptoms (13).

Prior studies have examined the diagnostic yield of universal screening in single centers with varied diagnostic yield estimates between 0 and 15.5% (3–8). Many of these were case series with limited methods from the early pandemic. There is one known multi-center study which examines the benefit of universal screening for elective and emergent surgical admissions at 14 centers in the Netherlands (1). Like our study, the authors found that the overall COVID-19 NAAT positivity varied with community prevalence. Our finding that positive SARS-CoV-2 tests were associated with self-reported or measured fever is in keeping with a prior Cochrane systematic review that noted considerable variability in COVID-19 associated symptoms (16).

Our study is interesting in the context of current IDSA recommendations which were based on expert opinion and of "very low certainty" (12). The IDSA panel recommended avoiding universal screening for COVID-19 in times and areas of low COVID prevalence, defined as a disease prevalence of under 2%, or fewer than 2,000 active cases per 100,000 population, a threshold so high that it was never met at any of our study sites, even though multiple sites were in COVID-19 hotspots in 2020 (12). The IDSA threshold would have equated to over 6 million cases of active COVID-19 infection in the United States at any given time, which would have vastly overwhelmed hospital capacity, and thus represents an untenable threshold for hospitals. It is therefore not surprising that the prevalence of COVID-19 during the study period was far below the IDSA recommended threshold for initiating screening. While the number needed to screen to identify one positive case among admitted patients in our study was between 110 and 250 among unvaccinated patients, we propose that new screening thresholds need to be adopted which would ideally be based on readily available measures of local incident cases or test positivity.

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

BMJ Article Template

A limitation of our study is that we only considered NAATs and did not consider the diagnostic yield of antigen-based COVID-19 tests, as they were not widespread in Canada in 2020 (16). We were unable to examine the sensitivity and specificity of the SARS-CoV-2 NAATs as we were unable to define false positive tests, so it is possible that some of the positive test results we encountered are false positives, leading to an overestimation of diagnostic yield. Additionally, our study was performed before the newer COVID-19 variants, such as Omicron, circulated widely. However, our methods are easily replicated, and we intend to repeat our study in a recent dataset reflective of new COVID-19 variants. While our study is based on a Canadian population without international sites, we believe our findings are generalizable given their wide geographic spread, and the cultural and racial diversity of our patient population. Finally, as data becomes available on the fourth wave of the pandemic, a future study should examine the impact of widespread vaccination on the yield of screening. As a larger proportion of the population is protected from severe disease and death through vaccination, decision makers should carefully consider the low diagnostic yield of a universal testing strategy going forward.

ACKNOWLEDGEMENTS

We gratefully acknowledge the assistance of Mr. Rajan Bola in the preparation of this manuscript. And we thank the UBC clinical coordinating center staff, the UBC legal, ethics, privacy and contract staff and the research staff at each of the participating institutions in the network outlined in the attached Supplement (Supplement Tables 1-4). The network would not exist today without the dedication of these professionals.

Thank you to all of our patient partners who shared their lived experiences and perspectives to ensure that the knowledge we co-create addresses the concerns of patients and the public. Creating the largest network of collaboration across Canadian Emergency Departments would not have been feasible without the tireless efforts of Emergency Department Chiefs, and research coordinators and research assistants at participating sites. Finally, our most humble and sincere gratitude to our colleagues in medicine, nursing,

BMJ Open

BMJ Article Template

and the allied health professions who have been on the front lines of this pandemic from day one staffing our ambulances, Emergency Departments, hospitals and ICUs bravely facing the risks of COVID-19 to look after our fellow citizens and after one another. We dedicate this network to you.

COMPETING INTERESTS

None identified.

FUNDING

The Canadian Institutes of Health Research (447679), Ontario Ministry of Colleges and Universities (C-655-2129), Saskatchewan Health Research Foundation (5357), Genome BC (COV024) Foundation du CHU de Québec (Octroi No. 4007) and the Public Health Agency of Canada provided peer-reviewed funding. The BC Academic Health Science Network and BioTalent Canada provided non-peer reviewed funding. These organizations are not-for-profit, and had no role in study conduct, analysis, or manuscript preparation.

AUTHOR CONTRIBUTION STATEMENT

All authors conceived and planned the study together, and iteratively refined the study objectives and analytic plan. PH, RJR, ADM, EL and CMH obtained funding for the study. PD, IC, ADM, RD, JT, JK, PRF, MS and BB supervised data collection. JPH analyzed the data under the supervision of RJR. All authors interpreted the analysis. PD drafted the manuscript. All authors were actively involved in reporting out work by revising the manuscript for content. All authors take responsibility for the manuscript as a whole.

BMJ Article Template

DATA SHARING

Data are available upon reasonable request. They can be shared after approval by the Executive Committee through a process outlined on our website (<u>https://www.ccedrm.com/</u>).

to peet eview only

	Patients without COVID-19 symptoms (N=3,113)	Patients with COVID-19 compatible symptoms attributed an alternate diagnos (N=12,570)
Demographics		
Age (mean, SD)	57.6 (22.6)	64.6 (20.4)
Female (%)	1,418 (45.6)	5,924 (47.1)
Pregnant (%)	18 (0.6)	45 (0.4)
Tobacco use (%)	491 (15.8)	1,656 (13.2)
Illicit substance use (%)	421 (13.5)	967 (7.7)
Arrival by Ambulance (%)	1,724 (55.4)	7,189 (57.2)
Arrival From (%)		
Home	2,552 (82.0)	10,943 (87.0)
Long-term care or rehab facility	217 (7.0)	832 (6.6)
Unstable housing*	190 (6.1)	414 (3.3)
Corrections	7 (0.2)	14 (0.1)
Interfacility transfer	121 (3.9)	262 (2.1)
Risk for Infection (%)		
Travel	32 (1.0)	134 (1.1)
Institutional (LTC/prison)	231 (7.4)	721 (5.7)
Household contact	28 (0.9)	144 (1.1)
Occupational	10 (0.3)	38 (0.3)
Unknown	1,502 (48.2)	5,377 (42.8)
Pre-ED Goals of Care (%)		
Full code	2,946 (94.6)	11,259 (89.5)
Intermediate GOC	18 (0.6)	173 (1.4)
Do not resuscitate	149 (4.8)	1,142 (9.1)
Acuity		
CTAS 1 (Resuscitation)	241 (7.7)	1,053 (8.4)
CTAS 2 (Emergent)	1,000 (32.1)	5,786 (46.0)
CTAS 3 (Urgent)	1,527 (49.1)	5,086 (40.4)
CTAS 4 (Less Urgent)	295 (9.5)	572 (4.6)
CTAS 5 (Non Urgent)	40 (1.3)	59 (0.5)
Arrival Vital Signs, Mean (SD)		
Heart Rate, beats per min	91.2 (21.2)	95.5 (23.9)
Systolic BP, mm Hg	134.7 (25.1)	133.6 (27.9)
Oxygen saturation, (%)	96.6 (3.4)	95.7 (4.1)
Respiratory Rate, beats per min	18.6 (4.4)	21.2 (6.3)
Temperature, degrees Celsius	36.6 (0.6)	36.8 (0.9)
Comorbidities (%)		
Hypertension	951 (30.6)	5,321 (42.3)
Psychiatric Condition	728 (23.4)	2,134 (17.0)
Dyslipidemia	425 (13.6)	2,434 (19.4)
Diabetes	427 (13.7)	2,577 (20.5)
Chronic Neuro Disorder	322 (10.3)	1,406 (11.2)

2 3		204 (0.1)	1 706 (14 2)
4	Coronary Artery Disease	284 (9.1)	1,796 (14.3)
5	Rheumatologic Disorder Dementia	229 (7.4)	1,249 (9.9)
6	Active Cancer	199 (6.4)	696 (5.5) 1 647 (12 0)
7		231 (7.4)	1,647 (12.9)
8	Chronic Kidney Disease	195 (6.3)	1,319 (10.5)
9 10	Chronic Lung Disease (not asthma)	199 (6.4)	1,691 (13.5)
10	Congestive Heart Failure	159 (5.1)	1,392 (11.1)
12	Asthma	125 (4.0)	712 (5.7)
13	Obesity	57 (1.8)	344 (2.7)
14	Symptoms (%)		
15	Cough	-	2,763 (22.0)
16	Dyspnea	-	4,757 (37.8)
17	Fever	-	2,531 (20.1)
18	General Weakness	-	3,183 (25.3)
19 20	Chest Pain	-	2,714 (21.6)
20 21	Diarrhea	-	1,339 (10.7)
22	Nausea/Vomiting	-	3,345 (26.6)
23	Headache	-	784 (6.2)
24	Chills	-	957 (7.6)
25	Myalgia	N -	466 (3.7)
26	Sore Throat	-	374 (3.0)
27	Altered Consciousness	-	2,502 (19.9)
28	Dysgusea/Anosmia		41 (0.3)
29 30	ED Diagnosis (%)		
30 31	Respiratory Disease, not specified	8 (0.3)	118 (0.9)
32	COPD Exacerbation	11 (0.4)	648 (5.2)
33	Asthma Exacerbation	<5	97 (0.8)
34	Congestive Heart Failure	44 (1.4)	1,003 (8.0)
35	Shortness of Breath, NYD*	- 7	466 (3.6)
36	Cough, NYD*	-	63 (0.5)
37	Fever, NYD*	-	482 (3.8)
38	Outcome (%)		
39 40	Positive SARS-CoV-2 NAAT	13 (0.4)) 💋 109 (0.9)
40 41	*NYD denotes "not yet determined"		
41			

	Univariate analysis odds ratio (95% CI)	Final model with fully adjusted odds ratio (95% Cl) ¹	P-value
Sex			
Male	Reference	Reference	0.18
Female	0.84 (0.59 – 1.21)	0.78 (0.54 – 1.12)	
Age			
	1.00 (1.00 – 1.02)	1.00 (0.99 – 1.01)	0.27
7-day average incident COVID-19 cases			
0 – 1.99 daily cases per 100,000 population	Reference	Reference	< 0.001
2 to 7.99 daily cases per 100,000 population	1.42 (0.91 – 2.22)	1.47 (0.94 – 2.31)	
≥8 daily cases per 100,000 population	2.99 (1.95 – 4.59)	3.17 (2.05 – 4.89)	
COVID-19 compatible symptoms present			
No	Reference	Reference	0.08
Yes	2.08 (1.71 – 3.71)	1.65 (0.90 – 3.00)	
Self-reported fever, or temperature \ge 37.5 °C			
No	Reference	Reference	< 0.001
Yes	2.72 (1.89 – 3.90)	2.53 (1.74 – 3.67)	
Diarrhea present			
No	Reference	Reference	0.11
Yes	1.74 (1.04 – 2.92)	1.57 (0.93 – 2.67)	
Healthcare worker			
No	Reference	Reference	0.06
Yes	5.62 (1.35 – 23.43)	4.67 (1.05 – 20.54)	
Household contact or caregiver			
No	Reference	Reference	< 0.001
Yes	9.48 (5.01 – 17.96)	7.74 (3.98 – 15.04)	
Institutional exposure			
No	Reference	Reference	< 0.002
Yes	3.46 (2.17 – 5.52)	3.39 (2.10 – 5.47)	
Dysgeusia or anosmia present			
No	Reference	-	
Yes	3.21 (0.43 – 23.52)	-	
Dyspnea present			
No	Reference	-	
Yes	1.16 (0.80 – 1.70)	-	
Nausea or vomiting present			
No	Reference	-	
Yes	0.81 (0.51 – 1.29)	-	

BMJ Article Template

¹ Final model determined by including variables with a p-value of p<0.20 from univariable analyses, and using the Akaike Information Criterion (AIC) to determine additional variables to exclude from the final model. Variables adjusted for all other variables present in the final model.

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

Figure 1: Patient Flow Diagram

Figure 2: 7-day working average of COVID-19 NAAT positivity over the study period across sites.

Figure 3: Diagnostic Yield by Presenting Symptoms

Figure 4: Diagnostic Yield by ED Diagnosis

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Article Template

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

ETHICAL APPROVAL STATEMENT

The research ethics boards of all participating institutions approved this study with a waiver of informed

tor beer terien only

consent for data collection and linkage (UBC REB: H20-01015).

REFERENCES


- 1. Puylaert CAJ, Scheijmans JCG, Borgstein ABJ, Andeweg CS, Bartels-Rutten A, Beets GL, et al. Yield of Screening for COVID-19 in Asymptomatic Patients Before Elective or Emergency Surgery Using Chest CT and RT-PCR (SCOUT): Multicenter Study. Ann Surg. 2020 Dec;272(6):919–24.
- 2. Sutton D, Fuchs K, D'Alton M, Goffman D. Universal Screening for SARS-CoV-2 in Women Admitted for Delivery. N Engl J Med. 2020 May 28;382(22):2163–4.
- 3. Ravani P, Saxinger L, Chandran U, Fonseca K, Murphy S, Lang E, et al. COVID-19 screening of asymptomatic patients admitted through emergency departments in Alberta: a prospective quality-improvement study. CMAJ Open. 2020 Oct;8(4):E887–94.
- 4. Goldfarb IT, Diouf K, Barth WH, Robinson JN, Katz D, Gregory KE, et al. Universal SARS-CoV-2 testing on admission to the labor and delivery unit: Low prevalence among asymptomatic obstetric patients. Infect Control Hosp Epidemiol. 2020 Sep;41(9):1095–6.
- Ossami Saidy RR, Globke B, Pratschke J, Schoening W, Eurich D. Successful implementation of preventive measures leads to low relevance of SARS-CoV-2 in liver transplant patients: Observations from a German outpatient department. Transpl Infect Dis [Internet]. 2020 Dec [cited 2021 Aug 9];22(6). Available from: https://onlinelibrary.wiley.com/doi/10.1111/tid.13363
- 6. Gruskay JA, Dvorzhinskiy A, Konnaris MA, LeBrun DG, Ghahramani GC, Premkumar A, et al. Universal Testing for COVID-19 in Essential Orthopaedic Surgery Reveals a High Percentage of Asymptomatic Infections. J Bone Jt Surg. 2020 Aug 19;102(16):1379–88.
- London V, McLaren R, Atallah F, Cepeda C, McCalla S, Fisher N, et al. The Relationship between Status at Presentation and Outcomes among Pregnant Women with COVID-19. Am J Perinatol. 2020 Aug;37(10):991–4.
- Bianco A, Buckley AB, Overbey J, Smilen S, Wagner B, Dinglas C, et al. Testing of Patients and Support Persons for Coronavirus Disease 2019 (COVID-19) Infection Before Scheduled Deliveries. Obstet Gynecol. 2020 Aug;136(2):283–7.
- Lee DD, Jung H, Lou W, Rauchwerger D, Chartier L, Masood S, et al. The Impact of COVID-19 on a Large, Canadian Community Emergency Department. West J Emerg Med [Internet]. 2021 Jun 9 [cited 2021 Jul 26];22(3). Available from: https://escholarship.org/uc/item/0xk8j1fj
- Sun BC, Hsia RY, Weiss RE, Zingmond D, Liang L-J, Han W, et al. Effect of Emergency Department Crowding on Outcomes of Admitted Patients. Ann Emerg Med. 2013 Jun;61(6):605-611.e6.
- 11. Shao F, Xu S, Ma X, Xu Z, Lyu J, Ng M, et al. In-hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in Wuhan, China. Resuscitation. 2020 Jun;151:18–23.
- 12. Hanson KE, Caliendo AM, Arias CA, Hayden MK, Englund JA, Lee MJ, et al. The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing. Clin Infect Dis. 2021 Jan 22;ciab048.
- 13. Hohl CM, Rosychuk RJ, McRae AD, Brooks SC, Archambault P, Fok PT, et al. Development of the Canadian COVID-19 Emergency Department Rapid Response Network population-based registry: a methodology study. CMAJ Open. 2021 Jan;9(1):E261–70.

- 14. Health Regional Archive (Public View). [Internet]. [cited 2021 Jun 4]. Available from: https://resourcescovid19canada. hub.arcgis.com/datasets/3aa9f7b1428642998fa399c57dad8045/data?layer=1
- 15. McRae AD, Hohl CM, Rosychuk RJ, Vatanpour S, Ghaderi G, Archambault PM, et al. Development and validation of a clinical risk score to predict SARS-CoV-2 infection in emergency department patients: The CCEDRRN COVID-19 Infection Score (CCIS) [Internet]. Emergency Medicine; 2021 Jul [cited 2021 Aug 9]. Available from: http://medrxiv.org/lookup/doi/10.1101/2021.07.15.21260590
- 16. Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Infectious Diseases Group, editor. Cochrane Database Syst Rev [Internet]. 2020 Jul 7 [cited 2021 Jul 26]; Available from: https://uplineliburg.com/doi/10.1002/14/51059.CD0126/5


https://onlinelibrary.wiley.com/doi/10.1002/14651858.CD013665


		 Exclude: 95 Patients diagnosed with COVID before the index admission or had history of Covid-19 925 Patients not swabbed within 24 hours of ED arrival 291 Patients swabbed prior to ED arrival 21 Patients diagnosed with COVID-19 > 5 days after ED arrival 2,769 Patients with ED diagnosis of (1-6): a 288 Suspect COVID-19 b 297 Confirmed COVID-19 b 297 Confirmed COVID-19 c 299 Influenza like illness d. 111 Upper Respiratory Infection e. 1,667 Pneumonia f. 107 Viral Pneumonia
15.690	Cohort	
	15,690	15,690 Cohort

Figure 2: The 7-day working average of COVID-19 NAAT positivity among all eligible study patients over the study period across study sites.



1 2 3 4 5 6 7 8 9 10	
3	
5	
6 7	
8 9	
11 12	
13 14	
15 16	
17	
18 19	
20 21	
22 23	
24	
25 26	
27 28	
29 30	
31	
32 33	
34 35	
36 37	
38	
39 40	
41 42	
43 44	
45	
46 47	
48 49	
50 51	
52	
53 54	
55 56	
57	
58 59	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
60	For peer review only - http://pmiopen.bmi.com/site/about/guidelines.xhtml





BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

APPENDIX & SUPPLEMENT

Appendix A: List of hospital sites, with an inclusion start and end date for this study.

Site Name	Province	Start Date	End Date
Vancouver General Hospital	British Columbia	1-Mar-2020	31-Aug-2020
Lions Gate Hospital	British Columbia	1-Mar-2020	29-Apr-2020
Saint Paul's Hospital	British Columbia	1-Mar-2020	23-May-2020
Mount Saint Joseph Hospital	British Columbia	1-Mar-2020	24-Mar-2020
Surrey Memorial Hospital	British Columbia	19-Mar-2020	30-Apr-2020
Royal Columbian Hospital	British Columbia	1-Mar-2020	31-May-2020
Abbotsford Regional Hospital	British Columbia	20-Apr-2020	15-Jul-2020
University of Alberta Hospital	Alberta	8-Apr-2020	7-May-2020
Foothills Medical Centre	Alberta	1-Mar-2020	7-Apr-2020
Rockyview General Hospital	Alberta	1-Mar-2020	7-Apr-2020
Peter Lougheed Centre	Alberta	1-Mar-2020	12-Dec-2020
South Health Campus	Alberta	1-Mar-2020	12-Dec-2020
St Paul's Hospital	Saskatchewan	17-Mar-2020	30-Apr-2020
Royal University Hospital	Saskatchewan	17-Mar-2020	31-Oct-2020
Saskatoon City Hospital	Saskatchewan	17-Mar-2020	30-Apr-2020
Sunnybrook Health Sciences Centre	Ontario	14-May-2020	31-Oct-2020
The Ottawa Hospital - Civic Campus	Ontario	14-May-2020	31-May-2020
Health Science North	Ontario	14-May-2020	29-Dec-2020
Toronto Western Hospital	Ontario	1-Sep-2020	31-Sep-2020
Hotel-Dieu de Lévis	Quebec	4-May-2020	18-May-2020
Jewish General Hospital	Quebec	1-Mar-2020	4-Jun-2020
Hôpital de l'Enfant-Jésus,CHU de Québec	Quebec	4-May-2020	23-Jul-2020
IUCPQ: Institut universitaire de cardiologie et de pneumologie de Québec	Quebec	4-May-2020	13-May-2020
Hôpital du Sacré-Coeur de Montreal	Quebec	4-May-2020	18-May-2020
Saint John Regional Hospital	New Brunswick	12-Mar-2020	12-Apr-2020
Halifax Infirmary	Nova Scotia	5-Apr-2020	15-Apr-2020
Dartmouth General Hospital	Nova Scotia	5-Apr-2020	15-Apr-2020
Hants Community Hospital	Nova Scotia	5-Apr-2020	15-Apr-2020
Cobequid Community Health Centre	Nova Scotia	5-Apr-2020	15-Apr-2020
Secondary Assessment Centers of Dartmouth General and Halifax Infirmary	Nova Scotia	26-Mar-2020	15-May-2020

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Name	Roles	Contributions
Jeffrey Hau	Data manager	REDCap, data processing and analysis for manuscripts.
Vi Ho	National coordinator	Coordinate with provincial coordinators and
		training/onboarding of research assistants.
Serena Small	Research	Ethics & privacy reviews, data management plan, privacy
	coordinator	impact assessment, and qualitative analyses
Amber Cragg	Research manager	Data and manuscript management
Wei Zhao	Data analyst	Data processing and analysis for manuscripts.
Vicky Wu	Data analyst	Data processing and analysis for manuscripts.
Elnaz Bodaghkhani	Research associate	Data and manuscript management

Supplement Table 1. Network coordinating center staff at the University of British Columbia

Supplement Table 2. Provincial Coordinators

Name	Province	Institutional affiliation	Contributions to CCEDRRN
Corinne DeMone	NS	Dalhousie University, Halifax, Nova Scotia	Research ethics board submission, manages research assistants, data cleaning and quality.
Jacqueline Fraser	NB	Dalhousie University, St. John New Brunswick	Site coordinator as well as research assistant.
Martyne Audet	QC	Centre intégré de santé et de services sociaux de Chaudière- Appalaches (Hôtel- Dieu de Lévis site), Lévis	Provincial research coordinator, translation of research material to French, ethics management.
Connie Taylor	ON	Queen's University, // Kingston	Coordination of research assistants in Ontario, maintenance of REB applications for the province
Kate Mackenzie	MB	Health Sciences Centre, Winnipeg	Lead RA for the province
Aimee Goss	SK	University of Saskatchewan, Saskatoon	Screens records in Saskatoon, data/extraction and entry, coordinates research assistants.
Hina Walia	AB	University of Calgary, Calgary	Provincial coordinator lead for Alberta, oversight of all Alberta sites.
Josie Kanu	BC	University of British Columbia, Vancouver	Provincial coordinator lead for BC, oversight of all BC sites.

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

BMJ Open: first published as 10.1136/bmjopen-2021-057852 on 10 August 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

Name	Province	Institutional affiliation(s)
Corinne DeMone	NS	Dartmouth General Hospital, Cobequid Community Health Centre
		Hants Community Hospital
		Secondary Assessment Centers of the Dartmouth General Hospital
		and Halifax Infirmary, Halifax
Jacqueline Fraser	NB	Saint John Regional Hospital, Saint John
Alexandra Nadeau	QC	CHU de Québec Université Laval, Quebec City
Audrey Nolet	QC	Centre intégré de santé et de services sociaux de Chaudière-
		Appalaches (Hôtel-Dieu de Lévis site), Lévis
Xiaoqing Xue	QC	Jewish General Hospital, Montréal
David Iannuzzi	QC	McGill University Health Center, Montréal
Chantal Lanthier	QC	Hôpital du Sacré-Cœur de Montréal, Montréal
Konika Nirmalanathan	ON	University Health Network, Toronto
Vlad Latiu	ON	Kingston General Hospital, Hotel Dieu Hospital, Kingston
Joanna Yeung	ON	Sunnybrook Health Sciences Center, Toronto
Natasha Clayton	ON	Hamilton General Hospital, Juravinski Hospital, Hamilton
Tom Chen	ON	London Health Sciences Centre, London
Jenna Nichols	ON	Health Sciences North, Sudbury
Kate Mackenzie	MB	Health Sciences Centre, Winnipeg
Aimee Goss	SK	St. Paul's Hospital, Royal University Hospital, Saskatoon City
		Hospital, Saskatoon
Stacy Ruddell	AB	Foothills Medical Centre, Peter Lougheed Centre, Rockyview
		General Hospital, South Health Campus, Calgary
Natalie Runham	AB	University of Alberta Hospital, Edmonton
Karlin Su	AB	Royal Alexandra Hospital/Northeast Community Health Center,
		Edmonton
	BC	St. Paul's Hospital, Mount Saint Joseph, Vancouver
Bernice Huynh	BC	Abbotsford Regional Hospital and Cancer Center, Abbotsford
Amanda Swirhun	BC	Royal Columbian Hospital, New Westminster
Tracy Taylor	BC	Eagle Ridge Hospital and Health Care Centre, Port Moody
Mai Hayashi	BC	Royal Inland Hospital, Kamloops
Mackenzie Cheyne	BC	Kelowna General Hospital, Kelowna
Sarim Asim	BC	Surrey Memorial Hospital, Surrey
Katherine Lam	BC	Vancouver General Hospital, Vancouver
Kelsey Compagna	BC	Lions Gate Hospital, Vancouver

Supplement Table 3. Institutional research assistant (RA) leads

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	
24 25 26 27 28	
29 30 31 32 33	
34 35 36 37	
38 39 40 41	
42 43 44 45 46	
47 48 49 50 51	
51 52 53 54 55	
56 57 58 59 60	
00	

Supplement Table 4. Contributing Study Sites and Investigators

Lead Investigator	Contributing Site / Code	Member Investigators		
Maritime				
Patrick Fok				
Nova Scotia				
Hana Wiemer	Halifax Infirmary/ 902	Patrick Fok		
	Dartmouth General Hospital/ 903	Hana Wiemer		
	Hants Community Hospital/ 904	Samuel Campbell		
	Cobequid Community Health Centre/ 905	Kory Arsenault		
	Secondary Assessment Centers of Dartmouth	Tara Dahn		
	General and Halifax Infirmary/ 908			
New Brunswick				
Kavish Chandra	Saint John Regional Hospital/ 901	Kavish Chandra		
Quebec				
Patrick Archambault	Hotel-Dieu de Lévis/ 701	Patrick Archambault		
	Jewish General Hospital/ 702	Joel Turner		
	Centre Hospitalier de l'Université Laval (CHU	Éric Mercier		
	de Québec)/ 703			
	L'hôpital Royal Victoria - Royal Victoria	Greg Clark		
	Hospital/ 705			
	Hôpital de l'Enfant-Jésus,CHU de Québec/706	Éric Mercier		
	Hôpital du Saint-Sacrement, CHU de Québec/	Éric Mercier		
	707			
	Hôpital Saint-François d'Assise, CHU de	Éric Mercier		
	Québec/708			
	Hôtel-Dieu de Québec, CHU de Québec/ 709	Éric Mercier		
	IUCPQ: Institut universitaire de cardiologie et de	Sébastien Robert		
	pneumologie de Québec/ 710			
	Hôpital du Sacré-Coeur de Montreal/711	Raoul Daoust		
Ontario				
Laurie Morrison &	Sunnybrook/ 401	Ivy Cheng		
Steven Brooks	The Ottawa Hospital - Civic Campus/ 403	Jeffrey Perry		
	The Ottawa Hospital - General Campus/ 404	Jeffrey Perry		
	Kingston/Queens/ 406	Steven Brooks		
	Hamilton General Hospital/ 407	Michelle Welsford		
	Health Science North, Sudbury Ontario/ 408	Rob Ohle		
	University Hospital – LHSC/ 409	Justin Yan		
	North York General Hospital, Toronto/ 410	Rohit Mohindra		
	Victoria Hospital – LHSC/ 412	Justin Yan		
	Toronto Western Hospital/ 414	Megan Landes		
Manitoba				
Tomislav Jelic	Health Sciences Centre/ 307	Tomislav Jelic		
Saskatchewan	Treata Serences Conder 567			
Phil Davis	St Paul's Hospital, Saskatoon/ 303	Phil Davis		
	Royal University, Saskatoon/ 304	Phil Davis		

BMJ Open

	Saskatoon City Hospital, Saskatoon/ 305	Phil Davis
Alberta		
Andrew McRae	University of Alberta Hospital, Edmonton/ 201	Brian Rowe
	Foothills, Calgary/ 202	Katie Lin
	Rockyview, Calgary/ 203	Andrew McRae
	Peter Lougheed Centre/ 204	Andrew McRae
	South Campus, Calgary/ 205	Stephanie VandenBerg
	Northeast Community Health Centre, Edmonton/	Jake Hayward, Jaspree
	206	Khangura
	Royal Alexandra Hospital, Edmonton/ 306	Jake Hayward, Jaspree
		Khangura
British Columbia		
Corinne Hohl	Vancouver General Hospital/ 101	Daniel Ting
	Lions Gate Hospital/ 102	Maja Stachura
	Saint Paul's Hospital/ 103	Frank Scheuermeyer
	Mount St Joseph's/ 104	Frank Scheuermeyer
	Surrey Memorial Hospital/ 105	Balijeet Braar
	Royal Columbian Hospital/ 106	John Taylor
	Abbotsford Regional Hospital/ 107	Ian Martin
	Eagle Ridge Hospital/ 108	Sean Wormsbecker
	Royal Inland Hospital/ 112	Ian Martin
	Kelowna General / Hospital/ 115	Lee Graham
	Kelowna General / Hospital/ 115	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

STROBE Statement	-chec	cklist of items that should be included in reports of observational studies	omjupen-zuzi-uoraa		
	Item No.	Recommendation			Relevant text from manuscript
Title and abstract	1	(<i>a</i>) Indicate the study's design with a commonly used term in the title or the abstract	2 guys	ibstract)	"Cohort from the CCEDRRN registry"
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2 022.	_	Included within the results and conclusions of the abstract
Introduction			DOWIN		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-aded Iron		Relevant scientific literature has been cited and the rationale for the study is outlined.
Objectives	3	State specific objectives, including any prespecified hypotheses	4-4-5		"Our aim was to determine the diagnostic yield of screening patients admitted to hospital with a diagnosis unrelated to COVID-19 for SARS-CoV-2 in 2020, and identify risk factors for a positive test"
Methods			יי חט	>	
Study design	4	Present key elements of study design early in the paper	5 5 5 202		The Study Design and Setting is outlined early in the Methods Section.
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	2024 by gu		Included in "Study Design and Setting" sub-section.
Participants	6	 (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants 	6		Included in the "Study Patients' sub-section. Eligibility, sources and methods of selection are described.

Page 3	5 of 3	8
--------	--------	---

ge 35 of 38		BMJ Open	/bmjopen-202	
		(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed Case-control study—For matched studies, give matching criteria and the number of controls per case	1-057852	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	0 August 6-	Variables are outlined in the "Data Collection" sub-section.
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	t 2022. Downloa	Data sources and methods of assessment are outlined in the "Study Design and Setting" and "Data Collection" sub-sections.
Bias	9	Describe any efforts to address potential sources of bias	6- 6-	Described within the "Study Patients" and the "Data Collection" sub-sections.
Study size	10	Explain how the study size was arrived at	ttp://bm	Described within the "Study Patients" sub-section.
Continued on next page		i feview on	024 by guest. Protected by copyright.	
		For peer review only - http://bmjope 2 .bmj.com/site/about/guidelines.xht	tml	

Page 36 of 38

/bmjopen-20

				02	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-8	1-057852	Included within the "Data Collection" and "Data Analysis" sub-sections.
Statistical methods	12	(<i>a</i>) Describe all statistical methods, including those used to control for confounding	7-8	on 10 August	Descriptive statistics, sub-group analyses, and regression models were used. Confounding was addressed via multivariable regression.
		(b) Describe any methods used to examine subgroups and interactions	8	2022. Dow	Sub-group analyses were planned for patients presenting with and without COVID compatible symptoms.
		(c) Explain how missing data were addressed	6-7	nloaded from http:	"Participating sites needed to demonstrate \geq 99% compliance in enrolling consecutive eligible patients for their data to be included in this study"
				nloaded from http://bmjopen.bmj.com/ on	"We imputed values for the first five weeks of the pandemic by modeling the reported COVID-19 cases that had accumulated in every health region over time using linear interpolation (0.1% missing)"
		(<i>d</i>) Cohort study—If applicable, explain how loss to follow-up was addressed Case-control study—If applicable, explain how matching of cases and controls was addressed Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy	7-8	April 19, 2024 t	Loss to follow-up was not an issue. Study enrolled consecutive patients who met the inclusion/exclusion criteria and data collected through chart review.
		(<u>e</u>) Describe any sensitivity analyses	N/A	by guest.	Not performed.
Results Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8	st. Protected by copyright.	"We identified 19,791 patients admitted to hospital who presented to a participating ED between March 1, 2020, and December 29, 2020 (Figure 1). We excluded 4,101 patients, of which 2,769 had ED diagnoses that were clinically

/bmjopen-202 1-057852 suspicious for COVID-19 and warranted SARS-CoV-2 testing on clinical grounds. The final cohort contained 15.690 g patients." 0 (b) Give reasons for non-participation at each stage N/A Study was based on chart review. Figure 19 (c) Consider use of a flow diagram ıst 2022 Descriptive 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information 8-9 Paragraph 2 of the results includes the descriptive summaries. data on exposures and potential confounders 0 (b) Indicate number of participants with missing data for each variable of interest N/A See methods. wnloaded from (c) Cohort study—Summarise follow-up time (eg, average and total amount) "We identified 19,791 patients admitted to 8 hospital who presented to a participating ED between March 1, 2020, and December 29, 2020". http://bmjopen.bmj "During the study period Canada Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time 8 experienced two pandemic waves with the local 7-day average incident case count ranging from between 0 and 42.6 cases per 100,000 population across sites." com/ *Case-control study*—Report numbers in each exposure category, or summary measures of N/A exposure o Cross-sectional study-Report numbers of outcome events or summary measures N/A Ą pril 19, Descriptive results and comparative (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their Main results 16 8-9 findings are described in the latter 2 precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and 2024 paragraphs of the "Results" why they were included Å (b) Report category boundaries when continuous variables were categorized N/A guest (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful N/A time period rotected by copyright Continued on next page

BMJ Open

Page 37 of 38

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22 23

24

25

26 27

28

29

30

31

32

33

34

35

		BMJ Open	/bmjopen-202	Page 3
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	1- 0 57852 on 10 August 2022	Follows the sentence "We divided the cohort into two groups, those without any COVID-19 compatible symptoms, and those with COVID- 19 compatible symptoms that were attributed to an alternate diagnosis in the ED (Table 1)."
Discussion				
Key results	18	Summarise key results with reference to study objectives	9-miloaded	The study objective is recalled and situated within the context of the results.
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	figm http://bmjopen.bmj.com/ on April 19, 2024 by g	"A limitation of our study is that we only considered NAATs and did not consider the diagnostic yield of antigen-based COVID-19 tests, as they were not widespread in Canada in 2020 (16). We were unable to examine the sensitivity and specificity of the SARS-CoV-2 NAATs as we were unable to define false positive tests, so it is possible that some of the positive test results we encountered are false positives, leading to an overestimation of diagnostic yield."
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	util 10\$1. Protected 10\$1	Key references are recalled, and the study results are situated with these references.
Generalisability	21	Discuss the generalisability (external validity) of the study results	tea by copyright.	"While our study is based on a Canadian population without international sites, we believe our

 /bmjopei

http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

	n-2021	
	I-057852 or	findings are likely generalizable given the wide geographic spread of our study sites."
Other information		
22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	August 2	Included under "Funding" Section.
	22 Give the source of funding and the role of the funders for the present study and, if applicable, for the	Station Station 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the 112

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohord and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.stro e-statement.org.